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ABSTRACT

Dabral, Neha, Ph.D., Purdue University, December 2014. Novel strategies to develop
better brucellosis vaccines using Brucella abortus RB51 and B. neotomae. Major
Professor: Ramesh Vemulapalli.
The genus Brucella consists of Gram-negative, facultative intracellular coccobacilli that
can cause chronic infections in several mammals. Brucella spp. can exhibit a smooth or
rough phenotype; smooth Brucella spp. contain a surface-exposed O-polysaccharide in
their cell wall structure while the rough Brucella spp. are devoid of the O-polysaccharide.
Acquired immunity against Brucella infection is primarily cell-mediated and involves both
CD4+ T cells and CD8+ T cell responses. However, antibodies to the O-polysaccharide also
play a role in enhancing the protection against infections by virulent Brucella species in
some hosts. B. abortus strain RB51 is a stable rough attenuated mutant which is used as a
licensed live vaccine for bovine brucellosis in the United States and several other countries.
Previous studies have shown that the wboA gene, which encodes a glycosyltransferase
required for the synthesis of O-polysaccharide in Brucella, is disrupted in B. abortus RB51
by an IS711 element. Although low-levels of intra-cytoplasmic O-polysaccharide were
produced when RB51 was complemented with a functional wboA gene (strain
RB51WboA), it did not result in a smooth phenotype. This suggests that mutations in
several genes of the O-polysaccharide biosynthesis pathway contribute to the rough
phenotype of RB51. However, nucleotide sequence analysis has revealed that there are no
other gene-disrupting mutations that could affect the smooth LPS synthesis in strain RB51.
The first part of the study was undertaken to investigate whether overexpression of two
other glycosyltransferases, WbkA and WbkE, in strain RB51 would result in the expression
of O-polysaccharide and restore the smooth phenotype. No O-polysaccharide expression
was detected on overexpression of wbkA or wbkE in RB51. However, wbkA overexpression
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(strain RB51WbkA) leads to the development of extremely mucoid bacterial colonies that
form clumps/strings in liquid culture. This mucoid phenotype is attributed to the production
of exopolysaccharide(s) containing mannose, galactose, N-acetylglucosamine and Nacetylgalactosamine. The clumping RB51WbkA strain exhibited increased adherence to
polystyrene matrices; however, it was similar to strain RB51 in its attenuation characteristic
and conferred a similar level of protection against virulent B. abortus 2308 as strain RB51.
The second part of the study was carried out to determine whether increasing the amount
of bactoprenol primed molecules in strain RB51WboA would lead to the expression of
higher levels of O-polysaccharide and confer it a smooth phenotype. We generated strain
RB51WboAKF by overexpressing wbkF gene, which encodes

undecaprenyl-

glycosyltransferase involved in bactoprenol priming for subsequent O-polysaccharide
polymerization, in strain RB51WboA. Strain RB51WboAKF expressed high levels of Opolysaccharide and its Western blot reactivity profile with the O-polysaccharide-specific
monoclonal antibody was similar to that of the smooth Brucella strains. Immunoelectron
microscopy revealed that the O-polysaccharide was present mostly on the bacterial cell
surface. However, RB51WboAKF strain exhibited rough phenotypic characteristic in
acriflavine agglutination test. Although there was no difference between strains RB51 and
RB51WboAKF in their ability to persist in spleens of BALB/c mice, strain RB51WboAKF
was more resistant to the bactericidal effect of polymyxin B. Mice immunized with strain
RB51WboAKF developed increased levels of smooth LPS-specific serum antibodies,
primarily of IgG2a and IgG3 type, when compared with those immunized with strain
RB51WboA. Levels of serum IL-12p70, IFN-γ and IL-10 were higher in mice immunized
with strain RB51WboAKF when compared to the mice immunized with strain RB51.
Splenocytes from the RB51WboAKF vaccinated group of mice secreted higher levels of
antigen-specific IFN-γ, IL-10 and TNF-α when compared to those of the RB51 or
RB51WboA vaccinated groups. Also, increased numbers of antigen-specific IFN-γ
secreting CD4+ and CD8+ T lymphocytes were detected in RB51WboAKF immunized
mice. Importantly, immunization of mice with strain RB51WboAKF conferred greater
protection against virulent B. abortus 2308 and B. melitensis 16M than immunization with
RB51 or RB51WboA.
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Human brucellosis is one of the most frequently encountered zoonotic diseases worldwide.
It is a major public health concern in several developing, Brucella-endemic countries.
Occupational exposure and consumption of infected dairy and meat products are the main
routes for human infection. B. abortus, B. melitensis, and B. suis are the most frequent
causes of disease in humans. These Brucella spp. are considered as potential weapons of
biowarfare and are categorized by the CDC as Category B select agents. Emergence of new
foci of zoonotic Brucella spp. around the world has significantly changed the global map
of human brucellosis. Currently, there is no brucellosis vaccine available for use in humans.
Safety concerns preclude the use of live attenuated animal vaccine strains for human
vaccination.
The final part of the study was conducted to test the ability of orally inoculated gammairradiated strains B. neotomae and B. abortus RB51 in a prime-boost immunization
approach to induce mucosal as well as systemic protection against virulent B. abortus 2308.
Heterologous prime-boost vaccination regimens and homologous prime-boost vaccination
of mice with B. neotomae led to the production of serum and mucosal antibodies specific
to the smooth LPS. All oral vaccines induced antigen-specific CD4+ and CD8+ T cells
capable of secreting IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated
with B. neotomae showed the highest level of resistance against virulent B. abortus 2308
colonization in spleen and liver. Experiments with vaccination with different doses of B.
neotomae showed that all tested doses of 109, 1010 and 1011 CFU-equivalent conferred
significant protection against the intra-peritoneal challenge. However, only the highest
tested dose of 1011 CFU-equivalent of B. neotomae afforded protection against intranasal
challenge.
Overall,

the

present

research

discovered

that

gene

wbkA

is

involved

in

exopolysachharide(s) production in Brucella spp. and adds to the growing evidence for the
exopolysaccharide synthesis in Brucella. Also, our studies show that the vaccine efficacy
of strain RB51 can be enhanced by inducing high levels of O-polysaccharide expression;
the recombinant strain RB51WboAKF can be a more efficacious vaccine than its parent
strain in natural hosts of Brucella. Finally, our study demonstrates the feasibility of using
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gamma-irradiated B. neotomae as an effective and safe oral vaccine to induce mucosal and
systemic protection against brucellosis.

1

INTRODUCTION

Bacteria belonging to the genus Brucella are Gram-negative, facultative intracellular, nonmotile, non-encapsulated, non-spore forming aerobic coccobacilli that can cause
brucellosis in several mammals, including humans. Brucella species are transmitted by
direct contact with infected animal tissues and fluids or consumption of contaminated dairy
and meat products. In natural animal hosts, Brucella spp. primarily target tissues of the
reproductive tract and can cause abortion and infertility [1]. Till date, several species of
Brucella have been identified and are classified based on, primarily, their host preference.
Except for B. canis and B. ovis, all other Brucella species known to date possess an Opolysaccharide (O-PS) in their lipopolysaccharide (LPS) moiety and exhibit a smooth
colony phenotype. Rough strains that are devoid of the O-PS in their LPS are generally
attenuated than their smooth counterparts [2,3]. In the infected host, Brucella replicates
within the phagosomes of macrophage-monocyte lineage cells. Despite the intricacy of
microbicidal functions of professional phagocytes, Brucella possesses the ability to
circumvent host defense mechanisms and ultimately acquire a replication-permissive niche
by influencing the host intra-cellular vesicular pathway [4]. The ability of Brucella spp. to
persist within host tissues is critical as natural transmission of Brucella only occurs once
or twice annually during mating and parturition [5]. Interestingly, Brucella species lack
classical bacterial virulence factors such as exotoxins, capsules, flagella, fimbriae,
plasmids, lysogenic bacteriophages, antigenic variation and endotoxic LPS [6]. Instead,
Brucella expresses a set of virulence factors, including a non-classical LPS molecule,
which contribute to the establishment of chronic infections [4, 7]. Chapter 1 of this
dissertation includes a review of the virulence determinants of Brucella and how they
participate in its survival and trafficking within the host cells.
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According to the World Health Organization (WHO), brucellosis is one of the most
frequently encountered zoonosis worldwide [8]. Countries of the Mediterranean basin,
Middle East, Central Asia, South America and Africa have a high prevalence of brucellosis
[8]. Occupational exposure and consumption of contaminated food products are the main
routes of human infection. Most of the naturally occurring human infections are caused by
B. melitensis, B. abortus and B. suis. A few human brucellosis cases are caused by B. canis
that is associated with brucellosis in dogs [9]. Due to their highly infectious nature and ease
of aerosol spread, B. melitensis, B. suis and B. abortus are considered as potential
bioweapons and classified as Class B select agents by the Center for Disease Control
(CDC) [9]. Infected humans exhibit flu-like symptoms including general malaise, anorexia,
headache, myalgia, arthralgia, fever. If left untreated, the infection can lead to a chronic
disease and in rare cases complications like endocarditis, meningitis and spondylitis can
occur [9]. Successful treatment of human disease relies on a prolonged therapy with a
combination of antibiotics (usually an aminoglycoside or rifampicin and tetracycline);
however, relapses are common [10,11]. There is no brucellosis vaccine available for use in
humans.
Humans are dead-end hosts of Brucella; a reduction in animal brucellosis prevalence will
result in a substantially reduced number of human infections. Through concerted
comprehensive efforts, several countries including the United States, Canada and parts of
Europe have succeeded in controlling brucellosis in domestic livestock and are considered
to be ‘brucellosis-free’ [8]. However, there is a constant threat of Brucella re-introduction
due to spillback from wild life reservoirs. Also, worldwide emergence of new foci of
human brucellosis has made Brucella eradication difficult [12].

Human brucellosis

remains a major public health concern in several developing countries that still suffer with
a huge disease burden in animals and humans [13]. Due to differences in livestock
production systems as well as economic and social constraints, control measures that are
effective in developed countries may not be implementable in developing countries. For
this reason, vaccination is considered to be the most cost-effective intervention to control
disease spread and limit its severity [14]. Currently, live attenuated vaccines are used to
prevent brucellosis in livestock. Smooth strains B. melitensis Rev 1 and B. abortus S19 are
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used for vaccinating sheep and goats, and cattle, respectively [15,16]. However, these
strains exhibit some abortifacient potential in pregnant animals and are virulent for humans
[17]. A rough strain B. abortus RB51 is used as a licensed vaccine for cattle in the United
States and several other countries. It is a stable, attenuated, spontaneous mutant of the
virulent strain B. abortus 2308 [18]. Nevertheless, this vaccine is only 70% efficacious in
cattle and its efficacy in pigs, sheep and goats is questionable [19-21]. Safety concerns
preclude the use of these live attenuated strains for human use. A human vaccine would be
valuable as a means of direct intervention in areas where natural infections are very high
or in the event of deliberate misuse of Brucella as a bioweapon. Previously, numerous
attempts were made to vaccinate humans with live attenuated strains and ‘non-living’
subcellular fractions in the former USSR, China and France [22-24]. However, the use of
these vaccines was discontinued on account of safety issues and lack of substantial
evidence of their efficacy from large, well-controlled clinical trials [25]. A concise history
of human vaccination and strategies that need to be incorporated in any future efforts to
develop a safe and effective vaccine against human brucellosis are discussed in Chapter 2.
Despite the availability of live attenuated vaccines for ruminants, there is a need for
developing a new generation of improved vaccines. A safe vaccine that can provide longlasting protection in multiple animal species would be ideal for controlling brucellosis.
Several previous studies have demonstrated that exposure to an optimum dose of gammarays can enhance the safety of the current live Brucella vaccine strains by abolishing the
replicative ability of the bacteria [26-28]. Minimum exposure to gamma-rays creates
sufficient number of breaks in the genome that makes the bacteria unable to replicate but
still contain a large portion of the genomic nucleic acid intact for transcriptional and
translational activity [26-28]. This ensures the downstream effectiveness of elicited host
immune responses against the expressed proteins of the pathogen. Gamma-irradiated
vaccines are metabolically active [29]; metabolic activity is a potential pathogen-associated
molecular pattern (PAMP) that is associated with microbial viability (vita-PAMP) and is
exploited by the host defense system to differentiate viable pathogens from killed
pathogens [30]. vita-PAMP signal allows the host defense system to scale the level of
microbial threat and deploy a more robust immune response against viable organisms [31].
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Hence, while possessing the safety profile of killed vaccines, gamma-irradiated vaccines
are capable of inducing protection at levels comparable to live vaccination strategies [2628]. A review of the role of gamma-rays in the development of replication-deficient safer
vaccines that stimulate effective protection is presented in Chapter 3.
Cell-mediated immune responses play a major role in acquired immunity against Brucella.
In particular, IFN-γ-secreting CD4+ and CD8+ T lymphocytes are crucial for controlling
Brucella infection [32,33]. At least in certain animal species, O-PS-specific antibodies also
participate in protection against B. melitensis, B. abortus and B. suis infection [34-37]. In
contrast to smooth vaccines Rev 1 and S19, the rough vaccine strain RB51 does not induce
detectable levels of anti-O-PS antibodies in the vaccinated hosts [18]. Previous studies have
demonstrated that wboA gene, which encodes a glycosyltransferase required for O-PS
synthesis in Brucella, is disrupted by an IS711 element in strain RB51 [38]. Absence of OPS-specific antibodies prevent the development of cross-reacting immune responses in the
serodiagnostic assays that are used for distinguishing infected animals from vaccinated
animals (DIVA strategy). However, the absence of O-PS and the rough LPS make strain
RB51 more sensitive to complement-mediated lysis, limiting its persistence in the host and
vaccine efficacy [39,40]. Complementation of RB51 with a functional wboA gene (strain
RB51WboA) did not restore the smooth phenotype but resulted in low levels of
cytoplasmic O-PS expression [41]. When compared with strain RB51, immunization of
mice with RB51WboA resulted in a superior level of protection against virulent B. abortus
2308 and B. melitensis 16M [41,42]. Several genes in the wbk and wbo genetic loci are
shown to be essential for the O-PS synthesis in Brucella [2,3]. The objectives of the studies
in Chapters 4 and 5 were to enhance the vaccine efficacy of strain RB51 through
recombinant engineering to induce high levels of O-PS expression. To achieve this, we
overexpressed selected genes of the O-PS biosynthetic pathway in strain RB51 by
transforming RB51 with a multi copy plasmid containing the specific Brucella gene under
a strong synthetic promoter. We hypothesized that such recombinant vaccines would
possess enhanced protective efficacy when compared with strain RB51 due to their ability
to stimulate O-PS-specific antibodies in the vaccinated animals. Studies to determine
whether overexpression of two glycosyltransferases, WbkA and WbkE, in strain RB51
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would result in the synthesis of O-PS and confer it a smooth phenotype are described in
Chapter 4. The studies in Chapter 5 were carried out to determine whether increasing the
amount of bactoprenol priming precursor molecules in strain RB51WboA would increase
the level of O-PS expression and result in smooth phenotype of the recombinant bacteria.
For this purpose, we overexpressed wbkF, which is involved in priming bactoprenol for OPS polymerization [2,3], in strain RB51WboA. Also, the immunogenicity and the
protective efficacy of the constructed strain was evaluated in the mouse model of
brucellosis.
The studies in Chapter 6 were aimed at developing an oral vaccine against brucellosis for
use in humans. Brucella infection is generally acquired through mucosal routes; however,
human brucellosis is a systemic disease. Accordingly, it is important that an effective oral
vaccine should induce both mucosal and systemic immunity. Oral vaccines have proved
effective in providing protection against diseases like typhoid [43] and polio [44]. An
attenuated Salmonella enterica serovar Typhi strain, which is used as a licensed oral
vaccine against typhoid fever in humans, requires 4 doses to be taken at prescribed alternate
day intervals [45]. Using a similar empirical selection, experiments in Chapter 6 were
conducted to identify the optimum prime-boost vaccine-dose approach that would afford
the highest level of protection against parenteral as well as mucosal challenge with virulent
Brucella. Most research pertaining to prime-boost approach has been directed towards the
assessment of DNA vaccines, viruses or purified proteins as immunogens. However, it is
well accepted that vaccines that mimic the antigenicity of live infectious organisms have
greater likelihood to possess better protective efficacy as they would be able to stimulate
all facets of the immune system. Therefore, we used gamma-irradiated strains B. abortus
RB51 and B. neotomae in various prime-boost combinations and assessed the induction of
mucosal and systemic immunity. Previous studies have demonstrated that intra-peritoneal
(i.p) vaccination with gamma-irradiated RB51 or gamma-irradiated B. neotomae protects
mice against i.p challenge with virulent Brucella species [28,29]. In general, parenteral
vaccination strategies do not afford protection at mucosal surfaces [46]. We hypothesized
that oral delivery of gamma-irradiated Brucella strains would prime the host immune
system for subsequent mucosal as well as systemic recall responses leading to enhanced
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protection at both sites. Inducing a robust mucosal immunity would enhance resistance to
brucellosis by limiting bacterial invasion through the primary route of infection.
The final Chapter 7 summarizes the conclusions of the present research and discusses their
implications. Also, potential areas of future work are discussed. Overall, the present
research provides evidence that vaccination with recombinant Brucella abortus RB51
strain engineered to express increased levels of O-PS provides enhanced protection against
virulent Brucella challenge. Also, it demonstrates the feasibility of using gamma-irradiated
strain B. neotomae as an oral vaccine against parenteral as well as mucosal Brucella
infection.
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CHAPTER 1. BRUCELLA AND ITS VIRULENCE DETERMINANTS

Abstract

Members of the bacterial genus Brucella are facultative intracellular pathogens that reside
predominantly within macrophages of infected hosts. The capacity of Brucella to persist
within the phagosomes of macrophages is critical to their ability to produce chronic
infections in their mammalian hosts. Within macrophages, Brucella species regulate their
intracellular trafficking to avoid degradation along the endocytic pathway. A precise
sequence of programmed intracellular events allow Brucella to efficiently subvert host
defense mechanisms and create a niche that permits replication while protecting them from
microbicidal functions of host cells. This sophisticated lifestyle of Brucella is strongly
dependent on the expression of several bacterial factors that are crucial to its protracted
survival within the host system. In this chapter, we review the virulence determinants of
Brucella and how they contribute to its pathogenicity.

Introduction

Brucella genus belongs to the α-2 subclass of the Proteobacteria that also includes several
other phylogenetically related plant pathogens, symbionts and intracellular animal
pathogens such as Bartonella. Brucella spp. are Gram-negative, aerobic, non-motile,
nonsporulating, facultative intracellular coccobacilli that primarily replicate in the
monocyte-macrophage lineage of host cells. They are the causative agents of brucellosis,
a chronic disease of humans and several animal species. In pregnant animals, Brucella also
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replicates in placental trophoblasts leading to frequent contagious abortions [1].
Transmission of Brucella occurs through direct contact with contaminated aborted fetal
tissues or consumption of contaminated meat and dairy products. Human brucellosis is
strictly a zoonotic disease; the incidence of human disease is dependent on the prevalence
of animal brucellosis.
The genus Brucella is classified into several species based on their host preference. Natural
hosts for Brucella species are: cattle (B. abortus), sheep and goats (B. melitensis), swine
(B. suis), dogs (B. canis), rams (B. ovis), desert wood rats (B. neotomae), seals (B. ceti),
dolphins, porpoises and whales (B. pinnipedialis) and common voles (B. microti) [2]. More
recently, Brucella has been isolated from baboons (B. papionis), Australian rodents, and
an infected breast implant (B. inopinata) [3,4,5]. Due to their highly infectious nature and
the ease of aerosol spread, B. melitensis, B. suis, and B. abortus are considered as potential
biowarfare agents and are classified as Class B pathogens by the Centers of Disease Control
(CDC).
Brucella lacks the well-known classical bacterial virulence factors such as capsules,
exotoxins, lysogenic bacteriophages, plasmids, flagella, fimbriae, antigenic variation and
endotoxic LPS [6]. The virulence of Brucella relies on its ability to modulate its trafficking
within host cells to avoid the formation of a degradative phagolysosome. Bacterial factors,
such as lipopolysaccharide (LPS) [7], type IV secretion system (T4SS) [8], and the
BvrR/BvrS two-component system [9] are essential for the intracellular lifestyle of
Brucella and therefore, they are considered as virulence factors of these pathogens.
Although these virulence determinants may not directly mediate clinical symptoms of
brucellosis, they have been identified to be critical for Brucella to survive and replicate in
the vacuolar phagocytic compartment of macrophages. This chapter reviews the molecular
mechanisms underlying intracellular trafficking of Brucella and the virulence factors that
contribute to Brucella persistence.
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Invasion and intracellular trafficking of Brucella in phagocytic cells

Brucella are mostly transmitted through mucosal routes, especially at the respiratory and
the gastrointestinal surfaces. The bacteria are eventually taken up by phagocytic cells lying
underneath the submucosa. Previous studies have shown that macrophages ingest Brucella
through ‘zipper-like’ phagocytosis [10]. Opsonized Brucella are internalized via
complement or Fc receptors while non-opsonized smooth bacteria exploit lipid rafts and
some other unidentified receptors to enter macrophages [11,12,13]. Mechanism of cellinvasion is linked to bacterial fate; opsonized Brucella employ lipid raft-independent entry
and are preferentially degraded in macrophages [13].
Upon internalization, surviving bacteria are found within Brucella-containing vacuoles
(BCVs). The bacteria in BCV modulates the vesicle trafficking to reach endoplasmic
reticulum (ER)-derived vacuole which is the replicative niche for Brucella (Fig. 1.1).
During the first few minutes after cellular invasion, BCV undergoes a series of transient
interactions with components of the endosomal pathway. Interaction with early endosomes
is confirmed by the presence of early endosomal antigen 1 (EEA 1), transferrin receptor
and small GTP binding protein Rab5 in the BCV (Fig. 1.1) [14]. BCVs also interact with
late endosomes and lysosomes. These interactions are transient and occur prior to the
interactions of BCV with ER membranes and the formation of a replication-permissive
compartment. Presence of CD63, Rab7-interacting lysosomal protein (RILP), lysosomalassociated membrane protein 1 (LAMP-1) and small GTPase Rab7 in BCV is suggestive
of its interaction with late endosomes/lysosomes (Fig. 1.1) [15]. At this point, unlike killed
Brucella, live Brucella spp. limit interaction of their vacuoles with the lysosomes, possibly
to avoid accumulating degradative contents to bactericidal levels [15]. These vacuole
maturation steps take up to 12 hrs to be completed after which BCVs transform into ERderived replicative organelles. Sustained interaction of BCVs with ER leads to the
progressive loss of LAMP-1 and acquisition of ER-specific markers including calreticulin
(Fig. 1.1) [14,16,17].
The formation of ER-derived replicative organelle depends on the interaction of BCV with
specific components of the early secretory pathway [17]. The early secretory pathway is
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initiated at ER-exit sites (ERES), where transport vesicle formation is mediated by the coat
complex II (COPII). The organization and functionality of ERES domains are regulated by
small GTPase Sar1 [18]. Subsequent protein transport requires the activity of ADPribosylation factor 1 (ARF1) which recruits components of COPI to the ER membranes
[19]. A previous study by Celli et al. demonstrates that BCV interacts with ERES and
disruption of ERES by inhibiting Sar1 activity impairs Brucella replication; however,
inhibition of Arf1 activity had no effect on the ability of BCVs to mature into replicative
organelles [17].

Virulence factors of Brucella

Persistent infection is an adaptation that Brucella needs to evade the host defense system
until transmission can occur. Brucella spp. rely on several virulence factors that contribute
to disarming the host macrophages and ensuring Brucella survival. Knowledge of these
factors has significantly enhanced our understanding of how Brucella directs its
intracellular cycle to avoid the formation of phagolysosomes and acquire a replicationpermissive niche.

Lipopolysaccharide (LPS)

LPS of Brucella is composed of three components: lipid A, a core oligosaccharide and an
O-polysaccharide (O-PS). Lipid A forms the hydrophobic anchor of the LPS while O-PS
extends into the extracellular environment. LPS is one of the major virulence factors of
Brucella [7]. Based on the LPS structure, Brucella spp. can be separated into smooth and
rough strains. Smooth strains possess O-PS in their LPS moiety while strains that are
devoid of O-PS exhibit a rough phenotype. O-PS of Brucella confers serum and
complement resistance and it is also involved in protecting Brucella against microbicidal
phagocytic conditions [7]. Consequently, smooth forms are generally more virulent than
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their rough counterparts [20]. However, B. canis and B. ovis are rough species that are
virulent in their natural hosts [20].

Genetics of Brucella O-PS biosynthesis
The biosynthetic pathway of smooth LPS of Brucella has not yet been fully characterized.
However, several genes have been found to be essential for the synthesis of O-PS. These
genes are located on two genetic loci, wbk and wbo, of Brucella chromosome I (Fig. 1.2)
[21]. Region wbo contains two genes, wboA and wboB, encoding glycosyltransferases
while region wbk contains genes involved in synthesis of perosamine (gmd and per), its
formylation (wbkC) and polymerization (wbkA and wbkE), its translocation (wzm and wzt)
as well as those for bactoprenol priming (wbkD and wbkF) (Fig. 1.2) [21]. wbk also contains
genes encoding products that furnish the perosamine precursor, mannose [21]. Brucella OPS is first assembled onto bactoprenol phosphate on the cytoplasmic face of inner bacterial
membrane, following which it is translocated across the inner membrane. This
translocation event is mediated by an ATP-binding cassette (ABC) transporter system [20].
Mutations in genes that are required for the synthesis of perosamine or bactoprenol-P-PNAc-aminosugars also affect the synthesis of O-PS (Fig. 1.2) [20]. Using transposon
mutagenesis, Gonzales et al. demonstrated that mutations in 13 genes (wa**, wbkE, wbkA,
gmd, per, wzm, wbkF, wbkD, prm, ManBcore, wboA, wboB and manB) conferred a rough
phenotype to B. melitensis [20]. They also found that wboA and wboB genes are absent in
B. ovis genome contributing to its rough phenotype [20,21]. B. canis, on the other hand,
was found to have disruptions in wbkF (encodes undecaprenyl-glycosyltransferase) and
wbkD (encodes epimerase/dehydratase) genes, both of which are required for O-PS
synthesis [20,21].

Function of smooth LPS during Brucella infection
The LPS of Brucella is non-classical when compared with the classical LPS moiety of
enterobacterial species. The endotoxin component of Brucella LPS, lipid A, has several
distinct features that distinguish it from the lipid A of other Gram-negative bacteria.
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Brucella lipid A contains a diaminoglucose backbone (rather than glucosamine) and long
chain fatty acids C28 (instead of C18-C19) [22]. Due to the difference in lipid A
composition, Brucella LPS is several hundred times less toxic than E. coli LPS [23]. It is
a poor inducer of respiratory burst, reactive nitrogen intermediates as well as lysozyme
[24,25]. Also, it is poorly recognized by the innate immune sensor Toll-like receptor (TLR)
4 and it does not induce the secretion of pro-inflammatory cytokines by infected host cells,
thereby evading host immune responses [23]. The presence of long-chain fatty acids in
lipid A also contributes to the reduced activity of Brucella LPS in inducing inflammatory
responses [26]. Also, smooth Brucella LPS impairs host cells from activating Brucellaantigen-specific adaptive immune responses. It forms large clusters or macrodomains with
MHC-II and interferes with antigen presentation to host CD4+ T cells [27].
Smooth Brucella LPS also plays a role in lipid-raft mediated entry into host cells. Brucella
strains lacking O-PS enter macrophages in a lipid-raft independent manner and are targeted
to lysosomes for degradation [28]. The BCVs containing O-PS deficient strains fuse more
rapidly with lysosomes when compared with BCVs containing heat-killed smooth Brucella
[28], indicating that O-PS is essential for the intracellular trafficking of Brucella. It is
possible that Brucella is able to exploit a survival-permissive entry only when its O-PS
interacts with particular receptor(s) associated with lipid-rafts or alternatively, the O-PS
might modify the fusogenic properties of the BCV membrane [29].

Brucella Type IV secretion system (T4SS)

Type IV secretion systems (T4SS) are membrane-associated transporter complexes which
are closely related to bacterial conjugation systems. They are present in many Gramnegative bacteria including Agrobacterium tumefaciens, Legionella pneumophila and
Helicobacter pylori. T4SSs mediate the secretion of multimeric protein toxins, monomeric
proteins and nucleoprotein complexes. Hence, they are extremely versatile (unlike other
secretion systems) in the choice of the secreted substrate and also the target-cell types,
which can be bacteria (same/different species), fungi, plants or mammalian cells [30-32].
Apart from delivering a wide variety of substrates into the target host cells, T4SS can also

18
mediate DNA uptake and subsequent release into the extracellular milieu. Moreover, T4SS
is involved in the conjugative transfer of plasmid DNA and transposons into a variety of
bacterial species. This genetic exchange helps the bacteria to adapt to the changes in the
host during infection while the delivery of effectors into target cells aids in suppressing the
host defense system thereby allowing the bacteria to replicate and persist.

Architecture of Brucella T4SS
T4SS of Brucella is encoded by virB operon which consists of 12 genes: virB1 to virB12.
Brucella T4SS is not yet fully characterized; however, much has been inferred from the
similarity of Brucella VirB proteins to components of T4SS in bacteria like Agrobacterium
tumefaciens [8]. Proteins VirB8, VirB9 and VirB10 interact with each other to form the
core structure that spans the outer and inner membrane of bacterium [8,33-35]. VirB6 and
VirB7 might act to stabilize the core structure [36,37] while the ATPase, which consists of
VirB4 and VirB11, provides energy for the assembly of the T4SS as well as for the delivery
of effector proteins [38,39]. VirB2 and VirB5 form the pilus while VirB3 mediates the
assembly of the pilus [40]. The effectors are translocated to the eukaryotic target cell
through the pilus. Previous studies have shown that virB1, virB7 and virB12 are not
essential for the enhanced persistence of B. abortus [41-43]. The encoded proteins VirB1,
VirB7 and VirB12 do not contribute to the structure of the core complex or the pilus in any
bacteria containing the T4SS and might be dispensable for the function of T4SS [43,44].

Function of T4SS during Brucella infection
Brucella strains lacking a functional T4SS are attenuated in macrophages as well as in
laboratory and natural host animals [8,45,46]. Brucella virB mutants are incapable of
preventing the fusion of phagosomes with lysosomes and are gradually cleared from the
host [47]. Although phagosomes containing wild-type Brucella do transiently fuse with
early and late endosomes and lysosomes, they restrict this interaction to avoid the
formation of phagolysosomes and subsequent degradation [15]. This transient fusion with
the components of the endosomal pathway leads to acidification of the Brucella-containing
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phagosomes; acidification is essential for the induction of expression of the virB genes. It
has been observed that wild-type Brucella are able to rescue the survival of virB mutants
[48] indicating that T4SS-intact Brucella secrete effectors that are translocated into the
cells containing virB mutants.

Regulation of Brucella T4SS
virB T4SS is induced in acidic pH and also in nutrient restricted conditions [49,50]. Three
regulators are involved in the induction of T4SS under nutrient starvation. They include
the stringent response regulator Rsh, integration host factor (IHF) and the histidine
utilization regulator HutC [51,52]. Also, two LuxR family regulators, VjbR (Vacuolar
jacking Brucella regulator) and BabR (Brucella abortus regulator), modulate the
expression of virB genes [53,54]. Both VjbR and BabR control the expression of genes
involved in virulence, stress response, metabolism and replication; however, they act in the
opposite manner [54-56]. It is possible that the activity of these regulators helps Brucella
to adapt in nutrient-limitied conditions after host cell infection until the formation of an
ER-derived replication-permissive vacuole [14]. At this stage, VjbR is turned off while
BabR is activated [55]. BabR represses T4SS activity and enables Brucella to replicate in
the ER-derived vacuole [14].

Effectors translocated by Brucella T4SS
Unlike Bartonella, the genes encoding the effector molecules in Brucella are not co-located
with the virB genes [57]. Thus, identification of effector proteins translocated through the
T4SS in Brucella has been a formidable task. Till date, only a few effector proteins have
been identified.
The first two T4SS effectors identified were virB-coregulated effectors A and C (VceA and
VceC) [58]. These effectors were identified in a screen for VjbR-activated promoters of
genes that are co-regulated with virB genes. Translocation of VceA and VceC was found
to be dependent on VirB as demonstrated by generating fusions of the effectors to TEM-1
beta-lactamase. Translocation of these fusion proteins was detected starting at 7-9 hrs post-
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infection which is consistent with the time of phagosomal acidification and induction of
T4SS. Legionella pneumophila Dot/Icm system was also able to translocate B. suis VceC
indicating that the secretion mechanisms are conserved to some extent [58]. A more recent
study has shown that VceC induces ER stress and secretion of proinflammatory cytokines
[59].
Translocation of four other effector proteins (BPE123, BPE005, BPE275 and BPE043) was
found to be dependent on VirB T4SS [60]. They were identified by screening for proteins
for eukaryotic-like domains or domains that participate in protein-protein interactions [60].
Their intracellular functions are still unknown. Also, Rab2-interacting conserved protein
(RicA), another effector translocated by T4SS, was identified by a yeast two-hybrid
screening assay for Brucella proteins that potentially interact with host proteins [61]. RicA
binds preferentially to GDP-bound Rab2 and is involved in recruiting Rab2 GTPase to the
Brucella-containing phagosome. The recruitment of Rab2 to BCV is considered crucial for
the sustained interactions of Brucella with ER by intercepting secretory vesicles [61].
Hence, Rab2 is essential for the intracellular replication and trafficking of Brucella [62].
However, ricA deletion mutant is not attenuated in virulence even though blocking Rab2
leads to inhibition of intracellular replication of Brucella [61]. This indicates that several
additional proteins might play a redundant role in the serial recruitment of eukaryotic
factors during the maturation of the BCV.
More recently, the translocation of 5 effector proteins (BspA, BspB, BspC, BspE, BspF)
has been demonstrated to be dependent on VirB T4SS [63]. Among them, BspA, BspB and
BspF inhibit the host protein secretion by impairing the vesicular cargo transport from ER
to the Golgi apparatus [63]. Mutation in these three genes (bspA, bspB and bspF) affect the
ability to replicate and persist within host cells [63].

Quorum sensing in Brucella

Quorum sensing (QS) is the regulation of gene expression in response to small diffusible
chemical signaling molecules, autoinducers, which are produced and secreted by bacteria.
These autoinducers increase in concentration in response to changes in cell-population
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density. The detection of a minimal threshold concentration of these signaling molecules
leads to modulation in gene expression. This sensing system is used both by Gram-positive
as well as Gram-negative bacteria to regulate diverse processes including virulence,
biofilm formation, conjugation, and antibiotic production etc. In general, Gram-negative
bacteria use N-acyl homoserine lactone (AHL) to communicate, and Gram-positive
bacteria use processed oligo-peptides as autoinducing molecules [64]. The ability of the
bacteria to communicate with each other allows them to coordinate gene expression and
therefore the behavior of the overall population.
AHL based QS requires an AHL synthase and a target transcriptional regulator that can
recognize the AHL molecules and alter the expression of target genes. The autoinducer in
Brucella was identified to be N-dodecanoylhomoserine lactone (C12-HSL) in the
supernatants of B. melitensis culture [56,65]. However, the concentration of C12-HSL in
Brucella culture supernatant was found to be low. It might be that the in vivo AHL
production is much higher than in vitro production, or alternatively, the hydrophobic longchain AHLs interact with the Brucella membrane leading to a lowered concentration in the
culture supernatant. Attempts to identify an AHL synthase in Brucella have not yielded
any promising results.
Two bonafide QS regulators in Brucella are VjbR and BabR [53,54]. They both contain an
AHL binding domain as well as a C-terminal HTH (helix turn helix) DNA binding domain.
vjbR mutants are attenuated and unable to reach their ER-derived replicative vacuole [14].
As discussed above, VjbR is required for virB expression. Previous experiments have
demonstrated that addition of exogenous C12-HSL impairs Brucella trafficking to its
replicative vacuole. Also, C12-HSL decreases the production of VirB8 by repressing the
transcription from virB promoter. C12-HSL-mediated repression of virB genes is through
its inhibitory effect on VjbR [55,56]. In contrast, C12-HSL has an activating effect on BabR
[55,56]. Previous transcriptomic studies and qRT-PCR analysis suggest that there is crosstalk between VjbR and BabR; significant overlap exists between VjbR- and BabRregulated genes [55,56]. However, comparative studies indicate that the loss of VjbR has
a more pronounced effect on Brucella virulence when compared to the loss of BabR
suggesting that both these regulators are not functionally redundant [54].
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The two-component BvrR/BvrS system in Brucella

Most prokaryotic signal transduction units consist of two components: a histidine kinase
that senses the environmental alterations and a response regulator protein. The histidine
protein kinase autophosphorylates at a conserved histidine residue creating a high energy
phosphoryl group that subsequently phosphorylates a conserved aspartate residue in the
response regulator protein. This phosphorylation induces activation of factors that interact
with specific DNA sequences to affect gene expression. In this way, two-component
systems control the response of bacteria to a number of stimuli that regulate important cell
functions including response to stress and virulence [66].
BvrR/BvrS (Bvr: Brucella virulence related) is one of the best characterized twocomponent system in Brucella. Mutants in this system are highly attenuated and sensitive
to the bactericidal action of polycations including polymyxin and also to non-immune
human and cattle sera. The bvrS mutant is unable to recruit the small GTPases that are
required for polymerization of actin and subsequent cell invasion [67]. The BvrR/BvrS
system also regulates intracellular trafficking of Brucella as the mutant strains are
incapable of replicating in macrophages and epithelial cells; they are unable to avoid the
formation of phagolysosomes and are cleared from the host in less than 12 days [68].
Numerous genes are subject to BvrR/BvrS regulation: some examples include genes
encoding specific outer membrane proteins (Omp3a and Omp3b), lipoproteins,
glycosyltransferases, ABC-type transport system, genes required for biosynthesis of fatty
acids and flagellum, genes involved in the Krebs cycle and metabolism of amino acids,
fatty acids and nitrogen [9,69]. All these genes are differentially expressed in the bvrR
mutant. Also, seven transcriptional regulators including VjbR are differentially regulated
in the bvrR mutant. BvrR/BvrS system regulates the expression of VirB at the
transcriptional level and also directly controls the vjbR expression [70]. Hence, BvrR/BvrS
is a master system that interacts with other regulators to alter the expression of genes
involved in synthesis of the cell envelope, metabolism and virulence-related genes and
potentially benefits Brucella spp. in successful adaptation to their intracellular lifestyle.
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Other virulence factors that contribute to Brucella survival and replication

Brucella resistance to the microbicidal activity of phagosomes
Several virulence factors of Brucella are involved in enhancing the resistance to the
microbicidal host defenses. Microbicidal function of professional phagocytes relies in part
on the reactive oxygen species (ROS) which are generated either directly or indirectly by
NOX2 NADPH oxidase. Superoxide is released within the phagosomal lumen when the
active oxidase transfers the electrons from cytosolic NADPH to O2 [71]. Dismutation of
superoxide can lead to the formation of H2O2 which in turn reacts with superoxide to
generate hydroxyl radicals and singlet oxygen [72]. Similar to ROS, reactive nitrogen
species (RNS) are also important microbicidal effectors. Within the phagosomal
compartment, nitric oxide can undergo a spontaneous or catalytic conversion into RNS
such as nitrogen dioxide, peroxynitrite, dinitrogen trioxide and nitrosothiols [73]. These
RNS and ROS can interact with a variety of microbial targets like nucleic acids, protein
tyrosine residues, thiols, and lipids [74] ultimately resulting in inhibition of microbial
replication.
Phagocytes also secrete a set of proteins that either prevent the growth of the pathogen or
compromise the microbial membrane integrity. For example, scavengers can directly limit
the availability of essential nutrients to prevent microbial growth. Also, phagosomal
membranes can acquire various transporters. As an example, natural resistance-associated
macrophage protein 1 (NRAMP1) can be recruited to the phagosomal membrane from late
endosomes and lysosomes. NRAMP1 exerts a bacteriostatic effect on pathogens by
exclusive extrusion of divalent cations from the phagosomal lumen [75]. Phagosomes can
also disrupt the integrity of pathogens by the action of defensins, lysozymes, proteases and
lipases. Defensins induce membrane permeabilization of bacteria by binding to negatively
charged molecules on the pathogen surface and forming ion-permeable channels [76].
Despite the presence of these microbicidal host factors, Brucella spp. can survive inside
host cells. They have evolved various strategies to counteract host defenses. Brucella spp.
possess enzymes that can either directly detoxify the ROS or repair the oxidative damage
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to cellular components. Among them, superoxide dismutases (SODs) are a family of
metalloenzymes that can dismutate superoxide into H2O2 and O2 and protect Brucella from
the oxidative burst of macrophages [77]. Two enzymes, catalase (encoded by katA) and the
alkyl hydroperoxide reductase (encoded by ahpC and ahpD) have a role in protection from
H2O2 [78,79]. Peroxiredoxin AhpC scavenges endogenous H2O2 that is generated by
aerobic respiration while KatE detoxifies the supraphysiologic levels of H2O2 [78,79].
Brucella can also avoid oxidative damage indirectly. Cytochrome bd ubiquinol oxidase
and cbb3-type cytochrome c oxidases prevent ROS toxicity by scavenging O2 [80]. They
are involved in adaptation of Brucella to oxygen-limiting conditions [80]. Brucella also
expresses exonuclease III, encoded by xthA, which removes the oxidative lesions from the
bacterial DNA [81]. This base excision repair system has been found to protect Brucella
from oxidative damage in vitro [81]. For resistance to nitrosative damage, Brucella
expresses nitric oxide reductase (norD) which detoxifies NO and enhances intracellular
bacterial survival [82].
Brucella is inherently more resistant to the action of microbicidal cationic peptides due to
the structure of its non-canonical LPS. Brucella LPS is a poor inducer of respiratory burst,
reactive nitrogen intermediates as well as lysozyme (as discussed earlier) [24,25]. It also
protects the bacteria against a variety of cationic peptides such as defensins, lactoferrin,
lysozyme, bactenecin-derived peptides [83]. This resistance is partly due to the reduced
number of phosphate groups in the lipid A moiety which facilitate a close aggregation of
LPS molecules via their hydrophobic fatty acids, thereby reducing the penetration by
cationic peptides [7,83,84].
Following entry in phagocytes, Brucella needs to adapt under nutrient-deprived
intracellular environment to survive. This physiological adaptation is in part facilitated by
the stringent response mediator Rsh [52]. Rsh deletion mutants exhibit altered cellular
morphology and reduced survival under starvation conditions in vitro and in vivo [52].
Also, Rsh participates indirectly in the VirB-mediated formation of the ER-derived
replicative niche for Brucella [52]. Under iron-deprived conditions, Brucella is capable of
scavenging and storing iron. There is a link between the production of siderophores and
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the survival of Brucella in the presence of erythritol under iron-limiting conditions in vitro
[85]; however, the role of siderophores in virulence is not clearly understood.
Brucella spp. also inhibit apoptosis of the infected host macrophages [86] which is likely
a strategy exploited by Brucella to survive intracellularly and evade host adaptive
responses. The precise mechanism by which Brucella spp. inhibit host cell apoptosis is not
clearly understood; previous studies provide valuable insights into possible mechanisms
for inhibition of apoptosis. Brucella downregulates mitochondrion-associated proapoptotic
genes [87] and upregulates the expression of anti-apoptotic factors [86]. Further, a recent
study shows that Brucella infection results in calcium-dependent degradation of the
protease calpain2, and subsequent prevention of caspase 3 (apoptotic effector) activation
[88]. Brucella mutants lacking the O-PS fail to inhibit apoptosis [89] indicating that O-PS
of Brucella plays a crucial role in infection-induced inhibition of apoptosis.

Table 1.1 briefly summarizes the virulence factors of Brucella and their roles in enhancing
the survival of Brucella.

Concluding remarks

Brucella spp. employ several strategies to deceive the host and survive in host cells for a
considerable time. This is important as Brucella spp. have to persist within their hosts until
transmission occurs which in natural hosts is primarily via aborted fetal tissues, sexual
contact and shedding in milk. As some mammalian hosts of Brucella can only breed once
or twice annually, the capacity of Brucella to successfully survive intracellularly is critical
to their virulence [44]. Following cell invasion, Brucella spp. avoid the induction of an
aggressive inflammatory response and subsequently, regulate the trafficking of their
membrane-bound vacuole so as to avoid the fusion with lysosomes. Several virulence
factors of Brucella participate to promote its intracellular trafficking and persistence within
the host. Brucella also exploits some host defense mechanisms such as acidic pH and
nutrient limitation for the induction of genes that modulate its intracellular cycle. Recent
developments including the identification of the T4SS effector molecules and their
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functional characterization would further enhance our understanding of the molecular
complexity of Brucella adaptation during its coevolution with host animals.
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Table 1.1. Virulence determinants of Brucella and their functions.
Virulence factor

Gene

Function

Reference

Alkyl hydroperoxide

ahpC and ahpD

Scavenges endogenous H2O2

[79]

reductase

that is generated by aerobic
metabolism

Base excision repair

xthA

Protect Brucella from ROS

[81]

toxicity in vitro
Brucella virulence

bvfA

factor A

Induced by phagosomal

[90]

acidification and coregulated
with virB operon suggesting
a potential role in
establishment of a replicative
niche for Brucella

Catalase

katA

Protects from oxidative

[78]

intermediates including H2O2
and superoxide
Cu-Zn Superoxide

sodC

dismutase
Cyclic β-1,2-glucans

Protects from oxidative burst

[77]

of host macrophages
cgs - Cyclic β-

Mediate Brucella entry

1,2-glucan

through lipid-rafts and

synthetase

controls cellular trafficking

[91]

by preventing the fusion of
BCVs to lysosomes
Cytochrome oxidase

bd ubiquinol
oxidases
cbb3-type
cytochrome c
oxidases

Prevention of ROS toxicity

[80]
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Lipopolysaccharide

Several genes are Protects against cationic
involved in

peptides, respiratory burst of

smooth LPS

macrophages, and

biosynthesis

complement activity.

[7]

Prevents the induction of
pro-inflammatory cytokines
and impairs host adaptive
immune responses against
Brucella.
Nitric oxide

norD

reductase
Type IV secretion

[82]

damage
virB

system
Urease

Resistance to nitrosative

Effector translocation into

[58,60,63]

host cells
ure

Catalyzes the hydrolysis of
urea to ammonia facilitating
Brucella survival in acidic
conditions

[92]
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Figure 1.1. A revised model of Brucella intracellular trafficking. Following entry, Brucella
is found within BCVs. These BCVs traffic along the endocytic pathway, sequentially
interacting with early and late endosomes and lysosomes. Early BCVs interact with early
endosomes and transiently acquire EEA-1 and Rab5. They mature into intermediate BCVs
that transiently acquire LAMP-1 and Rab 7 and interact with ERES. Such interactions are
necessary for the formation of an ER-derived replicative organelle. Replicative BCVs
exclude LAMP-1 and acquire ER markers such as calreticulin, calnexin and sec61β. BCVs:
Brucella-containing vacuoles; EEA-1: early endosomal antigen-1; Lamp-1: lysosomalassociated membrane protein; ERES: endoplasmic reticulum exit sites.
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Figure 1.2. Genetic organization of the O-polysaccharide biosynthesis genes. The genes
required for O-polysaccharide synthesis are located on two loci, wbk and wbo. wbk region
contains genes coding for enzymes necessary for N-formylperosamine synthesis
(gmd, per, wbkC), O-PS glycosyltransferases (wbkE, wbkA), the ABC transporters
(wzm,wzt), the enzymes that lead to bactoprenol priming (wbkD, wbkF), as well as groups
of insertion sequences (ISs). wbo region contains genes coding for two O-PS
glycosyltransferases (wboA and wboB). Mutations in genes marked in dark brown generate
rough mutants.
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CHAPTER 2. DEVELOPING A VACCINE FOR HUMAN BRUCELLOSIS: WHY
AREN’T WE THERE YET?

Abstract

Brucella species are facultative intracellular coccobacilli that cause one of the most
frequently encountered zoonotic diseases worldwide. Most of the naturally occurring
human infections are mainly caused by B. melitensis, B. abortus and B. suis. These species
are classified as Center for Disease Control category B select agents. Brucellosis is
endemic in the Mediterranean basin, the Middle East, Central Asia, Central America and
parts of South America. If untreated, the infection can progress to a chronic phase that can
last from a few weeks to several years. Rare complications like endocarditis, meningitis
and spondylitis or death can occur. While treatment with a combination of antibiotics is
usually effective, relapses are fairly common. There is no licensed vaccine available for
use in humans. Safety concerns preclude the use of current live attenuated animal vaccines
for human vaccination. This review focuses on the need for a human brucellosis vaccine
and discusses strategies for the development of a safe and effective vaccine against human
brucellosis.

Introduction

Brucellosis is a chronic infectious disease that affects several mammals, including humans.
The first evidence of brucellosis in humans dates back to AD 79 as determined by bone
lesions characteristic of brucellosis found in human skeletal remains in Herculaneum [1].
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Cocco-bacillary forms, morphologically similar to the causative agent Brucella, were
found in the remnants of buried carbonized cheese [2]. However, it was not until 1886 that
Brucella was first isolated by Sir David Bruce from the spleen of a British soldier who had
died of a febrile illness (Malta fever) on the Mediterranean island of Malta, not far away
from Herculaneum [3]. The Roman name of Malta was ‘melita’ and hence the isolated
organism was initially named Micrococcus melitensis (now Brucella melitensis). Later on
in 1897, Bang’s bacillus (now Brucella abortus), the causative agent of cattle brucellosis,
was discovered by L.F Benhard Bang. The close homology of these two species was
demonstrated by Alice Evans of the Hygiene Laboratory of the U.S. Public Health Service
(now National Institutes of Health) in 1918 and the two species were regrouped under the
genus Brucella in honor of David Bruce [4,5]. Since then, several Brucella species have
been isolated from different mammalian hosts.
Brucella species are small, non-motile, non-spore forming, aerobic, facultative
intracellular Gram-negative coccobacilli. The species classification is mainly based on
their host preferences: B. abortus (found in cattle and buffalo), B. melitensis (sheep and
goats) B. suis (pigs), B. canis (dogs), B. ovis (rams), B. neotomae (desert wood rats), B.
cetaceae (whales, dolphins and porpoises), B. pinnipedialis ( seals and walruses), and B.
microti (voles) [6,7]. More recently, Brucella was isolated from a human breast implant
(B. inopinata) [8], Australian rodents [9] and from a baboon colony (B. papionis) [10]. In
infected animals, Brucella primarily targets the tissues of the reproductive tract leading to
contagious abortions and infertility. Most of the naturally occuring human infections are
caused by B. melitensis, B. suis, B. abortus, and B. canis in decreasing order of virulence
[11]. Marine mammal Brucella spp. have also been isolated from humans; however, their
infectivity and degree of virulence for humans is still largely unknown [8,10,12].

Need for a human brucellosis vaccine

Brucellosis is one of the most frequently encountered zoonosis [13]. Humans get infected
from consumption of contaminated animal products or from direct exposure to
contaminated aborted tissues. Aborted fetal tissues can contain as many as 1010 organisms
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per cm3 of the tissue [14]. Many cases of human infection from unintentional, accidental
exposure to animal vaccines have also been reported [15]. At the site of entry, the bacteria
are ingested by resident phagocytes and carried to regional lymph nodes where they
multiply leading to bacteremia. Brucella primarily colonizes the monocytes and the
macrophages of the reticulo-endothelial system (RES) including spleen, liver and lymph
nodes and the reproductive system [11]. Human brucellosis is frequently misdiagnosed and
underreported due to the existence of non-specific flu-like symptoms. It initially presents
as a febrile illness with symptoms including undulant fever, general malaise, anorexia,
arthralgia, fatigue and headache [11]. Enteric symptoms like diarrhea, abdominal pain and
ulceration of Peyer’s patches have been reported in cases associated with ingestion of
Brucella [16,17]. Complications like spondylitis, arthritis, meningitis and encephalitis can
ensue depending on the internal organ involved [11]. Infective endocarditis is a rare
complication (1-2% of the cases) [18] that accounts for almost 80% of the deaths due to
brucellosis [19,20].
Brucellosis has been eradicated from the livestock population in many parts of the world
including the United States of America, Canada, Japan and Scandinavian and several other
countries in Europe [13,20]. However, Brucella in wildlife reservoirs poses a constant
threat to reemergence of the disease in food animals. As an example, B. abortus is prevalent
in wildlife reservoirs including bison and elk populations in the Greater Yellowstone Area;
almost 50% of the 4000 bison and high numbers of elks have been exposed or are infected
with B. abortus [15]. Brucellosis is highly prevalent in the Mediterranean basin, the Middle
East, Central Asia, Northern Africa, and Central and Southern parts of America [13,20].
Humans are dead-end, incidental hosts of Brucella and the disease incidence in humans is
strongly dependent on the prevalence of brucellosis in animals. As animals are the only
source of Brucella infection to humans, successful strategies to control the disease in
animals would eliminate the risk of infection to humans. In fact, the control of brucellosis
in domestic livestock by rigorous surveillance, vaccination and slaughter programs has
resulted in a paralleled decrease in human brucellosis cases [21,22]. However, the
developing nations still suffer under a huge disease burden of animal and human brucellosis
[23]. Eradication of Brucella in these countries is a formidable task. Strategies used for
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eradication of the disease in developed countries may not be implementable in these nations
for several reasons including differences in livestock production systems, social culture,
and the lack of veterinary infrastructure and financial resources. Currently, there is no safe
and effective vaccine against Brucella infection in humans. Successful treatment of
brucellosis relies on antibiotic regimens administered for a prolonged period of time.
However, previous studies have shown that, despite successful therapeutic interventions, a
significant number of clinically asymptomatic patients could still remain infected [24]. As
Brucella resides in intracellular niches, relatively secluded from antibiotics, it is not
surprising that relapses following antibiotic therapy are common [25,26].
A vaccine would be invaluable for controlling human disease in Brucella-endemic regions
and for protection of people at occupational hazard including animal handlers, farmers,
veterinarians, abattoir workers and lab personnel. Brucellosis is also one of the most
frequently reported laboratory-acquired infections [27]. An infectious dose of 10-100
organisms has been found to be sufficient to establish disease in hosts by the aerosol route
[14]. Due to their highly infectious nature and the ease of aerosol spread, B. melitensis, B.
suis and B. abortus are considered as potential bioweapons by the CDC and listed as Class
B select agents [28]. Also, Brucella is included in the National Institute of Allergy and
Infectious Disease’s Strategic Plan for Biodefense Research [29]. In fact, B. suis was the
first organism that was weaponized in 1954 by the United States Government in an attempt
to develop its offensive biowarfare. However, the United States officially terminated the
development of bioweapons in 1969. As of now, there is a renewed interest in developing
a vaccine as a means of direct intervention to protect the military troops and the public in
the event of bioterrorism. Human brucellosis is rarely fatal; however, it is a notoriously
debilitating disease that incapacitates a person [11] and causes substantial financial losses
in terms of medical care for infected people [30]. A previous study has assessed that $477.7
million dollars would be incurred in the event of an aerosol exposure of 100,000 people to
a bioterrorist attack [30]. This study provides economic justification for investing in
preparedness measures, including vaccine development, to combat any deliberate misuse
of Brucella as a bioweapon [30].
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Currently used animal vaccines

Currently, three live vaccines, B. abortus strains 19 and RB51 for cattle and B. melitensis
Rev 1 for sheep and goats, are used to control brucellosis [31,32]. However, strain 19 and
Rev 1 retain some pathogenicity while RB51 is only 70% effective in cattle and its efficacy
in pigs, sheep and goats is questionable [33-36]. None of the vaccines induce a lifelong
100% protection against the infection that is encountered in heavily infected herds/flocks.

B. abortus Strain 19 (S19)

This strain was isolated from milk of a Jersey cow in the early twentieth century. It is an
attenuated strain obtained spontaneously after the virulent B. abortus was maintained at
room temperature for one year [37]. It exhibits a phenotypic sensitivity to erythritol owing
to the deletion of a region of 702 bp encompassing erythritol catabolic genes [38]. This
strain has been used worldwide and has been instrumental in achieving a significant
reduction in the prevalence of brucellosis in cattle. The use of S19 was discontinued in
United States after the introduction of the rough strain RB51 in the mid-1990s. This vaccine
is still being used in several countries [39, 40]. One drawback of this vaccine is the
induction of anti-O-polysaccharide (O-PS) antibodies in the vaccinated animals. These
antibodies interfere in the diagnostic assays that are routinely used to detect infected
animals. The persistence of these antibodies is dependent on the age of the vaccinated
animal, the dose and the route of immunization. Vaccination of adult cattle with a standard
dose of 3×1010 CFU-equivalent of S19 induces antibodies that persist for upto 10-11
months post-vaccination [41,42]. Calfhood vaccination shortens the duration of antibody
persistence; however, a lower level of protection is induced in calves than in adults [31].
This strain is also associated with low abortifacient (approximately 5%) potential when
used for vaccinating pregnant animals [43,44]. When used in adults, it results in udder
infections in 2% of the animals which also shed the bacteria in milk [45,46]. Less
frequently, S19 vaccination results in the development of arthropathy [47]. S19 vaccine is
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virulent for humans; several cases of human disease have been due to accidental
inoculation of S19 vaccine [32,33,48].

B. melitensis Rev 1

B melitensis Rev 1 is a live attenuated strain developed in 1957 that has been successful in
preventing brucellosis in small ruminants [49]. It protects against both B. melitensis
infection in sheep and goats and B. ovis infection in rams [49,50]. Controlled studies show
that Rev 1 vaccination can induce high levels of immunity that can last longer than 4 years
in goats and for at least 2.5 years in sheep [49]. In spite of being attenuated when compared
with field strains, Rev 1 retains some virulence [51]. It is abortifacient and the abortion rate
can be as high as 80% if the animals are vaccinated in their second to third month of
pregnancy [49]. To avoid abortions, animals are vaccinated prior to the first gestation at 37 months of age. Also, conjunctival administration can substantially reduce the abortion
rate [52]. Rev 1 vaccine has been found to be of very low virulence in rams [53]. Being a
smooth strain, vaccination with Rev 1 results in induction of antibodies against the O-PS
that interfere with the serodiagnosis. Also, although rarely excreted in sheep milk, Rev 1
can be secreted in goat milk for several weeks to months posing a hazard for the farmers
[52]. Despite being attenuated in animals, Rev 1 is capable of infecting humans [54].

B. abortus RB51

B. abortus strain RB51 was licensed for use in cattle by Animal and Plant Health Inspection
Service (APHIS), U.S. Department of Agriculture (USDA), in February 1996 [55]. This
vaccine is being currently used in a number of countries including the United States. It
induces a good level of protection in cattle; however, its protective efficacy in swine, sheep
and goats is still unclear [33-36]. B. abortus RB51 is a genetically stable, live, attenuated,
spontaneous mutant of B. abortus 2308 obtained after repeated in vitro passages in the
presence of penicillin and rifampin [56]. The wboA gene, that encodes a
glycosyltransferase required for O-PS synthesis in Brucella, is disrupted by an IS711
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element in RB51 [57]. Although RB51 synthesizes low levels of M-like O-chain [58], it
does not induce any measurable amounts of anti-O-PS antibodies that might interfere in
smooth-LPS serological tests [59]. Also, it possesses low virulence and does not induce
abortions in the vaccinated animals [60]. RB51 affords a similar level of protection as S19
in cattle [61]; however, it is considered less virulent than S19 on the basis of results from
animal testing. Calves are generally vaccinated subcutaneously (SC) at 4-12 months of age
with a dose of 1-3.4×1010 organisms without adverse effects. A vaccine dose of 109
organisms can be safely used to vaccinate pregnant cattle via SC route without the
induction of abortions or placentitis [62]. Despite its efficacy in cattle, two major
drawbacks preclude its use for vaccination of humans. Firstly, accidental exposure of
humans to RB51 is known to cause local and systemic adverse reactions [55,63]; secondly,
RB51 is resistant to rifampin which is an effective antibiotic for treating brucellosis [56].
Although RB51 is genetically stable, the exact nature of mutations affecting its attenuation
characteristic is not known. Previous studies document that complementing strain RB51
with a functional wboA gene does not restore the smooth phenotype suggesting that
mutations in several genes might be contributing to its rough colony morphology and
attenuation [64].

History of vaccination of humans against brucellosis

Previously, numerous attempts have been made to vaccinate humans against brucellosis.
Formerly, a strain derived from Strain 19, Strain 19-BA, was used extensively during a
period extending from 1940-1960 to immunize at least 3 million people in the former
USSR [65]. People were vaccinated with 1×109 cells via skin scarification. It delivered
partial protection that did not result in long-lasting immunity and frequent reimmunizations were required. Local adverse reactions including hyperaemia and
induration were exhibited by 76% of the vaccinates while generalized symptoms like
headache, lethargy and fever occurred in 3 to 7% of the immunized people [65,66]. Also,
vaccination with 19-BA was associated with the appearance of variable degrees of
hypersensitivity reactions especially with repeated vaccinations [65,66]. A decline of 60%
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in acute human brucellosis cases during 1952-1958 was attributed to the use of 19-BA
vaccine [65,66].
Other live attenuated strains like B. abortus VA19 and B. abortus 104M were used in the
former USSR and China, respectively [67]. They were administered intradermally or in
aerosolized forms [67]. Severe adverse reactions were associated with their improper use
or use in sensitive individuals [67]. On account of safety issues, emphasis was shifted
towards non-living vaccines. Vaccines based on subcellular fractions including a
peptidoglycan fraction (PI) and an extracted protein-polysaccharide fraction (BCVBrucella chemical vaccine) were used in France and Russia, respectively [68]. PI was a
phenol-insoluble residue obtained from lipid-extracted B. melitensis M15 [69,70,71].
Subsequently, B. abortus S19 was used for developing PI. Two doses of PI at 2 week
interval were administered SC to high-risk populations including laboratory workers [69].
The vaccine was non-toxic and less reactogenic. Protection in vaccinates lasted for about
18-24 months [69,70]. Although PI was used as a vaccine against brucellosis for almost
two decades, conclusive evidence of its efficacy from controlled clinical trials does not
exist [72]. This vaccine is no longer in production.
Similarly, an acetic acid extracted protein-polysaccharide fraction of cell wall was
developed in USSR [73,74]. It was prepared from B. abortus strain 19-BA and was
administered via intra-muscular (IM) route in humans [73,74]. Studies involving the use of
75,000 vaccine doses in Kazakhstan indicated that the protective efficacy of BCV was
similar to that of strain 19-BA [73,75]. However, BCV was shown to have lower
reactogenicity than strain 19-BA [73,75]. The efficacy of this vaccine has not been
rigorously tested under controlled clinical trials [75].

Immune responses against Brucella

Immune response studies and gene expression patterns in mouse and macrophage cell lines
during Brucella infection have contributed significantly to our current knowledge about
immunity to Brucella. Both humoral [76-80] and cell-mediated responses [80,81]
participate in immunity against brucellosis. However, cell-mediated immunity (CMI) plays
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a major role in acquired resistance against Brucella infection [81]. Th1 type of immune
response is considered essential for clearing Brucella from mice [81-83]. Interferon- γ
(IFN-γ) is an important cytokine for resistance to Brucella infection. It is secreted by T
cells and natural killer (NK) cells and activates the bactericidal function of macrophages
by promoting the production of reactive oxygen intermediates, enhancing the production
of cytokines, and by inducing isotype switching to immunoglobulin (Ig)G2a and IgG3
[81,84]. Consequently, IFN-γ-knockout mice or mice lacking interferon regulatory factor
-1 (IRF-1) are unable to control Brucella and succumb to infection within 6 weeks [84,85].
Tumor necrosis factor-α (TNF-α) also plays a similar role of enhancing the bactericidal
activity of macrophages [86]. Previous studies document the role of interleukin-12 (IL-12)
in resistance against brucellosis; in a mouse model, depletion of IL-12 before Brucella
infection exacerbated the infection and enhanced the chronicity of the disease [87].
Both CD4+ and CD8+ T lymphocytes help to control Brucella infection as shown by
specific T cell depletion experiments using T cell-specific monoclonal antibodies and also
by using gene knock-out mice [80,81]. Importantly, both cell populations are sources of
IFN-γ which helps to control the intracellular growth of Brucella [81]. Studies in human
primary cells have helped to identify some aspects of immune responses that are restricted
to humans. Gamma delta (γδ) T cells appear to play a role in brucellosis that is especially
prominent in humans. A human-specific population of γδ T cells (V γ9δ2) can kill B. suis-

infected cells by releasing microbicidal peptides [88]. γδ T cells might also exert their

protective effect in humans by release of IFN-γ and through cytotoxic activity [89]. Also,
previous studies showed that human natural killer (NK) cells can mediate killing of B. suisinfected cells in a contact-dependent manner [90]. While human NK cells play a role
against Brucella infection, murine NK cells are not important in controlling brucellosis
[91].
B. abortus infection also induces the production of IL-10 which inhibits the microbicidal
function of macrophages and antagonizes the activity of IFN-γ [92,93]. CD4+ T cells have
been identified as the major source of IL-10 during the early phase of Brucella infection.
A recent study demonstrates that mice lacking IL-10 are better able to control Brucella
infection. Also, blocking IL-10 production restricts the ability of Brucella to escape
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LAMP1+ late endosomes and replicate intracellularly thereby limiting the establishment of
chronic infection [94].
The significance of humoral immunity has been repeatedly demonstrated, both in murine
model of brucellosis as well as in natural hosts [76-80]. IgG2a and IgG3 are the dominant
antibody isotypes detected in infected mice and natural hosts, again emphasizing the
prominent role of Th1 immunity against brucellosis [95]. Passive transfer of anti-LPS sera
as well as B. abortus O-PS specific monoclonal antibodies protect mice against challenge
with virulent Brucella species [76, 78-80]. These antibodies presumably play a direct role
in opsonization; antibody-mediated opsonization enhances the phagocytic uptake and
intracellular killing of Brucella [96].

Strategies for optimizing the design of a brucellosis vaccine for use in humans

A major challenge for development of a vaccine against human brucellosis is the absence
of well-established correlates of protection. However, extensive studies with mouse models
have helped to identify definite indices of immune responses that are required for
protection against Brucella. An ideal brucellosis vaccine should be avirulent and effective,
and should be able to provide long-term protection, preferably with a single dose.

Vaccine safety and protective response

Historically, live attenuated vaccine candidates, including the vaccines currently in animal
use, have delivered the most promising results against Brucella infection [97]. Live
attenuated organisms mimic the infection caused by live pathogens and can deliver
multiple antigens for processing and presentation by dendritic cells (DCs) and
macrophages for stimulation of a robust immunity. However, lack of knowledge about the
molecular basis of attenuation as well as safety risks preclude the use of currently used
field vaccines in humans. Recent years have seen a considerable amount of research on the
identification of genes required for Brucella to successfully survive in the host and cause
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disease [98-100]. This knowledge can be exploited to design a safe and effective vaccine
by making the organism innocuous while still able to traffic within host cells and interact
with host components for induction of optimum protection. Inactivation of genes involved
in virulence and survival have yielded several promising Brucella attenuated strains [101104]. However, it is crucial that prospective vaccine candidates should not possess any
residual virulence. Such a vaccine design is often problematic as genetic mutations that
severely affect virulence may attenuate the organisms to levels where they are unable to
induce sufficient protection. Following a careful assessment of the residual virulence, the
attenuated candidates are evaluated for vaccine efficacy using laboratory animal models.
Previous studies have indicated that some level of persistence is essential for a vaccine to
stimulate an adaptive immune response [105-108]. Attenuated strains that undergo rapid
clearance are unable to produce sufficient protection. However, attenuated strains that
exhibit incomplete clearance from the host may be of questionable safety and might induce
symptoms of full-blown brucellosis. Only the vaccine candidates that meet the desired level
of attenuation and immunogenicity in mice can be evaluated rigorously for safety and
protective efficacy in non-human primates. It is also important to take into account the
genetic predispositions to potential side effects or that can influence vaccine
immunogenicity.
In the absence of identification of genes that can enhance persistence without
compromising safety, several alternate strategies such as encapsulation can be employed.
Encapsulation of highly attenuated organisms that are otherwise rapidly cleared can
enhance the immune responses and protection against pathogens by providing gradual
timed release of the vaccine (discussed later in section ‘Mucosal delivery of vaccines’).
Alternatively, attenuated strains that exhibit optimal persistence can be further subjected
to gamma-irradiation to enhance their safety by rendering them incapable of reverting to
virulence [109-113]. An optimal dose of gamma-rays can abolish the replicative ability of
organisms by creating sufficient number of breaks in the genomic DNA. Gamma-ray
attenuation of microbes leaves a large portion of the genomic nucleic acid intact for
transcriptional and translational activity. This ensures the downstream effectiveness of the
elicited immune responses against the expressed proteins of the pathogen. Several previous
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studies document that gamma-irradiated Brucella strains can induce potent protection [109,
111-113]. Gamma-irradiated strains are metabolically active; microbial metabolism is a
potential viability-associated PAMP (vita-PAMP) that helps the host system to
differentiate between live and killed microbes [114]. vita-PAMPs signal microbial viability
that is identified by the innate immune system and consequently, the host system can
perceive the level of threat and launch a proportionally potent adaptive immune response
against the invading pathogen [114]. Killed vaccines lack vita-PAMPs and are only weakly
immunogenic [115]. Hence, while being safe, gamma-ray-attenuated vaccines possess
comparable efficacy to live vaccines.
Another concept that assures a safe vaccine design is the ‘killed-but-metabolically-active’
(KBMA) approach. This approach has yielded several safe, potential vaccines for
pathogens such as Listeria monocytogenes, Salmonella Typhimurium, Leishmania
infantum, and Bacillus anthracis [116-119]. According to the KBMA concept, bacterial
strains are mutated in the nucleotide repair system to make them exceedingly sensitive to
DNA damage induced via ultraviolet (UV) light [116]. Consequently, these mutants can
be inactivated using a synthetic psoralen that causes pyrimidine residues to cross-link on
exposure to UV radiation. Organisms are unable to repair this psoralen-induced DNA
damage as they are mutated in the ABC excision endonuclease (excinuclease) complex that
mediates nucleotide excision repair [120]. These vaccines are safe and induce protection
in the vaccinated hosts [116-119].
With increasing awareness of vaccine-associated potential adverse effects, rigorous
controlled studies need to be undertaken to gather convincing evidence of vaccine safety
and enable vaccine acceptance. With this in mind, significant efforts have been focused on
the development of subunit and DNA vaccines. These vaccines are well-defined, nonviable
and unable to cause disease. However, subunit vaccines exhibit weak immunogenicity
mostly as a result of the difficulty to target them to appropriate tissues or to mimic the
intracellular trafficking pattern of live infectious pathogen and stimulate various facets of
the host defense system. The immunogenicity of the subunit vaccines can be potentiated
by inclusion of supplements that can enhance the overall vaccine efficacy. However, even
with the use of such immunopotentiators (adjuvants), the induced CMI response may not
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be robust enough to provide protection against Brucella infection (CpG adjuvants are
discussed in the next page).
Alternatively, DNA vaccination can generate both humoral and CMI in the vaccinated
subjects. DNA vaccines can induce major histocompatibility complex (MHC) class Irestricted responses and mimic the effects of live attenuated vaccines [121]. This feature is
advantageous when compared to conventional protein-based vaccines. Also, DNA
vaccines do not possess the inherent risk of potential bacterial reversion as seen with live
attenuated vaccines. DNA vaccines are biologically stable, their manufacturing is cost
effective and simple and they do not require cold-chain maintenance as they can be
transported in lyophilized form [121]. Previous studies have shown that DNA vaccines
encoding protective antigens such as lumazine synthase (BLS), outer membrane protein
(Omp) 31 and Cu, Zn superoxide dismutase (SOD) of Brucella provide protection against
virulent Brucella challenge in mice [122-124]; the level of protection induced is similar to
live attenuated reference vaccines used in these studies. This protection is attributed to the
production of antigen-specific humoral and CMI responses, primarily of Th1 type. DNA
vaccine design also allows for the inclusion of multiple protective antigens. Immunization
with a divalent vaccine encoding L7/L12 and Omp 16 or a trivalent vaccine encoding
L7/L12, BCSP31 and SOD confers protection at comparable levels to that induced by
licensed field vaccines [125,126].
One of the principal advantages of DNA vaccines is that they be easily tailored to induce
desired immune responses. Several complementary strategies to alter the qualitative and
quantitative aspects of immune responses and enhance the potency of DNA vaccines have
been developed. Genes encoding cytokines, chemokines and co-stimulatory molecules can
be incorporated in DNA vaccines to amplify the induced immune responses as well as
control the type of immunity. As an example, while a range of T-cell responses including
Th1, Th2 and cytotoxic T lymphocytes (CTLs) are induced using granulocyte/macrophage
colony-stimulating factor (GM-CSF), IL-12 primarily induces CTL responses [127]. Also,
a combination of cytokines can be administered for the synergistic stimulation of T-cell
polarized immunity. Previous studies document that a combination of GM-CSF, TNF-α
and IL-12 enhances the protective efficacy of a vaccine [128,129]. GM-CSF increases the
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number as well as function of DCs, while IL-12 and TNF-α upregulate the expression of
IL-12 receptor and IFN-γ [129]. Also, genes for co-stimulatory molecules can be
incorporated for maximizing the vaccine efficacy. A combination of IL-12 and B7-1 acts
synergistically and enhances both the antigen-specific T helper cell proliferation and CTL
responses [130,131]. Thus, cytokines and costimulatory DNA that can induce Th1-biased
immune responses can be exploited for potentially enhancing the vaccine efficacy against
brucellosis.
Alternatively, adjuvants can be used to induce relevant cytokines and to upregulate the
expression of co-stimulatory molecules leading to increased vaccine efficacy. In particular,
CpG oligodeoxynucleotide (ODN) is considered as one of the most promising adjuvant for
the development of improved vaccines against infectious diseases including brucellosis. It
can be used as an adjuvant in both antigen-based conventional vaccines as well as DNA
vaccines against brucellosis. ODNs are immunostimulatory DNA sequences containing
unmethylated CpG dinucleotide motifs that can directly activate human B-cells to
proliferate and differentiate into IgG producing B-cells [132]. They exert their effect as a
polyclonal activator via TLR9. Overall, CpG ODNs induce a cytokine profile that is
characteristic of Th1 type of immune response including higher production of IL-12 and
IFN-γ [133]. They enhance CD4+ T cells, CD8+ T cells and antibody responses to a variety
to pathogens including Brucella [134]. All the published protection studies with subunit
and DNA vaccines were conducted in mouse models; whether these vaccines perform
similarly in target host species remains to be tested.
Before any of these strategies can be effectively translated into applicable vaccine
technology, associated potential risks and long term ethical implications should be
carefully considered. As an example, one major drawback of using cytokine-encoding
plasmids is that they can persist in the host for months or years. The overproduction of one
type of effector cytokine can skew the balance of Th1 and Th2 immune responses, disrupt
the immune homeostasis and alter the host’s susceptibility to various infections. As
multicomponent vaccines become more common, the possibility for detrimental adverse
effects will also increase. Rigorous preclinical studies are needed to adequately establish
the safety of any future vaccine candidate.

56
Induction of immunity at mucosal surfaces

Most infectious agents infect humans via mucosal sites, principally the digestive and
respiratory tracts. Therefore, mucosal immunity constitutes a very critical part of overall
protective responses against the invading microbes. Vaccines that elicit robust immunity
at mucosal sites would prevent colonization of mucosal surfaces and enhance resistance by
limiting the entry of pathogens beyond the mucosa. However, most licensed vaccines are
administered parenterally and target the systemic immune system. They either elicit only a
weak mucosal response or altogether fail to induce protective mucosal immunity [135].
The understanding that mucosal vaccination is required to fortify defenses at mucosal sites
and protect against infections has renewed interest in the development of efficacious
mucosal vaccines. Mucosal immunization can induce the expression of mucosal and
systemic homing receptors in lymphocytes and can prime the host immune system for
subsequent mucosal as well as systemic recall responses leading to enhanced protection at
both sites. However, direct mucosal immunization is challenging; the vaccine dose that
actually enters the body cannot be accurately assessed due to the difficulty of capturing
and analyzing the functionality of mucosal antibodies as well as mucosal T cells [136].
Also, mucosal vaccines have to face a similar range of host innate defenses as mucosal
pathogens do such as the degradative lytic enzymes, epithelial barriers and mucus
secretions. Vaccines delivered via mucosal routes tend to become diluted in mucosal
secretions limiting effective deposition onto mucosal epithelium [136]. Also, they can
become stuck in mucus and subsequently degraded by proteases [136]. To overcome these
limitations, relatively large doses are required to stimulate immune responses when
compared to parenteral vaccination strategy [136].
Despite the complications associated with mucosal vaccination, there are some mucosal
vaccines that are approved for human use. Among those are the live attenuated poliovirus
and Salmonella typhi oral vaccines that are both derived from pathogens that exploit M cell
transport to invade the enteric lymphoid tissues [137-140]. The effectiveness of these live
vaccines is partly a result of their ability to mimic the mucosal invaders in adhering to
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mucosal surfaces, invading the organized mucosal lymphoid tissues and stimulating innate
and adaptive immune responses against the target pathogen [136].
Prevention of mucosal transmission should be a goal in developing an effective brucellosis
vaccine as Brucella is mainly transmitted by mucosal routes. However, as human
brucellosis is a systemic disease, an ideal vaccine should be able to induce both mucosal
as well as systemic protection. The choice of vaccination route is partly dependent on the
expected site of challenge. Human brucellosis is often acquired through aerosol route;
protection against inhalational challenge should be considered while evaluating the vaccine
efficacy of potential candidates for humans. Several Brucella investigators have
demonstrated the generation of enhanced protection against intra-nasal (IN) challenge
infection with virulent Brucella spp. in mice following IN and oral immunization with live
attenuated Brucella vaccines [113,141-143]. These results are extremely promising; future
studies need to focus on the strategies to overcome the physiological barriers at mucosal
routes, specific targeting of antigen-presenting cells (APCs) at inductive sites for immune
activation and modulating the kinetics of antigen delivery to promote long-lasting
protection. One promising approach of mucosal vaccination involves entrapping antigens
within synthetic polymeric particles designed to mimic immunogenic properties of natural
pathogens. These carriers can protect the antigens from degradation, selectively target them
to preferential sites of antigen uptake, and release the antigens slowly over a prolonged
period of time (discussed in ‘mucosal delivery of vaccines’).

Mucosal delivery of vaccines

Notable advances to improve the delivery of vaccines to mucosal inductive sites have
focused on the use of particulate systems. These include carrier particles like poly (lactide
co-glycolide) (PLG), liposomes, chitosan, virosomes, ISCOMs etc. for controlled-release
of antigens and also for eliminating the need for booster immunizations [144,145].
Particulate carriers prepared from PLG are one of the most widely used delivery platforms
for vaccines. They are biodegradable, biocompatible, and have previously been used as
suture materials and other controlled-release therapeutic drug delivery systems [146,147].
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Particulate delivery systems potentiate vaccine efficacy through the efficient uptake of the
antigen by the APCs and subsequent delivery to lymphoid tissues [148]. The encapsulated
antigen can be released in a pattern to maximize the elicited immune response by varying
the release kinetics of the particles. Optimum rate of antigen release would result in
extended antigen presentation to the host immune system [149] potentially allowing for a
single-shot vaccine formulation to induce long-lasting effective immunity.
One important determinant of efficient antigen uptake and its cellular trafficking as well as
immune stimulation is the size of the encapsulating particles. Particles of 20-200 nm induce
a Th1-biased immune response following receptor-mediated endocytosis while particles
>0.5 µm stimulate humoral immunity following uptake by phagocytosis or pinocytosis
[150]. Simultaneous administration of particles of distinct size distributions can be
exploited to release the antigen in a pulsed pattern analogous to primary and booster
immunizations. Following oral immunization, particles of 5 µm-10 µm are taken up by
Peyer’s patches and remain detectable for about 35 days [151]. In contrast, particles of <5
µm are found in draining lymph nodes and spleen [151]. Also, the surfaces of particles can
be tailored to enhance particle diffusion through the mucosa as well as transcytosis by M
cells [152]. Following mucosal entry, the infectious agents are delivered through the
intestinal Peyer’s Patch Follicle-Associated Epithelium (FAE) and Nasal Associated
Lymphoid Tissue (NALT) by the activity of M cells [153]. For efficient uptake, vaccine
particles should mimic M cell-invasive pathogens. Particles that are small (<1 µm) and
adherent to M cells are taken up efficiently and transported to Peyer’s patches. Ligands can
be exploited for targeting particles to M cells. However, only a limited number of receptors
and their ligands have been identified; most of them including pathogen recognition
receptors (PRRs) are expressed by both M cells as well as by enterocytes. Previous studies
have demonstrated that Ulex europaeus agglutinin 1 (UEA-1), a lectin specific for α-Lfucose residues, selectively binds to the apical surface of murine M cells [153]. Coating
particles with such ligands can increase the antigen uptake and transport to mucosal
inductive sites, thus enhancing the protective efficacy of vaccines [153]. Oral vaccination
with killed Helicobacter pylori and UEA-1 resulted in the induction of protection against
challenge infection [154]. The glycosylation pattern of M cells is species-restricted; it
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remains to be determined whether UEA-1 can be used to effectively target human M cells
[155].
One of the main advantages of particulate delivery for mucosal immunization is the
protection of the antigen from degradation by extracellular proteolytic enzymes. This
would help reduce the antigen dose that is required for immune activation especially
following oral immunization. Also, various immunopotentiators such as cytokines can be
codelivered with encapsulated antigens to selectively modulate and enhance the potency
of elicited immune responses. Many of the cytokines have a short half-life in vivo and cause
adverse effects if administered at high doses. Sustained release of cytokines following their
encapsulation serves to overcome these limitations.
Microparticle-delivery of Brucella holds potential to enhance the vaccine efficacy.
Microencapsulation of Brucella antigens has been successful in inducing potent immunity
in animal models [156-160]. Studies with Brucella have also demonstrated that
microencapsulated delivery of live attenuated Brucella results in the induction of sustained
antibody responses, a Th1-biased immunity and enhanced protection against challenge
when compared to non-encapsulated counterparts [156,158,160].
Hence, microencapsulation is an attractive alternative that can optimally exploit controlledsustained release and preferential targeting for the development of a protective human
brucellosis vaccine.

Differentiating vaccinated humans from infected humans

The differentiation of infected humans from vaccinated ones can be challenging; however,
it is advantageous for any future potential human vaccine to possess this capability.
Diagnostic methods for brucellosis are mainly based on serology and detect antibodies to
the O-PS of smooth LPS. Vaccination of hosts with rough strains prevents the development
of smooth LPS-specific antibodies; however, absence of O-PS makes the rough strains
more susceptible to complement-mediated lysis, limiting their persistence in the host and
vaccine efficacy [97]. At least in some animal species, these anti-O-PS antibodies play a
role in enhancing protection against infections with B. abortus, B. melitensis and B. suis
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[78-80]. In many cases, Brucella strains affected in their ability to produce smooth LPS are
unable to induce enhanced protection when compared with live smooth strains. Previous
studies have shown that inducing O-PS expression in strain RB51 by complementing it
with a functional wboA gene enhances its protective efficacy against virulent B. abortus
and B. melitensis challenge [64,161]. Efforts to induce O-PS expression in rough strains
that exhibit optimum persistence might yield a safe vaccine with enhanced efficacy. Also,
smooth strains attenuated in virulence can be assessed for their safety and vaccine efficacy.
Vaccine safety can also be enhanced by subjecting the engineered strains to gamma-rays
to render them non-replicative. However, the use of O-PS expressing Brucella strains as
vaccines will require the development of alternate diagnostic tests for distinguishing
infected hosts from vaccinated ones.
Previous studies have shown that several strategies can minimize the intensity and the
duration of the antibody responses against smooth LPS. These include reducing the vaccine
dose, vaccination via conjunctival route and vaccinating young hosts; however, these
approaches do not completely eliminate the possibility of serologic interference. Another
way is to create genetic markers by either heterologous expression of GFP or by deletion
of specific genes in vaccine strains to allow for the differentiation of vaccinated hosts from
infected hosts. Previous studies show that expression of a heterologous gene in Brucella
vaccine strain provides a marker to differentiate the vaccine from the wild-type Brucella
spp. [162]. The authors modified the O-PS of Brucella to produce a distinct immunogenic
epitope that does not react with the antibodies from naturally infected animals [162]. Such
novel approaches will permit the use of smooth LPS intact vaccines for stimulating robust
immune responses leading to a long-lasting protection.

Conclusions

An efficiently attenuated Brucella strain with improved stability and safety is required for
use as a human vaccine. However, the rational design of such a vaccine is impeded by our
current lack of understanding of the precise immune correlates of protection against
brucellosis. As such, an effective vaccine would need to engage multiple immune
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mechanisms and mimic natural pathogens, without inducing disease. Numerous strategies
can be exploited to enhance the safety and immunogenicity of the vaccine, influence the
quality of the elicited immune response and circumvent any inhibitory immune
mechanisms. Important challenges lie ahead: we would have to rely on animal models to
examine the efficacy of vaccine candidates as clinical challenge in humans would face
ethical objections. In the coming years, it is likely that a combination of several of the
approaches reviewed here will allow the development of a safe and effective vaccine for
human brucellosis.
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CHAPTER 3. GAMMA IRRADIATION: REPURPOSING AN OLD TOOL FOR
DEVELOPING SAFER VACCINES AGAINST INTRACELLULAR PATHOGENS

Abstract

Successful vaccination strategies attempt to mimic natural infection for induction of long
lasting immunity against infectious diseases. An effective vaccine should stimulate both
antibody-mediated and cell-mediated immune responses that are required to eliminate the
pathogen from the body. Observations till date indicate that vaccines containing live
organisms are far superior to the killed ones in inducing protective immunity. Live vaccines
induce a broad, robust cell-mediated immune response and a long-lasting immunological
memory. In fact, only live vaccine are effective against some infectious diseases such as
tuberculosis and brucellosis, which are caused by intracellular bacterial pathogens.
However, the replication potential of organisms in live vaccines poses a safety risk, at least
to some individuals in a population. Exposure to ionizing radiation has been used to
generate non-replicative but metabolically active microorganisms. While possessing the
safety profile of killed vaccines, irradiated vaccines retain sufficient metabolic activity to
initiate potent immune responses similar to that of live vaccines. This review focuses on
gamma-irradiation and its applicability as a promising technique for development of safer
and efficacious vaccines against intracellular pathogens.
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Introduction

Vaccination is the most efficient medical intervention employed till to date to reduce
infectious disease burden in animals and humans [1]. Since the advent of vaccination,
inactivation and attenuation of pathogens have been the most widely used strategies for
development of vaccines. Undoubtedly, live attenuated vaccines are more immunogenic
and induce longer lasting protective responses than vaccines based on inactivated forms.
However, there are inherent safety risks associated with the use of live vaccines; they often
retain some pathogenicity and can also revert back to being fully virulent. Empirical
attenuation, in instances where the molecular basis of attenuation is not known, is often
unreliable. Even in cases of rational attenuation, the live attenuated vaccines can cause
serious adverse effects, especially in immunocompromised subjects [2]. In contrast,
inactivated vaccines, although reliably safe, induce a weaker immunity that often does not
translate to long-lasting protection. Developing vaccines that are efficacious and yet
possess the safety profile of killed vaccines is highly desirable.
Ionizing radiation, such as X-rays and gamma-rays, can cause damage to cellular
components, and at sufficiently high enough doses can cause cell death. Gamma-rays have
higher energy than X-rays.

In aqueous conditions of biological materials, ionizing

radiation causes formation of reactive oxygen species (ROS) from water, and ROS cause
the damaging effects on DNA, proteins, and other cellular components. Exposure to
gamma-rays (gamma-irradiation) is a widely used technique for inactivation of pathogens
in food to avoid spoilage [3], sterilization of pharmaceuticals [4,5], medical/research
supplies and tissue/biological based products [6]. The Center for Biologics Evaluation and
Research of the United States Food and Drug Administration has approved gammairradiation for sterilization of plastic containers and diluents used in vaccine
manufacturing. Using ionizing radiation for developing vaccines dates back to 1936, when
Moore and Kersten reported the use of X-rays to inactivate Shigella dysenteriae [7].
Remarkably, studies conducted in 1950s with X-ray irradiation led to the development of
a commercial vaccine (Dictol) against Dictyocaulus viviparous, a nematode parasite of
cattle. The third stage larvae of D. viviparous were subjected to an optimal dose of X-rays
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such that their development halted at the fourth larval stage and they did not form adult
worms. Vaccination with the irradiated larvae induced host immunity and conferred
protection to cattle [8]. Since then, gamma-rays and other ionizing radiations have been
used for the development of viral, bacterial and parasitic vaccines [9-15]; however, the
specific benefits of irradiation in the development of safer vaccines for intracellular
pathogens are yet to be fully explored. Thirty six years ago, gamma-irradiation as a
technique for vaccine inactivation was illustrated in a murine model of Rickettsia [16,17].
The findings established that irradiated scrub typhus rickettsiae induced protection in mice
which was superior to that of formalin-killed vaccine. Subsequently, many studies have
demonstrated the use of gamma-rays for development of effective and safer vaccines. The
focus of this chapter is limited to discussing the benefits of gamma-irradiation as a
technique for developing safer vaccines, especially for intracellular pathogens.

Immune sensing of pathogen metabolic activity

The mammalian immune system has innate and adaptive components; together they
orchestrate to protect the host against microbial infections. Innate immune responses
influence the development of subsequent adaptive immunity to the pathogens through
recruitment and activation of antigen presenting cells (APCs).
APCs express pattern-recognition receptors (PRRs) which can bind with distinct microbial
components that are unique to microorganisms, often referred to as pathogen-associated
molecular patterns (PAMPs). The best known PRRs are Toll-like receptors (TLRs), but a
number of other cell surface and intracellular receptors are also involved in sensing the
presence of PAMPs. [18,19]. The rapid and effective sensing of PAMPs stimulates the host
immune responses via activation of complex signaling pathways leading to an
inflammatory response that subsequently assists in pathogen clearance [20]. Both live and
killed vaccines contain PAMPs (Table 3.1). However, live attenuated vaccines like typhoid
or tuberculosis vaccine induce a potent immune response that leads to long-lasting
protection when compared with vaccines that are based on killed organisms (Table 3.1).
This suggests that the host innate defense can sense the presence of live microorganisms
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and launch a more robust immune response against them. A recent study has demonstrated
that the host immune mechanisms can make a fine distinction between live and dead
microorganisms by sensing their viability itself [21].
The host immune system perceives a vaccine as being ‘live’ or ‘viable’ only if the vaccine
contains viability-associated PAMPs (vita-PAMPs) which are present in live microbes. In
case of bacteria, bacterial messenger RNA (mRNA) are an example of vita-PAMPs
associated with live bacteria [21]. Products of microbial metabolism such as bacterial
pyrophosphates and second messengers such as cyclic di-GMP are other potential vitaPAMPs that help the host system to differentiate between live and killed microbes [22].
Recognition of vita-PAMPs leads to inflammasome activation and pyroptosis. Previous
reports have documented that replication-unfit ‘killed-but-metabolically-active’ (KBMA)
bacteria are able to mount a robust immune response indicating that bacterial metabolic
activity by itself may be sufficient to produce vita-PAMPs [23].
Several previous studies reported that gamma-ray attenuated bacteria and parasites retain
their metabolic activity, though they lose their ability to replicate [11-13,24]. Gammairradiation leads to the generation of ROS that cause random double-strand disruptions in
the DNA [25,26]. The extent of the resulting DNA damage is dependent on the genome
size of the organism and is inversely related to the dose of the gamma-rays [27,28].
Exposure of vaccine organism to a minimum dose of gamma-radiation that causes
sufficient DNA fragmentation and abrogation of its replication capacity is an attractive
strategy for developing effective vaccines. Sufficient DNA fragmentation can overwhelm
the DNA repair machinery of the bacteria and abolish their ability to replicate but leave an
ample portion of the genome still intact to permit the organism to be metabolically active
and express genes de novo and consequently, synthesize proteins [11,13]. This would help
facilitate the recognition, processing and presentation of the antigenic repertoire by the host
defense system leading to the induction of protective immunity at levels comparable to live
vaccines. In addition to irradiation, other approaches based on genetic manipulation of the
organism were used for developing non-replicative but metabolically active vaccines [2932]. Such vaccines were also demonstrated to be effective in inducing robust immune
responses on par with live vaccines. Taken together, these findings suggest that retention
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of metabolic activity by the vaccine organisms is crucial for induction of effective
immunity. Future studies should focus on demonstrating the role of vita-PAMP recognition
in immunity induced by gamma-irradiated vaccines.

Maintaining structural, functional and epitope integrity

Unlike inactivation by heat or chemical treatment, gamma-irradiated organisms remain
structurally intact. Gamma-irradiation at a dose used in vaccine preparation does not cause
denaturation of structures and proteins. Structural integrity of the functional domains of the
microbe is crucial for effective antigen processing and the development of immunity
against natural infections. For example, gamma-ray inactivation of pathogenic viruses like
Lassa, Marburg and Ebola, renders the microbes non-infectious without affecting their
immunological activity [33]. Gamma-irradiated viruses retain the ability to induce
cytotoxic T cells [34-36]. These findings suggest that the irradiated virus can infect target
host cells, allowing natural and efficient uptake of antigens by APCs and major
histocompatibility complex I (MHC I) presentation of viral antigens for the induction of
cell-mediated immunity. Chemical inactivation methods, on the contrary, cause extensive
cross-linking of the microbial proteins [37], thereby compromising the epitope structure as
well as functionality. Gamma-irradiated Brucella do not lose their structural integrity even
after 48 hours of infection of macrophage cells [13] indicating that gamma-rays have no
residual adverse effect on the microbe structure, for at least upto 2 days post-infection.
Gamma-irradiated organisms also remain functionally intact. For example, gammairradiated Listeria retains the ability to escape into the cytosolic compartment and induce
robust immunity [12]. This is only possible if the gamma-irradiated Listeria expresses
listeriolysin O which mediates its escape into the cytosol. Similarly, gamma-irradiated
Brucella is able to direct its intracellular trafficking in a way to avoid degradation within
phagolysosomes [13]. This indicates that, while inside the macrophages, gamma-irradiated
Brucella can express proteins that are necessary for its modulation of the endocytic
pathway and its survival. Gamma-irradiated Toxoplasma gondii is capable of infecting
cells, thereby inducing robust Th-1 biased immune responses. It exhibits intact ability to
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synthesize proteins and even nucleic acids [38]. Hence, gamma-irradiated organisms are
able to express effectors that allow them to mimic the infection pattern of live pathogens
and influence the effectiveness of the elicited immune responses. This intact transcriptional
and translational activity confers enhanced immunogenicity to the gamma-irradiated
vaccines.

Inducing protective immune responses

Gamma-irradiated vaccines are capable of eliciting protection in vaccinated hosts (Table
3.2). Attenuation by gamma-rays has been used for the development of a cross-protective
experimental vaccine against influenza. The most commonly used influenza vaccines are
trivalent split or subunit vaccines that are strain-matched to the seasonal circulating strains.
These vaccines rely on the induction of strain-specific neutralizing antibodies. In contrast
to the strain-matched influenza vaccines, natural influenza infections induce
heterosubtypic immunity. Protection against heterosubtypic strains has been attributed
mainly to the development of cross-protective cytotoxic T cells against the virus-infected
cells. Generally, whole virus based vaccines are more immunogenic against influenza than
subunit or split-product vaccines which frequently require adjuvants and/or multiple
immunization regimens. Whole virus based vaccines activate the innate immune system
through TLR-7 which leads to Th1-biased favorable immune responses. Polley et. al. first
demonstrated the induction of serum neutralizing antibodies and protection against
homotypic strains by intra-peritoneal (i.p.) vaccination with a gamma-irradiated H1N1
virus [39]. Subsequently, many reports confirmed the ability of gamma-irradiated viruses
to afford homologous protection [40,41]. The cross-protective potential of gammairradiated influenza vaccines was first demonstrated by Mullbacher et. al. [36]. These cross
protective responses are believed to be mainly directed against the internal proteins, such
as the nucleoprotein, which are conserved among the influenza A strains [42]. Interestingly,
equivalent doses of formaldehyde treated or ultraviolet (UV) irradiated whole inactivated
virus preparations failed to induce cross-protective cytotoxic T cell responses [43].
Recently, a study showed that a single intra-nasal (i.n.) administration of gamma-irradiated
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H1N1 virus afforded protection against a lethal H5N1 avian influenza virus challenge and
other heterosubtypic influenza A infections [44]. Gamma Vaccines Pty Ltd, Australia, is
currently working towards the development of a universal gamma-irradiated influenza
vaccine (GammaFluTM) that would target both seasonal as well as pandemic markets.
Unlike with the live-attenuated vaccines, there is no risk of reassortment with the newly
emerging strains and reverting to a virulent form with gamma-irradiated influenza virus
vaccines.
Radiation attenuation has also contributed significantly to the efforts of developing a
vaccine against malaria. Since the 1970s, researchers have studied vaccination by the bite
of mosquitoes containing radiation-attenuated sporozoites of Plasmodium falciparum in
their salivary glands [45-48]. A recent study reported that this type of vaccination induced
protection in more than 90% of the human volunteers [49].

Conclusions and future directions:

Till date, vaccination strategies, particularly against intracellular microorganisms, have
delivered limited success. Regarding vaccine research, the bottleneck is likely to lie in the
extensive regulatory restrictions which prevent the translation of promising vaccine
research from preclinical trials to the relevant subjects on account of safety or efficacy
concerns. This translational block can be overcome by using techniques which render the
vaccinal microorganisms permanently non-replicative but still capable of inducing high
levels of immunity. Subjecting the vaccine to an optimum dose of gamma-irradiation
assures non-reversion to virulence and, consequently, the research is more likely to ease
into the phase of clinical investigation to establish the vaccine efficacy. In contrast to
rational attenuation, gamma-irradiation is an easily applicable method for broadly
inactivating a large batch of vaccine preparation. It is likely that using gamma-irradiation
will allow the development of a more effective and safer alternative to the classicattenuated and killed-pathogen vaccine, especially for chronic infections caused by
intracellular microorganisms. Gamma-irradiation can also be used for the rapid production
of safer vaccines in-bulk for emerging pathogens, such as new strains of influenza viruses
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and Ebola virus. The process of gamma-irradiation also eliminates the purification steps
and other cumbersome procedural drawbacks associated with inactivation methods that
employ chemicals. Moreover, it is a relatively inexpensive process that can be an attractive
and indispensable alternative for nations with limited resources. However, further research
is needed to establish the shelf-life and thermal stability of irradiated vaccines. Gammairradiation can also be combined with vaccine adjuvants and targeted molecular strategies,
such as deleterious gene mutations or inclusion of additional genes, in order to obtain the
desired immunogenic priming and enhanced protective immunity.
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Table 3.1. Differences between killed, gamma-irradiated and live vaccines.
Killed vaccines
PAMPs
vita-PAMPs
Replication
Reversion to
virulence
Gene expression
Immunogenicity
Duration of
immunity
Type of immunity
Adjuvant
Stability


X
X
X

Gamma-irradiated
vaccines


X
X

Live vaccines

X
weaker
short lasting


stronger
long lasting


stronger
long lasting

mostly antibody
mediated
required
good

antibody and cell
mediated
not required
good

antibody and cell
mediated
not required
requires constant
refrigeration
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Table 3.2. Induction of antigen-specific immune responses and protection by gammairradiated vaccines in the indicated host species.
Name of vaccinal
organism

GammaHost
irradiation species
dose
(Gy)*

Antigen
specific
immune
responses

Protective
response

Reference

Bacterial vaccines
Brucella abortus
RB51

3000

Mice

Brucella melitensis

3500

Mice

Brucella neotomae

3500

Mice

IgG, IgG2a,
IFN- γ

[11]
Vaccinated
mice showed
a 0.85 log
reduction in
splenic
bacterial load
following
challenge with
virulent
Brucella spp.
Cytotoxic T 1 log
[13]
cells
reduction in
bacterial load
in the spleen
was observed
against
challenge with
virulent
Brucella spp.
IgG1,
Vaccinated
[24]
IgG2a,
mice showed
IgG2b,
a 2-3 log
IgG3, IFN-γ reduction in
secreting
bacterial load
CD4+ and
in the spleen
+
CD8 T
following
cells
challenge with
virulent
Brucella spp.
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Leptospira
500
icterohemorrhagiae

Guinea
pigs

No
information

92% of the
vaccinated
guinea pigs
were
protected
against
infection.

[10]

Listeria
monocytogenes

6000

Mice

IFN-γ
secreting
CD4+ and
CD8+ T
cells

Salmonella
enterica var
Typhimurium
toxoid

40,000

Kuroiler No
birds
information

Vaccinated
[12]
mice showed
a 2 log
decrease in
splenic and
liver bacterial
load and 80%
vaccinated
animals were
protected
against lethal
challenge.
100% birds
[50]
were
protected
against
homologous
challenge.
100% and
83% birds
were
protected
against
challenge with
heterologous
strain through
oral and intraperitoneal
routes,
respectively.
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Parasitic vaccines
Fasciola gigantica
metacercariae

200

Calves

Neospora caninum

528

Mice

Plasmodium
falciparum
sporozoites

150

Schistosoma
japonicum

200

Theileria annulata
sporozoites

100-150

Toxoplasma gondii

200

No
information

88% reduction [51]
in worm
burden when
challenged
with 1000
cercariae.

IgG1,
100%
IgG2a, IFN- protection was
γ, IL-10
observed
against lethal
challenge
infection.
Humans No
More than
information 90% humans
protected
against
Malaria
Pigs
IgG
More than
95%
resistance to
infection was
observed.
Calves
No
100% calves
information protected
against
pathogenic
challenge.

Mice

IgG and
IFN-γ

Vaccinated
mice survived
longer than
naturally
infected
control mice.

[52]

[49]

[53]

[54]

[38]
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Trypanosoma
brucei

600

Cattle

IgG and
IgM

Vaccination
[55]
7
with 10
irradiated
trypanosomes
protected
against
challenge with
103
homologous
trypanosomes

Viral vaccines
Blue Tongue virus

60000

Sheep

Neutralizing Vaccinated
antibodies
sheep were
protected
against
infection.

Influenza virus

10,000

Mice

Venezuelan equine
encephalitis virus

50,000

Mice

[34] and
Vaccinated
[44]
mice were
protected
against
homologous
and
heterosubtypic
challenges,
including
challenge with
a H5N1 avian
virus strain.
Neutralizing More than
[14]
antibodies
80% of the
vaccinated
animals were
protected
against a
subcutaneous
challenge.
Neutralizing
antibodies
against
homologous
strain,
crossreactive
cytotoxic T
cells

*Gy (Gray) indicates the SI derived unit of absorbed dose of gamma rays.

[56]
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CHAPTER 4. OVEREXPRESSION OF BRUCELLA PUTATIVE
GLYCOSYLTRANSFERASE WBKA IN B. ABORTUS RB51 LEADS TO
PRODUCTION OF EXOPOLYSACCHARIDE

Abstract

Brucella spp. are Gram-negative, facultative intracellular bacteria that cause brucellosis in
mammals. Brucella strains containing the O-polysaccharide in their cell wall structure
exhibit a smooth phenotype whereas the strains devoid of the polysaccharide show rough
phenotype. B. abortus strain RB51 is a stable rough attenuated mutant which is used as a
licensed live vaccine for bovine brucellosis. Previous studies have shown that the wboA
gene, which encodes a glycosyltransferase required for the synthesis of O-polysaccharide,
is disrupted in B. abortus RB51 by an IS711 element. Although complementation of strain
RB51 with a functional wboA gene results in O-polysaccharide synthesis in the cytoplasm,
it does not result in a smooth phenotype. The aim of this study was to determine if
overexpression of Brucella WbkA or WbkE, putative glycosyltransferases essential for Opolysaccharide synthesis, in strain RB51 would result in the O-polysaccharide synthesis
and smooth phenotype. Here, we demonstrate that overexpression of wbkA or wbkE gene
in RB51 did not result in the O-polysaccharide expression as shown by Western blotting
with specific antibodies. However, wbkA, but not wbkE, overexpression led to the
development of a clumping phenotype and the production of exopolysaccharide(s)
containing mannose, galactose, N-acetylglucosamine and N-acetylgalactosamine.
Moreover, we found that the clumping recombinant strain displayed increased adhesion to
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polystyrene plates. The recombinant strain was similar to strain RB51 in its attenuation
characteristic and in its ability to induce protective immunity against virulent B. abortus
challenge in mice.

Introduction

Members of the genus Brucella are Gram-negative, facultative intracellular coccobacilli
that can cause chronic infections in several mammals, including humans. Based on the
structure of the lipopolysaccharide (LPS) molecule and the colony morphology, Brucella
spp. can be separated into smooth and rough phenotypes. Smooth colony morphology of
Brucella strains is determined by the presence of LPS containing the O-polysaccharide (OPS) in their cell wall structure. Brucella spp. with LPS that is devoid of the O-PS display
rough colony morphology. Based on the reactive specificities of antibodies, the O-PS of
Brucella smooth LPS is defined to contain A (for Abortus), M (for Melitensis) and C (for
Common) epitopes [1,2]. Brucella O-PS is a linear homopolymer of 4,6-dideoxy-4formamido-α-D-mannopyranosyl (perosamine) subunits connected in α-1,2 linkage in A-

dominant smooth Brucella strains, with every fifth residue connected in α-1,3 linkage in

M-dominant smooth Brucella strains [3,4]. The O-PS is an immunodominant antigen, and
infected animals usually develop robust antibodies to this antigen. Detection of anti-O-PS
antibodies in the body fluids is the basis for several brucellosis diagnostic assays. At least
in some animal species, anti-O-PS antibodies play a role in conferring enhanced protection
against infections by B. abortus, B. suis and B. melitensis [5-7]. The O-PS also acts as a
virulence factor by protecting the bacteria against complement-mediated lysis and the
intracellular bactericidal milieu of phagocytic cells [8]. Consequently, the smooth Brucella
strains are generally more virulent than their rough counterparts, which are typically
attenuated [9]. B. abortus RB51, a laboratory derived stable rough attenuated strain, is used
as a licensed live vaccine in the control of bovine brucellosis in the US and several other
countries. Strain RB51 does not produce detectable levels of O-PS, and animals vaccinated
with this strain do not develop anti-O-PS antibodies [10]. However, presence of low levels
of M-like O-PS was detected in this strain [11].
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The complete biosynthetic pathway of Brucella smooth LPS is yet to be determined.
However, several genes are known to be essential for the biosynthesis of the O-PS [12-14].
These genes are located in two loci, wbo and wbk, on the Brucella chromosome [13].
Genes encoding four putative glycosyltransferases, wboA, wboB, wbkA, and wbkE, were
identified to be involved in the polymerization of perosamine subunits leading to O-PS
production [12-14]. The precise role of these four enzymes in O-PS synthesis is not yet
established. In B. abortus RB51, the wboA gene is disrupted by an IS711 element [15].
Sequence analysis of the wbo and wbk loci of strain RB51 did not reveal any other genedisrupting mutations [16]. Complementation of strain RB51 with a functional wboA gene
(RB51WboA) did not restore smooth phenotype, but resulted in the production of low
levels of O-PS which remained in the cytoplasm [17]. In mouse models, strain RB51WboA
vaccination induced low titers of anti-O-PS antibodies and conferred superior protection
against virulent B. abortus and B. melitensis challenge [17,18].
The initial objective of this study was to determine if overexpression of wbkA or wbkE in
strain RB51 would lead to production of detectable levels of O-PS. We cloned each gene
in a multi-copy plasmid under a strong synthetic promoter and used the resulting plasmids
to transform strain RB51. Although we did not detect any O-PS production by the
recombinant strains, unexpectedly, the overexpression of wbkA, but not wbkE, in strain
RB51 led to the development of hypermucoid colonies and the production of
exopolysaccharide(s) (EPS) containing mannose, galactose, N-acetylglucosamine and Nacetylgalactosamine. The EPS producing strain was similar to strain RB51 in its attenuation
and vaccine efficacy characteristics.

Materials and methods

Bacterial strains

B. abortus strains RB51 and 2308 were from our culture collection. B. neotomae and
Pseudomonas were obtained from American Type Culture Collection. Generation of strain
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RB51WboA was described previously [17]. Escherichia coli strain DH5α (Invitrogen,
Carlsbad, CA) was used for the preparation of the necessary plasmid constructs. All
bacteria were grown in tryptic soy broth (TSB) or on tryptic soy agar (TSA) at 37°C.
Ampicillin at 100 µg/ml was used for growing bacteria harboring plasmids. All
experiments with virulent Brucella were performed in a BSL-3 facility approved for the
select agents work.

Generation of recombinant strains RB51WbkA and RB51WbkE

The wbkA and wbkE genes were amplified by PCR using custom-designed primer-pairs
and the genomic DNA of B. abortus 2308 as template. For the wbkA gene, the forward
primer (5’-TTTTCCATGGCTCCCTACGAATACATTTGCA-3’) and the reverse primer
(5’-TTTTTCTAGATTAATAGGTCATGAGCTTAGATTC-3’) contained Nco I and Xba I
restriction sites, respectively, at the 5’ ends. Similarly, for the wbkE gene, the forward
primer (5’-AAGCTTATGCCGCATCTGTATTGGAGA-3’) and the reverse primer (5’GGATCCTCACTGCATCAGCGACGTATA-3’) contained Hind III and Bam HI
restriction sites, respectively, at the 5’ ends. The amplified fragments were first cloned in
pGEM-T Easy plasmid (Promega, Madison, WI) and sequenced to confirm the integrity of
their nucleotide sequences. The inserts were subsequently excised from the pGEM-T
plasmids using the restriction enzymes specific to the respective restriction sites engineered
into the primers and cloned in the same sites of pBB4Trc plasmid. The resulting plasmids,
pBB4TrcWbkA and pBB4TrcWbkE, were electroporated into strain RB51 as per
previously described procedure [19] to generate strains RB51WbkA and RB51WbkE,
respectively.

Sample preparation for electron microscopy

Freshly grown cultures of strains RB51 and RB51WbkA were mixed with an equal volume
of stock buffer (0.1 M cacodylate buffer, pH 6.8) and incubated at room temperature for
10 mins. The bacterial cells were then pelleted by centrifugation and resuspended in
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primary fixative solution (2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M stock
buffer, pH 6.8). After 1 hr of incubation, the cells were washed 2 times by centrifugation
with the stock buffer, followed by a final washing with water. Secondary fixation of the
bacteria was performed for 1 hr in a solution containing 1% osmium oxide and 1.5%
potassium ferricyanide.

Scanning electron microscopy
After the secondary fixation, the bacterial cells were washed 2 times with water and filtered
using a nucleopore membrane (25mm diameter, 0.2 mm pore size, Corning corp., 45 Nagog
Park, Acton, MA). The bacterial cells were dehydrated using increasing concentrations of
ethanol and the samples were mounted using a double-side carbon tape and sputter coated
with platinum (Pt) for 60 secs prior to imaging. Images were obtained using FEI NOVA
nanoSEM (FEI Company, Portland OR) with 5kV accelerating voltage.

Transmission electron microscopy
After the secondary fixation, the bacterial cells were washed 2 times with water and
pelleted by centrifugation. Melted (45°C) agarose (1.5% w/v) was added to the tube and
the bacterial cells were gently dispersed while keeping the tube in warm water. The
dispersed bacterial cells and agarose mixture was cooled and extracted from the tube using
10% ethanol. Samples were then sliced and dehydrated using increasing concentrations of
ethanol. Propylene oxide (PO) was used for a final rinse. Infiltration was carried out with
1/3 Spurr’s resin (3 parts PO : 1 part resin) overnight, followed by further infiltration with
1/1 Spurr’s resin (1 part PO : 1 part resin), 3/1 Spurr’s resin (1 part PO : 3 parts resin)
overnight, and finally with 100% Spurr’s resin for 6 hrs in a rotator. The cells were then
embedded in a fresh Spurr’s resin and polymerized for 2 days at 60oC. Samples were
viewed under the FEI/Philips CM-10 transmission electron microscope (FEI Company,
Hillsboro, OR) using an accelerating voltage of 80 kV.
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SDS-PAGE and Western blotting

To detect O-PS expression and compare the protein profiles of RB51 and its recombinant
strains, SDS-PAGE and Western blot analyses were performed as previously described
[20]. As controls, antigen extracts of the strains RB51, RB51WboA and B. neotomae were
used. Briefly, antigen extracts of strains RB51, RB51WboA, RB51WbkA, RB51WbkE and
B. neotomae were separated on a 12.5% denaturing polyacrylamide gel by electrophoresis
and stained with Coomassie Brilliant Blue. For Western blotting, the separated antigens
were transferred onto a nitrocellulose membrane which was subsequently blocked with 5%
skim milk and reacted with an appropriately diluted rat monoclonal antibody specific to
Brucella O-PS [10]. The bound primary antibody was detected by reacting with horseradish
peroxidase labelled-secondary antibody (KPL, Gaithersbur, MD), and developing the
enzyme reaction using a colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD).

Exopolysaccharide (EPS) staining

Recombinant strain RB51WbkA and the strain RB51 were grown for 24 hrs at 37°C in
TSB with ampicillin and TSB alone, respectively. The bacteria were fixed with 4%
paraformaldehyde (PFA) for 20 mins and used for staining.

Calcofluor white staining
For detection of polysaccharides, the fixed cells were washed three times with phosphatebuffered saline (PBS) (pH 8.5) and resuspended in 100 µl of the same buffer. 10 µl of the
cell preparation was placed on a slide and one drop of calcofluor white stain (Fluorescent
whitener 28, Sigma) was added to the cells. A coverslip was placed over the sample and
the cells were visualized immediately using a Nikon A1R confocal laser scanning
microscope with a 60X 1.4 NA oil immersion objective.
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Lectin staining of EPS
Fluorescently labelled lectins (Vector laboratories Inc, Burlingame, California),
conjugated with tetramethylrhodamine isothiocyanate (TRITC), with different sugar
specificities (Table 4.1) were used to characterize the EPS composition. Fixed RB51 and
RB51WbkA bacterial cells were stained with TRITC-labelled lectins (20 µg/ml in PBS).
4',6-diamidino-2-phenylindole (DAPI) was used to counterstain the bacterial cells. After
an incubation for 30 mins in the dark at room temperature, the cells were washed three
times with PBS, resuspended in 100 µl of the same buffer, and examined immediately
using a Nikon A1R confocal laser scanning microscope with a 60X 1.4 NA oil immersion
objective.

Competitive inhibition assay

The sugars D-(+)-galactose, D-(+)-mannose, N-acetyl-D-galactosamine and N-acetyl-Dglucosamine (all from Sigma) were used to evaluate the carbohydrate binding specificities
of the selected lectins (see Table 4.1). The sugars at a final concentration of 3 mg/ml or
100 mg/ml were mixed with solutions containing specific lectins at a concentration of 20
µg/ml. The mixtures were incubated for 30 mins in dark at room temperature to allow the
sugars to bind with specific lectins. Each sugar plus lectin mixture was then used for
staining the bacterial cells as described above.

Microtiter plate attachment assay

The attachment assay was performed as previously described [21], with few changes.
Briefly, strain RB51WbkA was freshly grown overnight in 10 ml of TSB with antibiotic at
37°C. As controls, strain RB51 and Pseudomonas were grown overnight in 10 ml of TSB
at 37°C. 100 µl of the overnight cultures was transferred to 10 ml of TSB, mixed thoroughly
by vortexing, and a 200 µl of each resuspended culture was transferred to 8 wells in a 96well polystyrene plate (USA Scientific, Ocala, FL). The plates were incubated at 37°C for
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20 hrs. Then, the liquid medium was removed and the attached cells were washed with
sterile PBS (pH 7.4). Plates were air dried for 45 mins and each well was stained with 150
µl of 1% crystal violet solution (GRAM’S solution, Merck) in water for 45 mins. The wells
were then rinsed with water, air dried, and the bound stain was released by adding 200 µl
of 95% ethanol. 100 µl from each well was transferred to a new microtiter plate and the
intensity of the color was determined by reading the absorbance at 595 nm in a
spectrophotometer (Molecular devices, Sunnyvale, CA).

Survival of strain RB51WbkA in mice

Female BALB/c mice of 4 to 6 weeks of age were used. Groups of 9 mice were inoculated
with 2×108 CFU-equivalent of strains RB51 or RB51WbkA. At days 1, 7 and 21 post
inoculation (p.i.), 3 mice from each group were euthanized by CO2 asphyxiation followed
by cervical dislocation. The spleens were collected aseptically and the Brucella CFUs per
spleen were determined as previously described [10]. Briefly, the spleens were
homogenized in TSB and ten-fold serial dilutions of the homogenates were plated on TSA
plates for RB51 and TSA plates containing ampicillin for RB51WbkA. The bacterial CFUs
were enumerated.

Mice immunizations

Groups of 4 female BALB/c mice of 4 to 6 weeks of age were used for the study. Mice
were purchased from a commercial source (Harlan Laboratories, USA), and housed in
cages with microisolator tops at 4 mice per cage. Feed and water were provided ad libitum.
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%)
and room temperature (22oC). After 1 week of acclimatization, mice were administered
with vaccine or control formulation.
Mice were immunized by intraperitoneal (i.p.) inoculation at day 0 with 2×108 CFUequivalent of RB51 or RB51WbkA. Mice inoculated with saline served as control. Blood
was collected from the mice by puncturing the retro-orbital plexus under anesthesia at 3
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weeks and 6 weeks p.i. The serum was separated from the clotted blood and stored at 20°C until further use for the detection of antigen-specific antibodies by indirect enzymelinked immunosorbent assay (ELISA).

Indirect ELISA

Indirect ELISA was used to determine the levels of serum immunoglobulin G (IgG), as
well as IgG1, IgG2a, IgG2b and IgG3 isotypes with specificity to whole antigens of RB51
and RB51WbkA. Prior to coating the plates for ELISA, RB51 and RB51WbkA were heatkilled by incubating at 65°C for 1 hr. The antigens were diluted in carbonate buffer, pH
9.6, to a final concentration of 1×108 CFU-equivalent/ml. The wells of polystyrene plates
(Nunc-Immunoplate with maxisorp surface) were coated with the diluted antigens (100
µl/well). Following overnight incubation at 4°C, the plates were washed four times in wash
buffer (TBS at pH 7.4, 0.05% Tween 20) and blocked with 5% skim milk in TBS. After 1
hr of incubation at 37°C, mouse sera at 1 in 100 dilution in blocking buffer were added to
the wells (50 µl/well). Each serum sample was tested in duplicate wells. Following
incubation at room temperature for 4 hrs, the plates were washed four times in wash buffer
and appropriately diluted horseradish peroxidase-labeled anti-mouse isotype specific
conjugates (Southern Biotechnology Associates Inc, Birmingham, Alabama) were added
to the wells (50 µl/well). After further 1 hr incubation at room temperature, the plates were
washed four times, and 100 µl of substrate solution (TMB Microwell peroxidase substrate;
KPL, Gaithersburg, MD) was added to each well. After 20 mins, the enzyme reaction was
stopped by adding 100 µl of stop solution (0.185 M sulfuric acid) and the absorbance at
450 nm was recorded using microplate reader (Molecular devices, Sunnyvale, CA).

Protection experiment

Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was
approved for work with select agents. Female BALB/c mice of 4-6 weeks of age (Harlan
Laboratories, USA) were used for the studies. Mice were housed in individually ventilated
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cages with high-efficiency particulate arresting-filtered air. Feed and water were provided
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled
humidity (55%) and room temperature (22oC). After 1 week of acclimatization, mice were
administered with vaccine or control formulation.
Groups of four mice were vaccinated by i.p. inoculation with 2×109 CFU-equivalent of
RB51 or RB51WbkA. A group of mice inoculated with saline alone served as a control. 7
weeks p.i, each mouse was challenged by i.p. inoculation with 3×104 CFU-equivalent of
B. abortus 2308. 2 weeks post-challenge, the mice were euthanized and the bacterial
burden in their spleens was enumerated as previously described [10].

Statistical analyses

Absorbance values of ELISA were analyzed for differences among the groups by
performing analysis of variance with post hoc Bonferroni and Tukey for pair-wise
comparison using SPSS version 21.0 (SPSS Inc., an IBM company, USA). For protection
study, Student t-test modified for unequal variances between groups was performed to
compare the log transformed bacterial loads in spleens of mice from each vaccinated group
with the respective saline group. P values of <0.01 were considered significant.

Ethics statement

The protocols of the mice experiments performed in this study were approved by the
Institutional Animal Care and Use Committees at Purdue University (Approval #
1112000488) and Virginia Tech (Approval # CVM-10-048). The animal studies were
conducted in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from
the retro-orbital plexus from mice under anesthesia. For anesthetizing mice, regulated
concentration of anesthetic mixture (oxygen and isoflurane) was administered via a
commercially available rodent anesthesia machine (Vetamac, Inc., Rossville, Indiana).
Following blood collection, a drop of proparacaine hydrochloride ophthalmic solution
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(Bausch & Lomb, Tampa, Florida) was placed on the eye to reduce pain. Mice infected
with virulent B. abortus 2308 do not develop clinical disease or exhibit any signs of
suffering for the duration of the experiments conducted in this study. Therefore, no humane
endpoints were utilized for the mice in this study.

Results

B. abortus RB51 overexpressing wbkA gene displays a clumping phenotype

The colonies of strain RB51WbkA exhibited an excessively mucoid phenotype on agar
plates and when grown in liquid culture, the bacteria formed strings and clumps (Fig. 4.1B).
Strains RB51 (Fig. 4.1A) and RB51WbkE (data not shown), on the other hand, displayed
uniform dispersion in liquid culture. As a result of the strikingly distinctive phenotype of
strain RB51WbkA, several colonies were analyzed by RB51-specific PCR [15] and all of
them were confirmed to be derived from strain RB51 (data not shown). One colony was
selected for further studies.
Scanning and transmission electron microscopy were performed to examine the
morphology of the bacteria. Strain RB51 culture contained well-defined coccobacilli, with
relatively little or no visible extracellular material (Fig. 4.2A). In contrast, the recombinant
strain RB51WbkA displayed formation of aggregates (Fig. 4.2B, left panel) containing
bacterial cells and extraneous matrix material (Fig. 4.2B, left panel) characteristic of EPS.
The recombinant bacterial cells also displayed altered cell walls (Fig. 4.2B).

Overexpression of wbkA in the strain RB51 does not result in O-PS synthesis

The antigen extracts of strain RB51WbkA did not react with Bru-38, a Brucella O-PSspecific monoclonal antibody, indicating the absence of O-PS expression (Fig. 4.3A, lane
3). As expected, strain RB51WboA and B. neotomae reacted with the antibody (Fig. 4.3A,
lanes 5 and 6, respectively), while no reaction was detected with strain RB51 (Fig. 4.3A,
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lane 2). Strain RB51WbkE also did not react with the O-PS specific monoclonal antibody
(Fig. 4.3A, lane 4).
SDS-PAGE analysis did not reveal any apparent qualitative differences in the protein
profiles between strains RB51 and RB51WbkA (Fig. 4.3B).

RB51WbkA bacterial clumps contain EPS

Bacterial extracellular matrices are frequently composed of polysaccharides. Therefore, a
general EPS dye, calcofluor white, was used to determine the presence of EPS in the
aggregate-forming strain RB51WbkA. As shown in Fig. 4.4B, a bright fluorescence was
exhibited by strain RB51WbkA, indicating the presence of an extracellular polysaccharide
composed of (1-4)- and/or (1-3)-β-D-linked glucan residues. The dye failed to bind with
strain RB51 (Fig. 4.4A). The bacterial cells of strain RB51WbkA also bound with
mannose-specific-TRITC-labelled LCA (Fig. 4.5B), mannose-specific-TRITC-labelled
PSA (data not shown), galactose-specific-TRITC-labelled GSL I (data not shown), Nacetylglucosamine-specific-TRITC-labelled succinylated WGA (data not shown) and Nacetylgalactosamine-specific-TRITC-labelled

SJA

(Fig.

4.6B).

However,

strain

RB51WbkA did not demonstrate any apparent binding to the lectins PHA-E and PHA-L
(data not shown), which have specificity for complex polysaccharide structures. The
bacterial cells of strain RB51 exhibited very weak fluorescence with mannose-specificTRITC-labelled LCA (Fig. 4.5A) and PSA lectins (data not shown) when compared to
strain RB51WbkA. Also, strain RB51 did not show any apparent binding with any of the
other lectins tested, including TRITC-labelled SJA (Fig. 4.6A).

EPS produced by RB51WbkA contains mannose, galactose, N-acetylglucosamine and Nacetylgalactosamine

In order to verify the specific lectin-binding pattern of strain RB51WbkA, competitive
inhibition assay was carried out using 5 selected lectins (TRITC conjugated LCA, PSA,
WGA, SJA and GSL I). Carbohydrate inhibition of the binding of specific TRITC-labelled
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lectins to the EPS components was accomplished by using their respective target primary
sugars (Table 4.1). The inhibition of lectin binding was evaluated microscopically by
comparing the binding characteristic as well as the fluorescence intensity of strain
RB51WbkA in presence and absence of the target carbohydrate. The observed binding
pattern of the TRITC-labelled LCA and SJA are shown (Fig. 4.5 and 4.6, respectively).
Original binding pattern of the TRITC-labelled LCA and SJA to the EPS(s) of the strain
RB51WbkA in the absence of target carbohydrate is shown in Fig. 4.5B and 4.6B,
respectively. Binding of the TRITC-labelled lectins to the EPS(s) was completely
abrogated when the lectins were incubated with their target sugars at a concentration of
100 mg/ml (Fig. 4.5D and 4.6D). At carbohydrate concentrations of 3 mg/ml, the binding
of TRITC-labelled LCA (Fig. 4.5C), PSA (data not shown), WGA (data not shown) and
GSL I (data not shown) to the bacterial strain RB51WbkA was greatly reduced when
compared with the binding pattern in the absence of the target sugars (Fig. 4.5B). However,
at 3 mg/ml, N-acetylgalactosamine only slightly inhibited the binding of TRITC-labelled
SJA lectin to the EPS(s) produced by strain RB51WbkA (Fig. 4.6C).

RB51WbkA displays increased adhesion property

We assessed the ability of strain RB51WbkA to adhere to a 96-well polystyrene plate when
compared to strain RB51. Pseudomonas spp. was used as a positive control for this
adherence assay. Strain RB51WbkA displayed significantly increased adherence to
polystyrene wells when compared to strain RB51 (Fig. 4.7).

Bacterial persistence in mice spleens

Bacterial persistence of strain RB51WbkA in mouse spleens was determined and compared
with that of strain RB51. As shown in Fig. 4.8, similar numbers of bacteria were present in
the spleens of mice at days 1, 7 and 21 after inoculation with strains RB51WbkA and RB51.
This result suggests that overexpression of wbkA did not affect the clearance of the
recombinant RB51 strain in mice.
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Induction of antigen-specific antibody responses

Serum samples collected from the groups of mice immunized with strains RB51 and
RB51WbkA were analyzed in comparison with the sera obtained from the salineinoculated group of mice (Fig. 4.9 and 4.10). Analysis with IgG-specific conjugate
revealed that significantly higher level of RB51-specific IgG was present at 6 weeks p.i. in
mice vaccinated with RB51 and RB51WbkA when compared with saline-inoculated mice
(Fig. 4.9). Moreover, mice vaccinated with RB51 and RB51WbkA developed significantly
higher levels of IgG2a, IgG2b and IgG3 isotypes specific to RB51 at 3 and 6 weeks p.i.
when compared with saline-inoculated controls (Fig. 4.9). However, only vaccination with
strain RB51WbkA resulted in a significant increase in RB51-specific IgG1 antibody at 6
weeks p.i. (Fig. 4.9).
Significantly increased levels of RB51WbkA-specific IgG, IgG2a and IgG3 antibodies
were detected in serum of mice vaccinated with strains RB51 and RB51WbkA at 3 and 6
weeks p.i. than in saline-inoculated mice (Fig. 4.10). Moreover, mice vaccinated with
RB51WbkA developed significantly higher levels of RB51WbkA-specific IgG at 3 and 6
weeks p.i., as well as RB51WbkA-specific IgG2a at 6 weeks p.i., when compared with
RB51 vaccinated group of mice (Fig. 4.10). Only vaccination of mice with RB51WbkA
resulted in significantly increased levels of RB51WbkA-specific IgG1 at 3 and 6 weeks
p.i. when compared with the saline-inoculated mice (Fig. 4.10). Assay with IgG2b-specific
conjugate revealed that RB51WbkA-specific IgG2b antibody was present at significantly
higher levels in RB51 and RB51WbkA vaccinated groups of mice at 6 weeks p.i. when
compared to saline-inoculated controls. However, at 3 weeks p.i., only the mice vaccinated
with strain RB51WbkA developed significantly higher levels of RB51WbkA-specific
IgG2b antibody than the saline-inoculated group (Fig. 4.10).

Protection against challenge with virulent B abortus 2308

Mice vaccinated with RB51 and RB51WbkA had significantly reduced number of virulent
Brucella in their spleens when compared with the saline-inoculated group of mice (Fig.
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4.11). However, there was no statistical difference in the splenic bacterial loads between
the two vaccinated groups of mice.

Discussion

In this study, we unexpectedly discovered that overexpression of wbkA in strain RB51
confers an extreme mucoid and clumping phenotype that is associated with the production
of EPS. It is known that wbkA, which encodes a putative glycosyltransferase, is essential
for the O-PS and smooth LPS synthesis in B. abortus and B. melitensis [14]. However, the
present study is the first to demonstrate the role of this gene product in EPS production in
a Brucella strain. Till date, production of EPS was reported in certain recombinant geneknockout or gene-overexpression strains of B. melitensis [22-25]. B. melitensis strain
deficient in transcriptional regulator VjbR, which is involved in quorum sensing, was
shown to produce EPS-like substance [23]. Overexpression of AiiD, an enzyme that
degrades quorum sensing molecule acylhomoserine lactone (AHL), also leads to
production of EPS in B. melitensis [24]. Interestingly, overexpression of MucR, an
orthologue of a Sinorhizobium meliloti transcriptional regulator of its succinoglycan EPS,
in B. melitensis resulted in clumping phenotype which is associated with EPS production
[22]. A study also showed that EPS production occurs in virB mutants of B. melitensis
[25]. Interestingly, overexpression of WbkA in strain VTRA1, a B. abortus wboA mutant
[26], also resulted in the development of mucoid colonies that formed strings in liquid
culture (result not shown). However, overexpression of WbkA in B. abortus 2308 resulted
in mucoid colonies on solid media but the bacteria did not form strings in liquid culture
(result not shown), suggesting the presence of some regulatory mechanism in the O-PS and
EPS synthetic pathways. Currently, it is not clearly known if Brucella produces EPS in
response to any natural environmental conditions or during the course of infection in
mammalian hosts. However, above mentioned studies document the genetic competence
of B. melitensis to produce EPS. Evidence for clumping phenotype and EPS production in
B. melitensis under certain hypertonic culture conditions [22], and in B. abortus under
microaerobic conditions [27] was also reported.
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Brucella belongs to the class Alphaproteobacteria; several members of the class
Alphaproteobacteria are known to produce EPS(s) during their life-cycle [28,29]. For
example, Sinorhizobium meliloti produces an EPS, succinoglycan, which is essential for
the expression of its full virulence including formation and invasion of nodules [28,30].
Interestingly, a family of glycosyltransferases was shown to be required for the synthesis
of succinoglycan by Sinorhizobium spp [31]. Similarly, Agrobacterium strains also
produce an EPS which is structurally identical to the succinoglycan EPS; however, it has
been found to be dispensable for the formation of crown gall tumors by Agrobacterium
tumefaciens [30]. The EPS produced by RB51WbkA increased the bacterial adherence to
plastic matrix, but it did not have an effect on the bacteria’s susceptibility to polymyxin B
killing and persistence in mice. This suggests that the EPS did not prevent the rough LPS
in the cell wall of RB51WbkA from external chemicals nor it was able to alter the
attenuation characteristic of the bacteria.
The structure of EPS produced by RB51WbkA still needs to be determined. However, the
qualitative results of our lectin binding studies indicate the presence of mannose, galactose,
N-acetylglucosamine and N-acetylgalactosamine in the EPS. This EPS composition is
similar to that reported for B. melitensis [24], where mannose was detected to be the
primary sugar in the EPS. Several of our attempts to purify the EPS from RB51WbkA
were unsuccessful. This could have been because of the molecular nature of the complexes
between EPS and rough LPS of RB51.

Any future studies should take this into

consideration for developing strategies for purification of EPS from RB51WbkA.
Two-component systems have been found to regulate the EPS formation in many plant
pathogenic bacteria, including Sinorhizobium meliloti [32,33]. These systems can sense the
specific bacterial requirements during pathogenesis and can subsequently regulate the
production of EPS. Global regulatory mechanisms, such as the two-component systems,
quorum sensing (QS), also fine-tune the synthesis and secretion of EPS, leading to an
increase in synthesis during nutritional stress and a decrease in EPS synthesis during
growth of cells under nutrient sufficient environment. A previous study has demonstrated
the formation of clumps in liquid culture by a vjbR mutant strain of B. melitensis [23].
Mutation in vjbR render the bacteria incapable of responding to the presence of AHL. One
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explanation of this phenomenon is that the bacteria are unable to regulate the vjbRdependent AHL-mediated repression of genes which are involved in clumping [23]. VjbR
was found to regulate the EPS synthesis and/or export, and also the production of several
outer membrane proteins (OMPs) [23]. Another study documented the induction of a
similar clumping phenotype by Brucella overexpressing AHL-acylase aiiD [24]. The
authors hypothesize that the overexpression of aiiD leads to the degradation of all of the
intrinsically synthesized AHLs, resulting in unbound VjbR regulators which activate the
expression of genes involved in clumping [24]. wbkA was found to be a QS-target using
proteomic and microarray analysis [34]. It is interesting that WbkA is the only
glycosyltransferase identified as a target of QS-regulators in the study. Further studies need
to be undertaken to investigate the role of the QS-regulators in modulating the expression
of wbkA under specific environmental conditions and the effect of gene-interplay on the
level of the EPS production.
Mice immunized with strain RB51WbkA appeared to develop antibodies to the EPS, as
significantly higher levels of IgG antibodies were detected to be specific to RB51WbkA
than RB51.

IgG1 and IgG2a were the prominent isotypes that contributed to this

difference. Nevertheless, both RB51 and RB51WbkA vaccines induced the same level of
protective response against the virulent B. abortus challenge, suggesting the minimal, if
any, role of EPS in modulating immune responses in mice.
In conclusion, our studies demonstrate that the overexpression of wbkA in RB51 results in
the production of EPS that confers increased adherence property to the polystyrene
surfaces. This EPS was found to contain mannose, galactose, N-acetylglucosamine and Nacetylgalactosamine. This finding adds to the growing evidence for the EPS synthesis in
Brucella. EPS has previously been shown to aid some bacteria to survive in a hostile
environment, evade the immune mechanism of the host, and adhere to the host cells
[35,36]. Further studies to identify the role of EPS in affecting the bacterial fitness under
different environmental conditions would help delineate the precise contribution of EPS to
the pathogenesis of Brucella.

116
References

[1]

Diaz, R., Jones, L. M., Leong, D., Wilson, J. B., 1968. Surface antigens of smooth
brucellae. J Bacteriol 96, 893-901.

[2]

Hurvell, B., Lindberg, A. A., 1973. Serological cross reactions between different
Brucella species and Yersinia enterocolitica. Acta Pathol Microbiol Scand Sect B
81, 113-119.

[3]

Bundle, D. R., Cherwonogrodzky, J. W., Perry, M. B., 1987. The structure of the
lipopolysaccharide O-chain (M antigen) and polysaccharide B produced by
Brucella melitensis 16 M. FEBS lett 216, 261-264.

[4]

Caroff, M., Bundle, D. R., Perry, M. B., Cherwonogrodzky, J. W., Duncan, J. R.,
1984. Antigenic S type lipopolysaccharide of Brucella abortus 1119-3. Infect
Immun 46, 384-388.

[5]

Vitry, M. A., Mambres, D. H., Trez, C. D., Akira, S., Ryffel, B., Letesson, J. J.,
Muraille, E., 2014. Humoral immunity and CD4+ Th1 cells are both necessary for
a fully protective immune response upon secondary infection with Brucella
melitensis. J Immunol 192, 3740-52.

[6]

Araya, L. N., Winter, A. J., 1990. Comparative protection of mice against virulent
and attenuated strains of Brucella abortus by passive transfer of immune T cells or
serum. Infect Immun 58, 254-256.

[7]

Ficht, T. A., Kahl-Mcdonagh, M. M., Arenas-Gamboa, A. M., Rice-Ficht, A. C.,
2009. Brucellosis: the case for live, attenuated vaccines. Vaccine 27, D40-D3.

[8]

Lapaque, N., Moriyon, I., Moreno, E., Gorvel, J. P., 2005. Brucella
lipopolysaccharide acts as a virulence factor. Curr Opin Microbiol 8, 60-66.

[9]

Allen, C. A., Adams, G. L., Ficht, T. A., 1998. Transposon-derived Brucella
abortus rough mutants are attenuated and exhibit reduced intracellular survival.
Infect Immun 66, 1008-1016.

[10]

Schurig, G. G., Roop II, R. M., Bagchi, T., Boyle, S., Buhrman, D., Sriranganathan,
N., 1991. Biological properties of RB51; a stable rough strain of Brucella abortus.
Vet Microbiol 28, 171-188.

117
[11]

Cloeckaert, A., Zygmunt, M. S., Guilloteau, L. A., 2002. Brucella abortus vaccine
strain RB51 produces low levels of M-like O-antigen. Vaccine 20, 1820-1822.

[12]

Godfroid, F., Cloeckaert, A., Taminiau, B., Danese, I., Tibor, A., De Bolle, X.,
Mertens, P., Letesson, J. J., 2000. Genetic organization of the lipopolysaccharide
O-antigen biosynthesis region of Brucella melitensis 16M (wbk). Res Microbiol
151, 655-668.

[13]

Zygmunt, M. S., Blasco, J. M., Letesson, J. J., Cloeckaert, A., Moriyn, I., 2009.
DNA polymorphism analysis of Brucella lipopolysaccharide genes reveals marked
differences in O-polysaccharide biosynthetic genes between smooth and rough
Brucella species and novel species-specific markers. BMC Microbiol 9, 92.

[14]

Gonzales, D., Grillo, M. J., De Miguel, M. J., Ali, T., Arce-Gorvel, V., Delrue, R.
M., Conde-Alvarez, R., Munoz, P., Lopez-Goni, I., Iriarte, M., Marin, C. M.,
Weintraub, A., Widmalm, G., Zygmunt, M., Letesson, J. J., Gorvel, J. P., Blasco,
J. M., Moriyon, I., 2008. Brucellosis vaccines: assessment of Brucella melitensis
lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis
and export. PLOS ONE 3, e2760.

[15]

Vemulapalli, R., McQuiston, R., Schurig, G. G., Sriranganathan, N., Halling, S. M.,
Boyle, S. M., 1999. Identification of an IS711 element interrupting the wboA gene
of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain
RB51 from other Brucella species and strains. Clin Diagn Lab Immun 6, 760-764.

[16]

Adone, R., Muscillo, M., La Rosa, G., Francia, M., Tarantino, M., 2011. Antigen,
immunologic and genetic characterization of rough strains B. abortus RB51, B.
melitensis B115 and B. melitensis B18. PLOS ONE 6, e24073.

[17]

Vemulapalli, R., He, Y., Buccolo, L. S., Boyle, S. M., Sriranganathan, N., Schurig,
G. G., 2000. Complementation of Brucella abortus RB51 with a functional wboA
gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in
rough phenotype and attenuation. Infect Immun 68, 3927-3932.

[18]

Vemulapalli, R., Contreras, A., Sanakkayala, N., Sriranganathan, N., Boyle, S. M.,
Schurig, G. G., 2004. Enhanced efficacy of recombinant Brucella abortus RB51
vaccines against B. melitensis infection in mice. Vet Microbiol 102, 237-245.

118
[19]

McQuiston, J. R., Schurig, G. G., Sriranganathan, N., Boyle, S. M., 1995.
Transformation of Brucella species with suicide and broad host-range plasmids.
Methods Mol Biol 47, 143-148.

[20]

Vemulapalli, R., Duncan, A. J., Boyle, S. M., Sriranganathan, N., Toth, T. E.,
Schurig, G. G., 1998. Cloning and sequencing of yajC and secD homologs of
Brucella abortus and demonstration of immune responses to YajC in mice
vaccinated with B. abortus RB51. Infect Immun 66, 5684-91.

[21]

Djordjevic, D., Wiedmann, M., McLandsborough, L. A., 2002. Microtiter plate
assay for assessment of Listeria monocytogenes biofilm formation. Appl Environ
Microbiol 68, 2950-2958.

[22]

Mirabella, A., Terwagne, M., Zygmunt, M. S., Cloeckaert, A., De Bolle, X.,
Letesson, J. J., 2013. Brucella melitensis MucR, an orthologue of Sinorhizobium
meliloti MucR, is involved in resistance to oxidative, detergent, and saline stresses
and cell envelope modifications. J Bacteriol 195, 453-65.

[23]

Uzureau, S., Godefroid, M., Deschamps, C., Lemaire, J., De Bolle, X., Letesson, J.
J., 2007. Mutations of the quorum sensing-dependent regulator VjbR lead to drastic
surface modifications in Brucella melitensis. J Bacteriol 189, 6035-6047.

[24]

Godefroid, M., Svensson, M. V., Cambier, P., Uzureau, S., Mirabella, A., De Bolle,
X., Cutsem, P. V., Widmalm, Letesson, J. J., 2010. Brucella melitensis 16M
produces a mannan and other extracellular matrix components typical of a biofilm.
FEMS Immunol Med Mic 59, 364-377.

[25]

Wang, Y., Chen, Z., Qiao, F., Zhong, Z., Xu, J., Wang, Z., Du, X., Qu, A., Yuan,
J., Jia, L., Song, H., Sun, Y., Huang, L., 2010. The type IV secretion system affects
the expression of Omp25/Omp31 and the outer membrane properties of Brucella
melitensis. FEMS Microbiol Lett 303, 92-100.

[26]

Winter, A. J., Schurig, G. G., Boyle, S. M., Sriranganathan, N., Bevins, J. S.,
Enright, F. M., Elzer, P. H., Kopec, J. D., 1996. Protection of BALB/c mice against
homologous and heterologous species of Brucella by rough strain vaccines derived
from Brucella melitensis and Brucella suis biovar 4. Am J Vet Res 57, 677-683.

119
[27]

Almiron, M. A., Roset, M. S., Sanjuan, N., 2013. The aggregation of Brucella
abortus occurs under microaerobic conditions and promotes desiccation tolerance
and biofilm formation. Open Microbiol J 7, 87-91.

[28]

Leigh, J. A., Signer, E. R., Walker, G. C., 1985. Exopolysaccharide-deficient
mutants of Rhizobium meliloti that form ineffective nodules. P Natl Acad Sci USA
82, 6231-6235.

[29]

Stredansky, M., Conti, E., 1999. Succinoglycan production by solid-state
fermentation with Agrobacterium tumefaciens. Appl Microbiol Biot 52, 332-337.

[30]

Leigh, J. A., Coplin, D. L., 1992. Exopolysaccharides in plant-bacterial
interactions. Annu Rev Microbiol 46, 307-346.

[31]

Glucksmann, A. M., Reuber, L. T., Walker, G. C., 1993. Family of glycosyl
transferases needed for the synthesis of succinoglycan by Rhizobium meliloti. J
Bacteriol 175, 7033-7044.

[32]

Cheng, H. P., Walker, G. C., 1998. Succinoglycan production by Rhizobium
meliloti is regulated through the ExoS-ChvI two-component regulatory system. J
Bacteriol 180, 20-26.

[33]

Skorupska, A., Janczarek, M., Marczak, M., Mazur, A., Krol, J., 2006. Rhizobial
exopolysaccharides: genetic control and symbiotic functions. Microb Cell Fact 5,
7.

[34]

Uzureau, S., Lemaire, J., Delaive, E., Dieu, M., Gaigneaux, A., Raes, M., De Bolle,
X., Letesson, J. J., 2010. Global analysis of quorum sensing targets in the
intracellular pathogen Brucella melitensis 16M. J Proteome Res 9, 3200-3217.

[35]

D’Haeze, W., Holsters, M., 2004. Surface polysaccharides enable bacteria to evade
plant immunity. Trends Microbiol 12, 555-561.

[36]

Zhu, M., Takenaka, S., Sato, M., Hoshino, E., 2001. Influence of starvation and
biofilm formation on acid resistance of Streptococcus mutans. Oral Microbiol
Immun 16, 24-27.

120
Table 4.1. Carbohydrate-binding specificities of lectins employed in this study for the
staining of EPS(s) produced by the recombinant strain RB51WbkA.

Lectin
Griffonia
simplicifolia lectin I
Lens culinaris
lectin
Phaseolus vulgaris
Erythroagglutinin

Phaseolus vulgaris
Leucoagglutinin
Pisum sativum
agglutinin
Wheat germ
agglutinin,
succinylated
Sophora japonica
agglutinin

Abbreviation

GSL I

LCA

Source
Griffonia simplicifolia
(Bandeiraea) seeds
Lens culinaris (lentil)
seeds

Primary sugar
specificity
Galactose

Mannose

Phaseolus vulgaris
PHA-E

(Red Kidney Bean)

Complex structures

seeds
Phaseolus vulgaris
PHA-L

(Red Kidney Bean)

Complex structures

seeds
PSA

Pisum sativum (Pea)
seeds

Succinylated

Triticum vulgaris

WGA

(wheat germ)
Sophora japonica

SJA

(Japanese
Pagoda Tree) seeds

Mannose

N-acetylglucosamine

Nacetylgalactosamine
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Figure 4.1. Observation of the clumping phenotype of the recombinant strain B. abortus
RB51WbkA. (A) B. abortus RB51; (B) strain B. abortus RB51 overexpressing the wbkA
gene.

Figure 4.2. Electron microscopic images of strain RB51WbkA. Scanning electron
micrographs (left panels; ×30,000) and transmission electron micrographs (right panels;
×15,000) of the strains (A) B. abortus RB51 and (B) B. abortus RB51WbkA. The
recombinant strain RB51WbkA displays a clumping phenotype and produces EPS(s).
Scanning electron micrograph show the clumping phenotype of the recombinant strain
RB51WbkA (B, left panel).
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Figure 4.3. (A) Western blot analysis to detect O-PS expression by the strain RB51WbkA
and (B) Coomassie Brilliant Blue staining of the polyacrylamide gel to detect difference in
the protein profiles of strain RB51 and strain RB51WbkA. Whole antigens of the strain
RB51, recombinant strain RB51WbkA, RB51WbkE, RB51WboA and B. neotomae were
separated by 12.5% SDS-PAGE and analyzed by (A) Western blotting with O-PS specific
monoclonal antibody, Bru-38. Lane 1: molecular weight marker (MW) in kilodaltons
(kDa); lane 2: strain RB51; lane 3: recombinant strain RB51WbkA; lane 4: recombinant
strain RB51WbkE; lane 5: recombinant strain RB51WboA; lane 6: strain B. neotomae.
Whole antigens of the strain RB51, RB51WbkA and RB51WbkE were analyzed for any
differences in the expressed protein profiles by (B) Coomassie Brilliant Blue staining of
polyacrylamide gel.
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Figure 4.4. Confocal microscopy of the EPS(s) produced by the recombinant strain
RB51WbkA. Interactions between the calcofluor white stain and the aggregates formed
by the strain RB51WbkA were visualized using confocal laser scanning microscopy. (A)
Strain RB51; (B) strain RB51WbkA. Selected differential interference contrast (DIC)
images (left panel) and fluorescent images (middle panel) merged are shown (right panel).
All images were acquired using the same settings and adjusted for display using the same
brightness/contrast settings.
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Figure 4.5. Confocal laser scanning microscopy showing the interactions between the
fluorescently labelled LCA lectin and the (A) strain RB51; (B, C & D) strain RB51WbkA.
Panel A and B show the bacterial cells stained with TRITC-labelled LCA lectin (red) in
the absence of the target carbohydrate. Panel C & D show the bacterial cells of the strain
RB51WbkA stained with TRITC-labelled LCA lectin preincubated with (C) 3mg/ml
mannose and (D) 100 mg/ml mannose, prior to staining. DAPI (blue) was used to stain the
bacterial nuclei. Selected differential interference contrast (DIC) images (left panel) and
fluorescent images (middle panels) merged are shown (right panel). All images were
acquired using the same settings and adjusted for display using the same
brightness/contrast settings.
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Figure 4.6. Confocal laser scanning microscopy showing the interactions between the
fluorescently labelled SJA lectin and the (A) strain RB51; (B, C & D) strain RB51WbkA.
Panel A and B show the bacterial cells stained with TRITC-labelled SJA lectin (red) in the
absence of the target carbohydrate. Panel C & D show the bacterial cells of the strain
RB51WbkA stained with TRITC-labelled SJA lectin preincubated with (C) 3mg/ml Nacetylgalactosamine and (D) 100 mg/ml N-acetylgalactosamine, prior to staining. DAPI
(blue) was used to stain the bacterial nuclei. Selected differential interference contrast
(DIC) images (left panel) and fluorescent images (middle panels) merged are shown (right
panel). All images were acquired using the same settings and adjusted for display using the
same brightness/contrast settings.
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Figure 4.7. Quantification of the microtiter plate adhesion assay of the recombinant strain
RB51WbkA. The surface attachment of the strain RB51, recombinant strain RB51WbkA
and Pseudomonas spp. is shown. Quantification of the microtiter plate adhesion is done by
staining the adherent bacterial cells with crystal violet, subsequent solubilization of the
crystal violet stain in ethanol and spectrophotometric determination of absorbance at 595
nm. Results are shown as mean ± standard deviation of absorbance of eight independent
samples. *Significantly different from the RB51 strain (P < 0.01). OD, optical density.
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Figure 4.8. Determination of bacterial persistence in spleens of mice immunized with
recombinant strain RB51WbkA. Mice spleens were collected at day 1, day 7 and day 21
after vaccination with live RB51 and live recombinant RB51WbkA. The Brucella CFUs in
their spleens were determined. Results are shown as mean ± standard deviation (n=3) of
the log CFU of Brucella recovered from spleens. Overexpression of wbkA in RB51 does
not result in increased survival in mice.
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Figure 4.9. Detection of RB51-specific antibodies in serum of mice vaccinated with live
recombinant RB51WbkA. Mice were vaccinated with live RB51, live recombinant
RB51WbkA, or inoculated with saline. Serum samples were collected at 3 and 6 weeks
after vaccination, and were diluted 1 in 100 and assayed for the presence of total antigenspecific IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are
shown as mean ± standard deviation (n=4) of absorbance of the color developed.
*Significantly different from the corresponding saline group at week 3 (P < 0.01).
**Significantly different from the corresponding saline group at week 6 (P < 0.01). OD,
optical density.
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Figure 4.10. Detection of RB51WbkA-specific antibodies in serum of mice vaccinated with
live recombinant RB51WbkA. Mice were vaccinated with live RB51, live recombinant
RB51WbkA, or inoculated with saline. Serum samples were collected at 3 and 6 weeks
after vaccination, and were diluted 1 in 100 and assayed for the presence of total antigenspecific IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are
shown as mean ± standard deviation (n=4) of absorbance of the color developed.
*Significantly different from the corresponding saline group at week 3 (P < 0.01).
**Significantly different from the corresponding saline group at week 6 (P < 0.01). OD,
optical density.
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Figure 4.11. Detection of the protective efficacy of RB51WbkA against challenge with the
virulent strain B. abortus 2308. Mice vaccinated with live RB51, live recombinant
RB51WbkA and saline-inoculated mice were challenged by i.p. inoculation of 3×104 CFUequivalent of virulent strain 2308. 2 weeks post-challenge, the mice were euthanized and
the Brucella CFUs in their spleens were determined. Results are shown as mean ± standard
deviation (n=5) of the log CFU of Brucella recovered from spleens. *Significantly different
from the corresponding saline group (P < 0.01).
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CHAPTER 5. OVEREXPRESSION OF WBKF GENE IN BRUCELLA ABORTUS
RB51WBOA LEADS TO O-POLYSACCHARIDE EXPRESSION AND ENHANCED
PROTECTION AGAINST BRUCELLA ABORTUS 2308 AND BRUCELLA
MELITENSIS 16M IN A MURINE BRUCELLOSIS MODEL

Abstract

Brucella abortus strain RB51 is an attenuated, stable, rough mutant derived in the
laboratory from the virulent strain B. abortus 2308. Animals vaccinated with strain RB51
do not produce antibodies to the O-polysaccharide (O-PS) of the smooth
lipopolysaccharide (LPS). Previous studies have shown that the wboA gene, which encodes
a glycosyltransferase required for the synthesis of the O-PS, is disrupted in strain RB51 by
an IS711 element. Complementation of strain RB51 with a functional wboA gene (strain
RB51WboA) results in low levels of cytoplasmic O-PS synthesis, but it does not confer a
smooth phenotype. In this study, we asked if increasing the amount of bactoprenol priming
precursors in strain RB51WboA would result in smooth LPS synthesis. To achieve this,
we overexpressed the wbkF gene, which encodes undecaprenyl-glycosyltransferase
involved in bactoprenol priming for O-PS polymerization, in strain RB51WboA to
generate strain RB51WboAKF. In comparison with strain RB51WboA, strain
RB51WboAKF expressed higher levels of O-PS. Immuno-electron microscopy revealed
that the expressed O-PS was present in the cell wall of RB51WboAKF. However,
RB51WboAKF strain exhibited rough phenotypic characteristic in acriflavine
agglutination test. Mice immunized with strain RB51WboAKF developed increased levels
of smooth LPS-specific serum antibodies, primarily of IgG2a and IgG3 type, when
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compared with those immunized with strain RB51WboA. Splenocytes from the
RB51WboAKF vaccinated group of mice secreted higher levels of antigen-specific IFN-γ,
IL-10 and TNF-α when compared to those of the RB51 or RB51WboA vaccinated groups.
Also, increased numbers of antigen-specific IFN-γ secreting CD4+ and CD8+ T
lymphocytes were detected in RB51WboAKF vaccinated mice. Immunization of mice with
strain RB51WboAKF conferred enhanced protection against virulent B. abortus 2308 and
B. melitensis 16M when compared with the RB51 and RB51WboA immunized groups of
mice. These results suggest that, in addition to wboA gene, mutations affecting expression
of several other genes involved in the synthesis of O-PS and smooth LPS contribute to the
rough phenotype of strain RB51. Our results also suggest that strain RB51WboAKF could
be a more efficacious vaccine than its parent strain in natural hosts.

Introduction

Bacteria belonging to the genus Brucella are Gram-negative, facultative intracellular
coccobacilli that cause one of the most frequently encountered zoonosis worldwide known
as brucellosis. Brucella spp. infect a wide variety of mammals and can cause abortions in
natural hosts and undulant fever in humans. They can exhibit smooth or rough colony
morphology depending on the structure of their lipopolysaccharide (LPS). Except for B.
canis and B. ovis, all other Brucella species known to date possess a surface-exposed Opolysaccharide (O-PS) in their LPS moiety and exhibit a smooth phenotype. Rough strains
are devoid of the O-PS in their LPS and are generally attenuated than their smooth
counterparts [1-5]. O-PS is a linear homopolymer of 4,6-dideoxy-4-formamido-α-Dmannopyranosyl (perosamine) subunits. These subunits are connected in α-1,2 linkage in

A-dominant strains, with every fifth residue connected in α-1,3 linkage in M-dominant

Brucella strains [6,7]. O-PS protects the smooth Brucella spp. from host defense
mechanisms including complement-mediated lysis and the phagocytic microbicidal
functions [1,8]. Acquired immunity against brucellosis is primarily cell-mediated and IFNγ producing CD4+ and CD8+ T cells play a major role in protection against Brucella [9].
However, O-PS-specific antibodies also participate in enhancing the protection against
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virulent B. abortus 2308, B. melitensis and B. suis [10-13]. Currently, B. abortus strain
RB51 is used as a licensed cattle vaccine in United States and several other countries [4].
It is a laboratory-derived rough, stable mutant of virulent B. abortus 2308 [4]. It can express
low levels of M-like O-PS; however, it does not induce detectable levels of antibodies to
the O-PS in vaccinated animals [4,14].
The complete smooth LPS biosynthetic pathway is still not fully understood. The genes
that are essential for the O-PS biosynthesis are located on two genetic loci, wboA and wbkA,
of Brucella genome [15]. Previous studies have demonstrated that an IS711 element
disrupts the wboA gene, which encodes a glycosyltransferase required for the synthesis of
O-PS in Brucella, in strain RB51 [16]. Complementing strain RB51 with a functional wboA
gene (strain RB51WboA) resulted in the expression of low levels of intra-cytoplasmic OPS; however, it did not restore the smooth phenotype [17]. Interestingly, when compared
with strain RB51, immunization of mice with RB51WboA resulted in superior level of
protection against virulent B. abortus 2308 and B. melitensis 16M strain [17,18]. Recent
nucleotide sequence analysis of genes in the wbo and wbk loci did not reveal any other
apparent mutation that could affect the O-PS synthesis in strain RB51 [19].
The objective of this study was to determine if increasing the amount of bactoprenol
priming precursors in strain RB51WboA would result in smooth LPS synthesis and
enhanced protection against virulent Brucella challenge. Gene wbkF, encoding putative
undecaprenyl-glycosyltransferase, was identified to be essential for O-PS synthesis in
Brucella [15]. We cloned the wbkF gene under a strong promoter in a multi-copy plasmid
vector harboring the wboA gene and transformed strain RB51 with the resulting plasmid
pBBR/wboAKF to generate strain RB51WboAKF. Our results indicate that strain
RB51WboAKF produces smooth LPS but does not exhibit smooth colony phenotype or
increased virulence. We also demonstrate that vaccination with strain RB51WboAKF
results in enhanced protection against challenge with virulent B. abortus 2308 and B.
melitensis 16M.
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Materials and methods

Bacterial strains

B. abortus strains RB51, RB51WboA and 2308, and B. melitensis strain 16M were from
our culture collection. The required plasmid constructs were prepared using Escherichia
coli strain DH5α (Invitrogen, Carlsbad, CA). Tryptic soy broth (TSB) and tryptic soy agar
(TSA) were used as growth media for all bacterial strains. The growth medium was
supplemented with chloramphenicol at 30 µg/ml for selection of bacteria harboring the
plasmids. All protection experiments with virulent Brucella were performed in a BSL-3
facility approved for the select agents work.

Generation of recombinant strains RB51WbkF, RB51WboAKF and RB51WboAKD

Genes wbkF and wbkD were amplified using custom-designed primer-pairs by PCR. B.
abortus 2308 genomic DNA was used

as template. Forward

TTTTGGTACCGGGCGTATGGTTGCGG)

and

reverse

primer (5’-

primer

(5’-

TTTTCTCGAGCGCTTCAGGAAGCTATGACC) containing Kpn I and Xho I restriction
sites, respectively, were used to amplify wbkD. Similarly, forward primer (5’TTTTGGTACCGAGCTTTGACATTATCCGTG)

and

reverse

primer

(5’-

TTTTCTCGAGGTCATAGCTTCCTGAAG) containing Kpn I and Xho I restriction sites,
respectively, were used to amplify wbkF. The amplified fragments were cloned in pGEMT Easy plasmid (Promega, Madison, WI) and the integrity of the nucleotide sequences was
confirmed by sequence analysis. The inserts were subsequently excised from the pGEM-T
plasmids using the restriction enzymes specific to the respective restriction sites engineered
into the primers. wbkF was subsequently cloned in the same sites of pBBR1Trc and
pBBR/wboA [20,21]. wbkD was cloned in the same sites of pBBR1Trc [20,21]. The
resulting plasmids, pBB1WbkF (wbkF), pBB1/wboAKF (wboA and wbkF) and
pBB1/wboAKD (wboA and wbkD) were electroporated into strain RB51 as per previously
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described procedure [22] to generate strains RB51WbKF, RB51WboAKF and
RB51WboAKD, respectively.

SDS-PAGE and Western blotting

SDS-PAGE and Western blot analyses were carried out as previous described [2]. Briefly,
antigen extracts of RB51, RB51WboA, RB51WboAKF, RB51WboAKD and B. neotomae
were separated electrophoretically on a 12.5% denaturing polyacrylamide gel. The gel was
subsequently stained with Coomassie Brilliant Blue. For Western blotting, the separated
antigens were transferred onto a nitrocellulose membrane. Following membrane blocking
in 5% skim milk for 3 hrs, the membrane was reacted with appropriately diluted Brucella
O-PS specific rat monoclonal antibody, Bru-38 [4]. Horseradish peroxidase labelledsecondary antibody (KPL, Gaithersburg, MD) followed by the development of the
enzymatic reaction by a colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD)
were used to detect the binding of the primary antibody.

Immuno-electron microscopy

Freshly grown cultures of B. neotomae and strains RB51 and RB51WboAKF were used.
The bacterial cells were fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M
sodium phosphate buffer. They were then pelleted in 2% agarose (Sigma-Aldrich),
dehydrated with a graded ethanol series to 85% ethanol and infiltrated with LR White resin.
Polymerization was done overnight at 53°C in flat embedding molds (Ted Pella, Inc.).
Sections were cut on a Reichert-Jung Ultracut E ultramicrotome and collected on 100 mesh
formvar-coated nickel grids. Grids were incubated on 50 mM glycine for 30 mins and then
on blocking solution (0.1 M sodium phosphate buffer containing 0.5% Aurion BSA-c™,
1% normal goat serum, and 0.2% Tween 20) for 1 hr. Primary antibody incubation was
done overnight at 4°C with a 1:100 dilution of the rabbit anti-B. neotomae LPS antibody
in blocking solution. Grids were rinsed seven times and incubated on goat anti-rabbit
secondary antibody conjugated with 10 nm gold in blocking solution for 90 mins. Grids
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were washed six times and stained with 2% uranyl acetate. Images were acquired on a FEI
Tecnai G2 20 electron microscope equipped with a LaB6 source and operating at 100 kV.

Extraction of LPS

Total LPS was extracted from live B. neotomae, RB51, RB51WboA and RB51WboAKF
by butanol-water method as previously described [23,24]. Briefly, freshly grown bacterial
cultures were pelleted by centrifugation and suspended in 0.85% NaCl at a concentration
of 0.25 g wet weight/ml. An equal volume of water saturated butanol was added with
constant mixing for 15 mins at 4ºC. The aqueous phase was collected by centrifugation at
35,000×g for 20 mins. The LPS was precipitated using 4 volumes of cold methanol. The
precipitate was dissolved in 0.1 M Tris buffer (pH 8) containing 2% SDS and 2% betamercaptoethanol and heated for 5 mins at 100ºC followed by incubation with proteinase K
at 56ºC. LPS was finally precipitated by cold methanol and dissolved in water. Purity of
the extracted LPS was confirmed by SDS-PAGE followed by silver staining of the gel. The
extracted B. neotomae smooth LPS was used as antigen in indirect ELISA.

LPS analysis

A 12.5% and a 15% denaturing polyacrylamide gel was used for Western blot analysis and
silver staining, respectively. The extracted LPSs were separated electrophoretically in
sodium dodecyl sulfate-polyacrylamide gel. For Western blotting, the separated LPSs were
transferred onto a nitrocellulose membrane. Following membrane blocking in 5% skim
milk for 3 hrs, the membrane was reacted with appropriately diluted B. neotomae LPSspecific

antibody.

Horseradish

peroxidase

labelled-secondary

antibody

(KPL,

Gaithersburg, MD) followed by the development of the enzymatic reaction by a
colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD) was used to detect the
binding of the primary antibody. Silver staining of the polyacrylamide gel was performed
using the Bio-RAD Silver Stain Plus kit according to the manufacturer’s directions.
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Polymyxin B sensitivity assay

Polymyxin B (PmB) sensitivity assay was performed as described previously [1,25].
Briefly, RB51, RB51WboAKF and B. neotomae were grown to log phase, in TSB for RB51
and B. neotomae and in TSB supplemented with 30 µg/ml chloramphenicol for
RB51WboAKF. The bacterial cultures were pelleted by centrifugation at 4,200×g,
resuspended in 10 mM phosphate buffer (pH 7.2) at approximately 1×104 CFU/ml, and
incubated for 1 hr with different concentrations of polymyxin B. Following incubation, the
cell suspensions were diluted 1:10 and 1:100 in 10 mM phosphate buffer and 50 µl was
plated on TSA plates. The plates were incubated at 37°C for 5 days and the bacterial
colonies on each plate were counted. Average results of three assays were expressed as
percentages of the Brucella surviving in the absence of polymyxin incubation.

Vaccine preparation

B. abortus RB51, RB51WboA and RB51WboAKF were grown in liquid media to mid log
phase, and aliquots of 1 ml were prepared and stored at -80ºC until further use. The number
of bacteria in the aliquots was enumerated by performing ten-fold serial dilutions and
plating them on TSA plates for RB51 and TSA plates supplemented with 30 µg/ml
chloramphenicol for RB51WboA and RB51WboAKF. The plates were incubated at 37°C
for 3-4 days and the bacterial CFUs were counted.

Persistence in mouse organs

Female BALB/c mice of 4 to 6 weeks of age were used for the studies. Mice were
purchased from a commercial source (Harlan Laboratories, USA), and housed in cages
with microisolator tops at 4 mice per cage. Feed and water were provided ad libitum.
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%)
and room temperature (22oC). Mice were allowed to acclimatize to the new environment
for 1 week before starting the experiments.
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Groups of twelve mice each were inoculated by intra-peritoneal (i.p.) route with 2×108
CFU of live RB51 or RB51WboAKF. Three mice from each group were euthanized by
CO2 asphyxiation followed by cervical dislocation on days 1, 7, 21 and 28 postimmunization (p.i.) and their spleens, livers, and lungs were aseptically collected. The
Brucella CFUs in the organs were enumerated as previously described [4]. Briefly, the
tissues were homogenized with a tissue micer and were serially diluted 10-fold in TSB.
Fifty µl from each serial dilution was plated on TSA plates for RB51 and on TSA plates
containing 30 µg/ml chloramphenicol for RB51WboAKF. The plates were incubated for
up to 5 days at 37ºC. The bacterial CFUs were enumerated.

Mice immunizations

Groups of 4 mice each were immunized by i.p. inoculation with 2×108 CFU of live RB51,
RB51WboA or RB51WboAKF. A group was inoculated with saline only as a control. At
3 and 6 weeks p.i., blood from anesthetized mice was collected by puncture of retro-orbital
plexus. The sera was separated from the clotted blood and was stored at -20°C until further
use for antibody-mediated immune response analysis by indirect ELISA. Also, at 6 weeks
p.i., the mice were anesthetized by CO2 asphyxiation followed by cervical dislocation and
their spleens were aseptically collected. The splenocytes were harvested from the spleens
and used for the analysis of cell-mediated immune responses.

Indirect ELISA

Levels of RB51-specific and B. neotomae LPS-specific serum immunoglobulin M (IgM),
IgG, as well as IgG1, IgG2a, IgG2b and IgG3 isotypes were determined using indirect
ELISA [17,24,26]. RB51 was heat-killed by incubation at 65°C for 1 hr. The antigens were
diluted in carbonate buffer (pH 9.6), to a final concentration of 1×109 CFU-equivalent of
killed RB51/ml and 1 in 10 for B. neotomae LPS. These diluted antigens were plated in the
wells (100 µl/well) of polystyrene plates (Nunc-Immunoplate with maxisorp surface). The
plates were incubated overnight in 4°C. The plates were washed four times with wash
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buffer (TBS at pH 7.4, 0.05% Tween 20) and incubated for 1 hr at 37°C with blocking
buffer (5% skim milk in TBS). Diluted mouse sera (1:200 in blocking buffer) were added
in duplicates to the wells (50 µl/well). After 4 hrs, the plates were again washed with wash
buffer. Appropriately diluted anti-mouse horseradish peroxidase labelled isotype specific
conjugates (Southern Biotechnology Associates Inc, Birmingham, Alabama) were added
to the wells (50 µl/well). Following 1 hr of incubation at room temperature, the plates were
washed with wash buffer to remove any unbound antibody. Substrate solution (TMB
Microwell peroxidase substrate; KPL, Gaithersburg, MD) was added to each well (100
µl/well). The plates were incubated for 20 mins in the dark and the enzyme reaction was
stopped by 100 µl of stop solution (0.185 M sulfuric acid). Finally, a microplate reader
(Molecular devices, Sunnyvale, CA) was used to record the absorbance at 450 nm.

Culture of splenocytes

Single cell suspension of the splenocytes was prepared as per previously described
procedure [24]. The erythrocytes were lysed using ACK lysis buffer and the splenocytes
were cultured in triplicates in 96-well flat-bottomed culture plates, 5×105 cells/well for the
quantification of cytokines and 106 cells/well for the analysis of antigen-specific IFN-γ
secreting CD4+ and CD8+ T cells. The splenocytes were cultured in the presence of
different stimulants: 107 CFU-equivalents of RB51 and RB51WboAKF. Cells stimulated
with 2.5 µg/ml of concanavalin A (ConA) and plain media were used as controls.

Quantification of cytokines

The splenocytes were cultured with different stimulants and controls (as described above
in culture of splenocytes) for 5 days in a humidified incubator with 5% CO2 at 37°C and
their supernatants were collected. The concentrations of the cytokines IL-2, GM-CSF, IFNγ, TNF-α, IL-4, IL-5, IL-10 and IL-12p70 were determined using Bio-RAD Bio-Plex
ProTM Mouse Cytokine Th1/Th2 Assay according to the manufacturer’s instructions.
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Flow cytometric analysis of antigen-specific IFN-γ secreting CD4+ and CD8+ T cells

A previously described procedure was followed for intracellular IFN-γ staining [24,27].
The splenocytes were cultured with different stimulants and controls (as described above
in culture of splenocytes) for 8 hrs in a humidified incubator with 5% CO2 at 37°C. Brefelin
A (Golgistop; Pharmingen) was added to the wells and the plates were incubated for
another 8 hrs. Cells from each treatment were suspended in FACS buffer (PBS containing
1% BSA and 0.2% sodium azide). They were incubated for 30 mins in ice with
appropriately diluted FITC-conjugated anti-mouse CD8 antibody (BD Pharmigen,
clone53-6.7) and APC-conjugated anti-mouse CD4 antibody (BD Pharmigen, clone L3T4RM 4.5). Following three washes with FACS buffer, the cells were stained for intracellular
IFN-γ with PE-conjugated rat anti-mouse IFN-γ antibody using the cytofix/cytoperm
(Pharmingen) using manufacturer’s instructions. As an isotype control, cells stained with
PE-conjugated rat IgG1 antibody were used. The cells were acquired on BD FACS Canto
II™ Flow cytometer (BD Biosciences, CA, USA). The data were analyzed using BD
FACSDIVA version 6 software (BD Biosciences, CA, USA) and the proportion of
CD4+ and CD8+ T cells that secreted IFN-γ was determined.

Quantification of serum cytokines

Groups of three mice each were infected with 2×108 CFU of live RB51 or RB51WboAKF.
A group of mice inoculated with saline alone served as the negative control. Mice from all
the groups were bled by retro-orbital puncture at days 1, 7 and 28 p.i. The serum was
separated from the clotted blood and concentrations of the cytokines IL-2, GM-CSF, IFNγ, TNF-α, IL-4, IL-5, IL-10 and IL-12p70 were determined using Bio-RAD Bio-Plex
ProTM Mouse Cytokine Th1/Th2 Assay according to the manufacturer’s instructions.
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Spleen histology

Groups of six mice each were infected with 2×108 CFU of live RB51 or RB51WboAKF.
A group of mice inoculated with saline was used as control. Two mice from each group
were euthanized at days 1, 7 and 28 p.i. and their spleens were aseptically collected. The
spleens were then weighed, and immersed in 10% neutral-buffered formalin, embedded,
sectioned, mounted on microscopic slides, and stained with hematoxylin and eosin. The
stained slides were digitized using an Aperio Digital Slide Scanner (Leica) and slides were
analyzed by a board-certified pathologist (Grant N. Burcham). They were annotated using
the ScanScope software (Leica).

Protection experiments

Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was
approved for work with select agents. Female BALB/c mice of 4-6 weeks of age (Harlan
Laboratories, USA) were used for the studies. Mice were housed in individually ventilated
cages with high-efficiency particulate arresting-filtered air. Feed and water were provided
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled
humidity (55%) and room temperature (22oC). After 1 week of acclimatization, mice were
administered with vaccine or control formulation.
Groups of ten mice each were vaccinated by i.p. inoculation with 2×108 CFU of live RB51,
RB51WboA or RB51WboAKF. Ten mice inoculated with saline alone served as a control.
Six weeks p.i, five mice in each group were challenged by i.p. inoculation with 5×104 CFU
of B. abortus 2308 and the remaining five mice in each group were challenged with 5×104
CFU of B. melitensis 16M. Two weeks post-challenge, the mice were euthanized and the
bacterial burden in their spleens was enumerated as previously described [4].
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Statistical analysis

Statistical analysis was performed using GraphPad Prism software. ELISA absorbance
values, cytokine concentrations and flow cytometry data were analyzed for differences
among groups by performing one-way analysis of variance (ANOVA) followed by
Bonferroni test. The protection data was analyzed using student t-test modified for unequal
variances between groups.

Ethics statement

The protocols of the mice experiments performed in this study were approved by the
Institutional Animal Care and Use Committees at Purdue University (Approval #
1112000488) and Virginia Tech (Approval # CVM-10-048). The animal studies were
conducted in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from
the retro-orbital plexus from mice under anesthesia. For anesthetizing mice, regulated
concentration of anesthetic mixture (oxygen and isoflurane) was administered via a
commercially available rodent anesthesia machine (Vetamac, Inc., Rossville, Indiana).
Following blood collection, a drop of proparacaine hydrochloride ophthalmic solution
(Bausch & Lomb, Tampa, Florida) was placed on the eye to reduce pain. Mice infected
with virulent B. abortus 2308 do not develop clinical disease or exhibit any signs of
suffering for the duration of the experiments conducted in this study. Therefore, no humane
endpoints were utilized for the mice in this study.
Results

O-Polysaccharide expression by strain RB51WboA overexpressing the wbkF gene

Strain RB51 was electroporated with plasmid pBB1/wboAKF, containing the functional
wboA and wbkF genes from strain 2308, to generate strain RB51WboAKF. Five of the
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plasmid-harboring recombinant colonies were selected for determination of O-PS
expression. Western blot analysis with Bru-38 showed that all five RB51WboAKF
colonies contained smooth LPS (Fig. 5.1A). The reactivity profile of the RB51WboAKF
recombinants was similar to that of B. neotomae. In contrast, strain RB51WboAKD had a
similar reactivity pattern as that of strain RB51WboA (data not shown). In strain
RB51WboA, Bru-38 reacted with a few bands in the 45 kDa range, which was similar to
previous descriptions [17] (Fig. 5.1A). As expected, RB51 did not show any reactivity with
Bru-38 [4] (Fig. 5.1A). Strain RB51WbkF also did not react with Bru-38 (data not shown).
One of the RB51WboAKF recombinants was selected for all the further studies.
SDS-PAGE followed by Coomassie Brilliant Blue staining was used to visualize any
differences in the protein profiles of the strains RB51 and RB51WboAKF. There was no
apparent qualitative difference in the protein profiles of the two strains (Fig. 5.1B).
Immuno-electron microscopy was carried out to determine the location of the expressed
O-PS in bacterial cells. Immuno-electron microscopy of thin sections of RB51WboAKF
revealed the presence of O-PS mostly on the surface of bacterial cells (Fig. 5.2C). As
expected, no O-PS was detected in strain RB51 (Fig. 5.2B) while the presence of O-PS in
strain B. neotomae was predominantly detected on the cell surface (Fig. 5.2A).
Indirect ELISA with whole bacterial cells as antigen was performed to determine the level
of O-PS expression on the surface of bacterial cells. As expected, RB51 and RB51WboA
whole cells did not react with smooth LPS-specific antibody (Fig. 5.3). In contrast, both
strain RB51WboAKF and B. neotomae exhibited a higher level of reactivity with antismooth LPS antibody when compared with RB51 and RB51WboA strains; however, B.
neotomae reacted with all tested dilutions of the smooth LPS-specific antibody at
significantly higher levels when compared with strain RB51WboAKF (Fig. 5.3).

LPS analysis

In order to assess the degree of roughness of strain RB51WboAKF, the electrophoretic
profile of the LPSs were examined by Western blotting and silver staining (Fig. 5.4A and
B). Western blot analysis of LPS from RB51WboAKF revealed a reactive smear that
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extended from 75kDa to 25kDa (Fig. 5.4A). In contrast, LPS from RB51 and RB51WboA
did not show any reactivity with smooth LPS-specific antibody (Fig. 5.4A). LPS from B.
neotomae exhibited positive reactivity with anti-smooth LPS antibody and a smear that
extended from >100kDa to <20kDa was visible on Western blotting (Fig. 5.4A).
On silver staining of the polyacrylamide gel, a major low-molecular weight band of the
same size (<10kDA) was visible in the LPSs of all the four strains indicating that all the
strains exhibit a complete core (Fig. 5.4B). Additionally, a high-molecular weight band
(≈23kDA) and a low-molecular weight band (≈11kDA) were present in the LPS profiles
of B. neotomae and RB51WboAKF but absent in RB51 and RB51WboA (Fig. 5.4B). A
band of intermediate size (≈18kDA) was present in the LPSs of strains RB51,
RB51WboAKF and RB51WboA but absent in LPS of B. neotomae (Fig. 5.4B).

Sensitivity to the bactericidal effect of polymyxin B

PmB at concentrations ranging from 2 µg/ml to 50 µg/ml was used to test the ability of
strain RB51WboAKF to resist bactericidal killing. Strain RB51WboAKF was less
sensitive to the bactericidal effect of PmB when compared to strain RB51 at concentrations
≥ 10 µg/ml (Fig. 5.5). The difference was more apparent at higher concentrations (20-50
µg/ml) of PmB (Fig. 5.5). As expected, tested concentrations of PmB had the least effect
on B. neotomae which exhibited enhanced survival percentage when compared to the
strains RB51 and RB51WboAKF (Fig. 5.5).

Persistence of strain RB51 and RB51WboAKF in mice.

Persistence of strains RB51 and RB51WboAKF in mice organs was compared in order to
assess the attenuation characteristic of strain RB51WboAKF. There was no difference in
the persistence pattern of RB51 and RB51WboAKF in spleens, livers and lungs of the
vaccinated mice at days 1, 7, 21 and 28 p.i. (Fig. 5.6). Both the strains were cleared from
the mice livers and lungs and persisted at very low levels in spleens of mice at day 28 p.i.
(Fig. 5.6).
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Induction of specific antigen-antibody responses in mice

Specific antigen-antibody responses induced in vaccinated mice were determined by
indirect ELISA. Higher levels of LPS-specific total IgG antibodies were detected in the
serum of mice vaccinated with RB51WboA and RB51WboAKF when compared with
RB51 vaccinated and saline-inoculated mice (Fig. 5.7). LPS-specific IgG levels were
significantly higher in RB51WboAKF vaccinated mice when compared with those
vaccinated with RB51WboA (Fig. 5.7). Mice vaccinated with RB51WboAKF also had
significantly higher levels of LPS-specific IgM, IgG2a, IgG2b and IgG3 at 3 and 6 weeks
p.i. and LPS-specific IgG1 at 3 weeks p.i. when compared with RB51 vaccinated and
saline-inoculated mice group (Fig. 5.7). In contrast, significantly higher levels of LPSspecific IgG2a and IgG3 antibodies were detected in mice vaccinated with RB51WboA
only at 6 weeks p.i. when compared with the RB51 vaccinated and unvaccinated groups of
mice (Fig. 5.7). The levels of LPS-specific IgG2a and IgG3 were significantly higher in
the serum of RB51WboAKF vaccinated mice than those vaccinated with RB51WboA (Fig.
5.7).
All the vaccinated groups of mice (RB51, RB51WboA and RB51WboAKF) had
significantly higher levels of RB51-specific IgG, IgM, IgG2a, IgG2b and IgG3 when
compared with the saline inoculated controls (Fig. 5.8). Only the levels of RB51-specific
IgG2a were significantly higher in the serum of RB51WboAKF vaccinated mice when
compared with RB51WboA vaccinated group of mice (Fig. 5.8).

Histology of spleens

RB51WboAKF vaccinated mice had higher spleen weights (453.33 ± 20.54 mg) at day 7
p.i. when compared to RB51 vaccinated mice (403.33 ± 26.25 mg) (P < 0.05). Splenic
histology in saline-inoculated and RB51 vaccinated mice was considered normal at day 7
p.i. (Fig. 5.9A and B). In contrast, markedly increased extramedullary hematopoiesis (EH)
was observed in RB51WboAKF vaccinated mice at day 7 p.i. (Fig. 5.9C). At day 28, a
trend towards increase in the number of germinal centers per spleen was observed in
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RB51WboAKF vaccinated mice spleens when compared with the spleens of RB51
vaccinated mice.

Analysis of serum cytokines

Vaccination of mice with RB51 and RB51WboAKF resulted in significantly higher levels
of IL-12 and IFN-γ at day 1 and TNF-α at day 7 p.i. when compared with the salineinoculated mice (Fig. 5.10). The level of IL-12 and IFN-γ was significantly higher at day
1 p.i. in the serum of WboAKF immunized mice than those immunized with RB51 (Fig.
5.10). Moreover, significantly increased levels of GM-CSF at day 27 p.i. and IL-10 at days
1 and 7 p.i. were detected in the serum of mice vaccinated with RB51WboAKF when
compared with RB51 vaccinated and saline inoculated mice groups (Fig. 5.10). The
concentrations of IL-4 and IL-5 were below the limit of detection in the vaccinated groups
of mice as well as the saline-inoculated group (data not shown).

Induction of specific cell-mediated responses in mice

Specific cell-mediated responses were analyzed at 6 weeks p.i. in the vaccinated mice by
determining the number of IFN-γ secreting CD4+ and CD8+ T cells as well as by
quantifying cytokines secreted by splenocytes upon in vitro stimulation with specific
antigens.
Upon in vitro stimulation with RB51 and RB51WboAKF, higher proportions of IFN-γ
secreting CD4+ and CD8+ T cells were detected in all the vaccinated groups of mice but
not the saline-inoculated group when compared with the corresponding unstimulated
controls (Fig. 5.11A and B). When stimulated with RB51WboAKF, significantly higher
proportions of IFN- γ secreting CD4+ and CD8+ T cells were detected in RB51WboAKF
vaccinated mice when compared to the other vaccinated groups of mice (Fig. 5.11).
Upon in vitro stimulation with RB51 and RB51WboAKF, splenocytes of all groups of
vaccinated mice, but not the saline-inoculated group, secreted significantly increased levels
of IFN-γ, GM-CSF and IL-10 when compared to the corresponding unstimulated controls
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(Fig. 5.12). In contrast, concentrations of IL-4 and IL-5 in the culture supernatants of all
groups of mice were below the detection limit and not different from the corresponding
unstimulated controls (data not shown). Stimulation with RB51WboAKF resulted in the
secretion of significantly higher levels of IFN-γ and IL-10 by the splenocytes of
RB51WboAKF vaccinated group of mice than the other vaccinated mice groups (Fig.
5.12). Also, upon in vitro stimulation with RB51 and RB51WboAKF, significantly higher
levels of TNF-α were detected in the culture supernatants of mice vaccinated with
RB51WboAKF and RB51WboA, but not the saline-inoculated group, when compared with
their unstimulated controls; the level of TNF-α was significantly higher in the
RB51WboAKF vaccinated mice group when compared with other vaccinated groups of
mice (Fig. 5.12). In contrast, only stimulation with RB51 resulted in the secretion of higher
levels of TNF-α by splenocytes of RB51 vaccinated mice when compared to the
corresponding unstimulated control (Fig. 5.12). In vitro stimulation with RB51 resulted in
the secretion of higher levels of IL-2 by splenocytes of RB51 and RB51WboAKF
vaccinated groups of mice, but not the saline-inoculated group, when compared with the
corresponding unstimulated controls (Fig. 5.12); however, higher levels of IL-2 were only
detected in the culture supernatants of mice vaccinated with RB51WboAKF, after in vitro
stimulation with RB51WboAKF, when compared to the corresponding unstimulated
control (Fig. 5.12).

Enhanced protection against virulent challenge infection

To assess the protection afforded by different vaccine strains in a mouse model of
brucellosis, bacterial CFUs were calculated in the vaccinated groups of mice two weeks
post-challenge with virulent Brucella species. Vaccination with RB51, RB51WboA and
RB51WboAKF resulted in significant reduction of the splenic bacterial load following
challenge with virulent B. abortus 2308 and B. melitensis 16M when compared with the
saline inoculated group of mice (Fig. 5.13A and B). Following challenge with virulent B.
abortus 2308 and B. melitensis 16M, RB51WboAKF immunized group of mice showed
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the highest reduction in the splenic bacterial load when compared with RB51 and
RB51WboA vaccinated groups (Fig. 5.13).

Discussion

The studies in this paper demonstrate that overexpression of wbkF in strain RB51WboA
leads to the expression of O-PS similar to the smooth Brucella strains and enhanced
protection against B. abortus 2308 and B. melitensis 16 M. Our immunoelectron study as
well as indirect ELISA using whole live bacterial cells as antigens suggests that the
synthesized O-PS by the strain RB51WboAKF is present mostly on the bacterial cell
surface (Fig. 5.2 and 5.3). However, strain RB51WboAKF still exhibited rough strain
characteristics as evidenced by agglutination with acriflavin. Also, silver stained profile of
the extracted LPS from strain RB51WboAKF was partly similar to that of both rough and
smooth strains (Fig. 5.4B). A previous study has described a strain of B. melitensis (strain
EP) which simultaneously exhibits smooth and rough characteristics [28]. This type of
‘smooth-rough’ phenotype of strain EP was attributed to the presence of fewer O-PS chains
and higher amounts of rough-LPS when compared to the strain 16M [28]. Similarly,
reduced level of reaction of RB51WboAKF bacterial cells with smooth LPS-specific
antibody when compared with B. neotomae indicates that fewer O-PS chains are expressed
on RB51WboAKF cell surface. Fewer surface-expressed O-PS chains can also explain the
enhanced sensitivity of strain RB51WboAKF to the bactericidal effect of polymyxin when
compared to B. neotomae (Fig. 5.5). In case of RB51WboA, absence of positive reactivity
with anti-smooth LPS antibody is expected as the O-PS is only expressed in the cytoplasm
of the bacteria [17].
The complete biosynthetic pathway of Brucealla O-PS is yet to be determined. However,
a pathway for it has been proposed based on the prediction of protein functions from
comparisons with homologous proteins in other microorganisms and identification of
rough Brucella phenotypes [2,15,29-32]. In the purported biosynthetic pathway of smooth
LPS, WbkD and WbkF catalyzed steps lead to bactoprenol priming for Nformylperosamine polymerization by glycosyltransferases [29]. Consequently, Brucella
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strains with mutations in wbkF or wbkD genes cannot produce O-PS [29]. wbkD encodes
an epimerase/dehydratase that takes part in the synthesis of N-acetylquinovosamine
[29,33] that has been found in the smooth LPS [3,7,34]. Previously, it has been proposed
that N-acetylquinovosamine might act as a substrate for WbkF (undecaprenylglycosyltransferase) for the synthesis of bactoprenol primed N-acetylaminosugar [29]. In
our study, overexpression of wbkD in strain RB51WboA did not change the level of O-PS
expression when compared to that expressed by RB51WboA (data not shown). This finding
suggests that a mere increase in the level of WbkD expression or quinivosamine does not
affect O-PS expression. In contrast, increasing the level of WbkF in RB51WboA leads to
enhanced O-PS expression (Fig. 5.1A) suggesting that overexpression of wbkF furnishes
higher amounts of bactoprenol primed moieties for O-PS polymerization by wboA and
other glycosyltransferases. As expected, overexpression of wbkF alone in RB51 did not
lead to O-PS expression (data not shown) indicating that wboA encoded glycosyltransferase
is required for O-PS polymerization.
The attenuation characteristic of strain RB51WboAKF did not differ from the parent strain
RB51. Based on the increased resistance to polymyxin B treatment, we had expected that
strain RB51WboAKF would persist longer in mice organs than strain RB51. The lack of
any increase in the virulence characteristic of strain RB51WboAKF suggests that the
attenuation of strain RB51 is because of mutations in multiple yet to be identified genes.
Vaccination of mice with strain RB51WboAKF resulted in the induction of increased
IgG2a and IgG3 subisotype antibodies specific to the smooth LPS than other vaccinated
and non-vaccinated groups (Fig 5.7). This indicates that a Th1 type of immune response
was induced by RB51WboAKF vaccine. Previous studies have validated the contribution
of Th1 immunity in protection against intracellular bacterial infections including
brucellosis. Detection of significantly higher concentration of IFN-γ in the culture
supernatants of antigen-specific splenocytes as well as significantly higher proportions of
antigen-specific IFN-γ secreting CD4+ and CD8+ T cells in the RB51WboAKF vaccinated
group of mice also indicates the induction of Th1 type of immunity. The presence of
increased concentrations of TNF-α also suggests the development of Th1 effector cells.
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Significantly enhanced TNF-α secretion might also play a role in the induction of
splenomegaly and EH in RB51WboAKF vaccinated mice spleens. Pro-inflammatory
cytokines such as TNF-α help in the recruitment of inflammatory cells leading to
splenomegaly during Brucella infection [35]. Cytokines such as TNF-α and GM-CSF also
increase myelopoiesis by supporting the growth and maturation of myeloid progenitors
[36]. This enhanced production of mature myeloid cells helps in clearing pathogens from
body [37].
RB51WboAKF vaccine conferred significantly higher protection against virulent Brucella
species than strain RB51 and RB51WboA (Fig. 5.13). Both, T cell-mediated responses as
well as O-PS specific antibodies, play a role in providing enhanced protection against
brucellosis [9,13,29]. IFN-γ secreting T cells are implicated as the main effectors that
provide acquired resistance against Brucella infection [9]. Previous studies show that
antibodies to the O-PS including IgM, IgG2a, IgG2b and IgG3 can also mediate protection
in mice [12,26,38,39]. The enhanced protection afforded by RB51WboAKF might be
attributed to the anti-O-PS antibodies and/or to the enhanced cell-mediated immune
responses. Further studies involving adoptive transfer experiments of O-PS-specific
antibodies and/or immune T cells can characterize their specific contribution to the
protective efficacy of RB51WboAKF.
In conclusion, our results suggest that RB51 carries mutations in several genes required for
the synthesis of smooth LPS. Also, our study demonstrates that RB51WboAKF strain,
while maintaining the attenuation characteristic of strain RB51, is more immunogenic and
protective than strain RB51 and can be a more efficacious vaccine in natural hosts.
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Figure 5.1. (A) Western blot analysis to detect O-polysaccharide expression by the strain
RB51WboAKF and (B) Coomassie Brilliant Blue staining of the polyacrylamide gel to
detect difference in the protein profiles of RB51, B. neotomae, RB51WboA and
RB51WboAKF. Whole antigens of the strain RB51, recombinant strain RB51WboA,
RB51WboAKF and B. neotomae were separated by 12.5% SDS-PAGE and analyzed by
(A) Western blotting with O-polysaccharide specific monoclonal antibody, Bru-38. Lane
1: strain B. neotomae; lane 2: recombinant strain RB51WboA; lane 3-7: recombinant strain
RB51WboAKF; lane 8: strain RB51. Whole antigens of the strain B. neotomae,
RB51WboA, RB51WboAKF and RB51 were analyzed for any differences in the expressed
protein profiles by (B) Coomassie Brilliant Blue stained polyacrylamide gel.
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Figure 5.2. Detection of Brucella O-polysaccharide expression in strain RB51WboAKF by
immunoelectron microscopy. Thin sections of (A) B. neotomae, (B) RB51 and (C)
RB51WboAKF were reacted with anti-B. neotomae LPS followed by gold-labeled goat
anti-rabbit IgG. The black arrows in panel A and C indicate the gold-labeled particles. Bars
= 0.2 µm.
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Figure 5.3. ELISA detection of O-polysaccharide expression on the cell surface of strain
RB51WboAKF. RB51, RB51WboA, RB51WboAKF and B. neotomae whole cells (108
CFU/well) were reacted with specific dilutions of anti-B. neotomae LPS antibody. The
results are shown as mean ± standard deviation of the optical density (OD) at 450 nm of
the color developed. Asterisks indicate statistically significant differences from strain
RB51WboAKF. *, P < 0.05; **, P < 0.01; ***, P < 0.001. OD, optical density.
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Figure 5.4. (A) Western blot analysis and (B) silver staining of the polyacrylamide gel to
detect the differences in the LPS profiles of strains RB51, B. neotomae, RB51WboA and
RB51WbkA. LPSs extracted from strain RB51, RB51WboA, RB51WboAKF and B.
neotomae were separated by SDS-PAGE and analyzed by (A) Western blotting; Lane 1:
strain B. neotomae; lane 2: recombinant strain RB51WboA; lane 3: recombinant strain
RB51WboAKF; lane 4: strain RB51, and (B) silver staining; Lane 1: strain B. neotomae;
lane 2: recombinant strain RB51WboAKF; lane 3: strain RB51; lane 4: recombinant strain
RB51WboA.
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Figure 5.5. Determination of the bactericidal effect of polymyxin on strains RB51,
RB51WboAKF and B. neotomae. Polymyxin-sensitivity assay was performed as described
in Materials and methods. Average results from three assays are expressed as percentage
of the bacteria surviving in the absence of polymyxin. Asterisks indicate statistically
significant differences from the RB51 strain. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

161

Figure 5.6. Determination of bacterial persistence of strain RB51WboAKF in mice. Mice
spleens, livers and lungs were collected at days 1, 7, 21 and 28 after vaccination with live
RB51 and live RB51WboAKF. The Brucella CFUs in these organs were determined as
described in Materials and methods. Results are shown as mean ± standard deviation (n=3)
of the log CFU of Brucella recovered from each organ.
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Figure 5.7. Detection of B. neotomae LPS-specific antibodies in serum of mice vaccinated
with live recombinant RB51WboAKF. Mice were vaccinated with live RB51,
RB51WboA, RB51WboAKF, or inoculated with saline. Serum samples were collected at
3 and 6 weeks after vaccination, were diluted 1 in 200 and assayed for the presence of B.
neotomae LPS-specific IgM, IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect
ELISA. Results are shown as mean ± standard deviation (n=4) of absorbance of the color
developed. Asterisks indicate statistically significant differences from the corresponding
saline group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. OD, optical density.
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Figure 5.8. Detection of RB51-specific antibodies in the serum of mice vaccinated with
live recombinant RB51WboAKF. Mice were vaccinated with live RB51, RB51WboA,
RB51WboAKF, or inoculated with saline. Serum samples were collected at 3 and 6 weeks
after vaccination, were diluted 1 in 200 and assayed for the presence of RB51-specific IgM,
IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are shown as
mean ± standard deviation (n=4) of absorbance of the color developed. Asterisks indicate
statistically significant differences from the corresponding saline group. *, P < 0.05; **, P
< 0.01; ***, P < 0.001. OD, optical density.
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Figure 5.9. Spleen histology in BALB/c (A) saline-inoculated mice and mice infected intraperitoneally with 108 CFU-equivalent of live (B) RB51 and (C) RB51WboAKF. The mice
were sacrificed 7 days post-vaccination and a portion of the spleen was fixed in formalin,
processed and stained with hematoxylin and eosin. Pictures were taken with a 10X
magnification. White arrowheads indicate megakaryocytes, a key feature of
extramedullary hematopoiesis.
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Figure 5.10. Detection of specific cytokines in the serum of RB51WboAKF vaccinated
mice. Mice were immunized intra-peritoneally with 108 CFU-equivalent of live RB51,
RB51WboAKF, or inoculated with saline. Values are shown as mean ± standard deviation
(n=4). Asterisks indicate statistically significant differences from the corresponding saline
group. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 5.11. Flow cytometric analysis showing the percentage of interferon-γ secreting (A)
CD4+ and (B) CD8+ T cells in the spleens of mice immunized with live recombinant
RB51WboAKF. Mice were immunized intra-peritoneally with 108 CFU-equivalent of live
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RB51, RB51WboA, RB51WboAKF, or inoculated with saline. The mice splenocytes were
stimulated with media (unstimulated), heat-killed strains RB51 and RB51WboAKF and
the percentages of IFN-γ secreting (A) CD4+ and (B) CD8+ T cells were analyzed by flow
cytometry. (C) Representative figure of the flow cytometric analysis. Values are shown as
mean ± standard deviation (n=4). Asterisks indicate statistically significant differences
from the corresponding unstimulated control. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 5.12. Detection of specific cytokines produced by splenocytes of mice vaccinated
with live recombinant RB51WboAKF. Mice were vaccinated intra-peritoneally with 108
CFU-equivalent of live RB51, RB51WboA, RB51WboAKF and saline-inoculated mice
after in vitro stimulation with media (unstimulated), heat-killed RB51 and RB51WboAKF.
Values are shown as mean ± standard deviation (n=4). Asterisks indicate statistically
significant differences from the corresponding unstimulated control. *, P < 0.05; **, P <
0.01; ***, P < 0.001.
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Figure 5.13. Determination of the protective efficacy of strain RB51WboAKF against
virulent strains B. abortus 2308 and B. melitensis 16M challenge. Mice vaccinated intraperitoneally with live RB51, RB51WboA, RB51WboAKF and saline-inoculated mice
were challenged by i.p. inoculation of 3×104 CFU of virulent strains (A) B. abortus 2308
and (B) B. melitensis 16M. 2 weeks post-challenge, the mice were euthanized and the
Brucella CFU in their spleens were determined. Results are shown as mean ± standard
deviation (n=5) of the log CFU of Brucella recovered from spleens. Asterisks indicate
statistically significant differences from the corresponding saline group. *, P < 0.05; **, P
< 0.01; ***, P < 0.001.
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CHAPTER 6. ORAL IMMUNIZATION OF MICE WITH GAMMA-IRRADIATED
BRUCELLA NEOTOMAE INDUCES PROTECTION AGAINST INTRAPERITONEAL
AND INTRANASAL CHALLENGE WITH VIRULENT BRUCELLA ABORTUS 2308

Abstract

Brucella spp. are Gram-negative, facultative intracellular coccobacilli that cause one of the
most frequently encountered zoonosis worldwide. Humans naturally acquire infection
through consumption of contaminated dairy and meat products and through direct exposure
to aborted animal tissues and fluids. No vaccine against brucellosis is available for use in
humans. In this study, we tested the ability of orally inoculated gamma-irradiated B.
neotomae and B. abortus RB51 in a prime-boost immunization approach to induce antigenspecific humoral and cell mediated immunity and protection against challenge with virulent
B. abortus 2308. Heterologous prime-boost vaccination with B. abortus RB51 and B.
neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the
production of serum and mucosal antibodies specific to the smooth LPS. The elicited serum
antibodies included the isotypes of IgM, IgG1, IgG2a, IgG2b and IgG3. All oral
vaccination regimens induced antigen-specific CD4+ and CD8+ T cells capable of secreting
IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae
showed the highest level of resistance against virulent B. abortus 2308 colonization in
spleen and liver. Experiments with different doses of B. neotomae showed that all tested
doses of 109, 1010 and 1011 CFU-equivalent conferred significant protection against the
intra-peritoneal challenge. However, a dose of 1011 CFU-equivalent of B. neotomae was
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required for affording protection against intranasal challenge as shown by the reduced
bacterial colonization in spleens and lungs. Taken together, these results demonstrate the
feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to
induce protection against respiratory and systemic infections with virulent Brucella.

Introduction

Brucella species, Gram-negative, facultative intracellular coccobacilli, are the causative
agents of brucellosis, a chronic bacterial infection in a variety of mammals, including
humans. B. melitensis, B. abortus and B. suis are the most frequent causes of human
infections [1]. These Brucella species are also categorized in the class B list of select agents
by the CDC due to their highly infectious nature and their potential use in bio-warfare. In
natural animal hosts and wildlife reservoirs, brucellosis commonly results in abortion and
infertility. Chronically infected animals also shed the bacteria in milk. Human brucellosis
is truly a zoonotic disease. Humans usually get infected by consuming unpasteurized
contaminated milk or dairy products, or by getting exposed to infected animal tissues or
secretions. Few human infections are also documented to occur through accidental
exposure to live bacteria in the laboratory or inoculation of live vaccine strains used for
controlling animal brucellosis in the field. Human brucellosis can manifest in a variety of
clinical symptoms, starting from a subclinical infection to a protracted febrile illness which
can progress to lethal endocarditis [1,2]. Treatment of brucellosis requires prolonged
therapy with a mixture of antibiotics; even then relapses of infection are often noticed.
There is no vaccine available for use in humans against brucellosis.
A safe and effective human vaccine would benefit as a prophylactic measure to protect
personnel at high risk of occupational exposure to pathogenic Brucella, especially in
Brucella endemic regions. Cell-mediated immunity plays a major role in enhancing the
resistance against brucellosis in animals. Antigen-specific CD4+ and CD8+ T lymphocytes
that secrete Th1-type cytokines such as IFN-γ and TNF-α are important in immunity
against Brucella infection [3-5]. In some animal species, antibodies to the Opolysaccharide (O-PS) of the lipopolysaccharide also play a role in protection against
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infections by B. abortus, B. melitensis and B. suis [6-8]. Only live vaccines are shown to
be effective in providing long term protection against brucellosis in animals. Attenuated
strains such as B. abortus S19 and RB51, and B. melitensis Rev1 are used as parenteral
vaccines to immunize cattle, and sheep and goats, respectively. None of the live vaccines
licensed for use in domestic animals are considered safe for human application [9,10].
Gamma-irradiated bacteria cannot replicate but remain metabolically active, and they can
be a safer alternative to live bacteria for immunization purposes. We previously showed
that parenteral immunization of mice with gamma-irradiated B. abortus RB51 or B.
neotomae induces protection against challenge with virulent Brucella spp. [11,12]. As
parenteral route of vaccination is seldom favored due to its invasive delivery and is unlikely
to be a preferred route of immunization against brucellosis in humans, in this study we
examined the feasibility of oral vaccination with gamma-irradiated B. neotomae and B.
abortus RB51 in a prime-boost approach to induce protection against systemic and mucosal
challenge infections.
We show that oral immunization with gamma-irradiated B. neotomae in a homologous
prime-boost regimen results in production of antigen-specific antibody, cell-mediated and
mucosal immune responses and increased resistance to intra-peritoneal and intranasal
challenge with B. abortus 2308.

Materials and methods

Bacterial strains

B. neotomae strain 5K33 was obtained from the American Type Culture Collection,
Manassas, VA. B. abortus vaccine strain RB51 and B. abortus virulent strain 2308 were
from our culture collection. B. neotomae and RB51 were grown in tryptic soy broth (TSB)
or tryptic soy agar (TSA) at 37°C. All experiments with B. neotomae were performed in a
Biosafety level (BSL)-2 facility using BSL-3 practices. All experiments with virulent B.
abortus were performed in a BSL-3 facility approved for the select agents work.
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Vaccine preparation

B. neotomae and B. abortus RB51 were grown in TSB to mid log phase, and aliquots
containing approximately 1×1012 colony forming units (CFU)/ml were exposed to 350
krads of gamma irradiation using a 60Co source irradiator (Gammacell 220 irradiator). The
irradiated aliquots were plated on TSA to confirm the inability of the bacteria to replicate.
The irradiated bacteria were stored at 4ºC until use.

Quantification of irradiated B. neotomae in mice spleens and mesenteric lymph nodes by
real-time PCR

A group of 8 female BALB/c mice were orally administered with 1×1011 CFU-equivalent
of gamma-irradiated B. neotomae. On days 1 and 3 post-vaccination, 4 mice from the
group were euthanized and their spleens and mesenteric lymph nodes were collected
aseptically. The organs were homogenized in PBS and DNA from the homogenates were
extracted using a commercial kit (DNeasy Blood and Tissue Kit, Qiagen Inc.).
Quantification of B. neotomae DNA in the samples was accomplished using real-time PCR
as previously described [11].

Immunization of mice

Groups of 4 female BALB/c mice of 4 to 6 weeks of age were used for the study. Mice
were purchased from a commercial source (Harlan Laboratories, USA), and housed in
cages with microisolator tops at 4 mice per cage. Feed and water were provided ad libitum.
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%)
and room temperature (22oC). After 1 week of acclimatization, mice were administered
with vaccine or control formulation.
The gamma-irradiated bacteria were pelleted, washed with sterile phosphate-buffered
saline (PBS) and adjusted to 5×1011 CFU-equivalent/ml. In some designated experiments,
the irradiated bacteria were further diluted to concentrations of 5×1010 cells/ml and 5×109
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cells/ml. A total of 200 µl of the vaccine suspension was used to vaccinate mice 15 mins
after oral administration of 100 µl of sterile 10% sodium bicarbonate via a disposable
feeding needle attached to a 1-ml syringe.

Comparison of different prime-boost immunization strategies
Mice were vaccinated by oral inoculation of 1×1011 CFU-equivalent of gamma-irradiated
RB51 and/or gamma-irradiated B. neotomae in a prime-boost immunization regimen as
shown in Table 6.1. Priming dose was administered at day 0. Booster immunizations with
the same dose as the priming dose were given on days 3, 7 and day 10. A group of mice
inoculated with saline was used as a negative control.

Comparison of different vaccine doses of the B. neotomae vaccine
Mice were vaccinated by three oral inoculations, on days 0, 3 and 10, with either 1×109
CFU-equivalent or 1×1010 CFU-equivalent or 1×1011 CFU-equivalent of gamma-irradiated
B. neotomae. A group of mice inoculated with saline was used as a negative control.

Collection of blood and intestinal secretions

Blood was collected by puncturing the retro-orbital plexus of the anesthetized mice at one
and two weeks post-immunization (p.i) (1 and 2 weeks after the last booster immunization,
respectively). The serum was separated and used for detection of antigen-specific
antibodies by enzyme-linked immunosorbent assay (ELISA). At 2 weeks p.i., CO2
asphyxiation followed by cervical dislocation was used to euthanize all the mice. The small
intestines were separated and the intestinal contents were collected by flushing with 3 ml
of PBS and centrifuged to remove the particulate matter. The supernatants were transferred
to clean tubes and were used for the analysis of antigen-specific antibody responses by
ELISA. Spleens of the euthanized mice were collected aseptically and used for analysis of
the antigen-specific cell-mediated immune responses by flow-cytometry.
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Preparation of B. neotomae LPS antigen

Butanol-water extraction was used to obtain total LPS from live bacteria as previously
described [13,14]. Briefly, 10g of wet pellet obtained by centrifugation of live B. neotomae
organisms was resuspended in PBS at a concentration of 0.25 g wet weight/ml followed by
addition of an equal volume of water saturated butanol. The aqueous phase was collected
by centrifugation at 35,000×g for 15 mins. 4 volumes of cold methanol was added to
precipitate the LPS. The precipitate was dissolved in 0.1M Tris buffer (pH 8) containing
2% SDS and 2% mercaptoethanol and heated for 5 mins at 100ºC. Following another
incubation with proteinase K for 3 hrs at 60ºC, cold methanol was added to precipitate LPS.
The precipitate was dissolved in water. SDS-PAGE of the polyacrylamide gel was carried
out to determine the purity of the LPS.

Indirect ELISA

Levels of B. neotomae LPS-specific immunoglobulin G (total IgG), as well as selected IgG
isotypes and IgM were determined by indirect ELISA [15]. Level of serum IgG with
specificity to heat-killed RB51 total antigens was also determined. In the intestinal
secretions, levels of IgG, IgM and IgA with specificity to B. neotomae LPS and RB51 total
antigens were determined. Using carbonate buffer, pH 9.6, B. neotomae LPS was diluted
1 in 10, and the RB51 total antigens were diluted to obtain 1×109 CFU-equivalent/ml. The
diluted antigens were used for coating wells (100 µl/well) of polystyrene plates (NuncImmunoplate with maxisorp surface). The plates were incubated at 4°C for 12 hrs. They
were subsequently washed with wash buffer (Tris-buffered saline (TBS), pH 7.4, with
0.05% Tween 20) and blocked with 5% skim milk in TBS. Following an incubation of 1
hr at 37°C, mouse sera with a 1:200 dilution in blocking buffer were added to the wells (50
µl/well). All serum samples were tested in duplicates. For intestinal secretions, 1 in 10
dilution was used. The plates were incubated for 4 hrs. Appropriately diluted mousespecific

horseradish

peroxidase-labeled

immunoglobulin

conjugates

(Southern

Biotechnology Associates Inc, Birmingham, Alabama) were added (50 µl/well) to the wells
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after washing the plate four times with wash buffer. After another hr of incubation at room
temperature, the plates were washed four times and 100 µl of substrate solution (TMB
Microwell peroxidase substrate; KPL, Gaithersburg, MD) was added to each well. 100 µl
of stop solution (0.185 M sulfuric acid) was further added to the wells in order to stop the
enzymatic reaction, and the absorbance (450nm) was recorded using a microplate reader
(Molecular devices, Sunnyvale, CA).

Intracellular cytokine staining and flow cytometry analysis

Intracellular staining for IFN-γ and TNF-α was performed as previously described with
some modifications [16]. Spleens were collected aseptically after euthanizing the mice and
single cell suspensions of the splenocytes were prepared. ACK lysis buffer was used to
lyse the RBCs and the splenocytes (106 per well) were seeded in 96 well flat-bottomed
plates. They were cultured with different stimulants: 107 CFU-equiv. of gamma-irradiated
B. neotomae and 107 CFU-equiv. of gamma-irradiated RB51. As controls, cells were
stimulated with plain medium and 2.5 µg/ml of concanavalin (ConA). They were incubated
in a humidified incubator with 5% CO2 for 8 hrs at 37 °C. Subsequently, brefeldin A
(Golgistop; Pharmingen) was added to the splenocytes and the plates were incubated for
another 8 hrs. Cells from each well were resuspended in PBS containing 1% BSA and 0.2%
sodium azide (FACS buffer) and were incubated with PE-Cy7-conjugated anti-mouse CD8
antibody (BD Pharmingen, clone53-6.7) and APC-conjugated anti-mouse CD4 antibody
(BD Pharmingen, clone L3T4-RM 4.5) for surface staining. They were washed three times
with FACS buffer and were further stained for intracellular IFN-γ and TNF-α by incubating
with PE-conjugated rat anti-mouse IFN-γ antibody and FITC-conjugated rat anti-mouse
TNF-α antibody using the Cytofix/Cytoperm kit (Pharmingen). Cells stained with PEconjugated rat IgG1 and FITC-conjugated rat IgG1 antibody served as the isotype controls.
BD FACS Canto II™ Flow cytometer (BD Biosciences, CA, USA) was used to acquire
the data which was analyzed using BD FACSDIVA version 6 software (BD Biosciences,
CA, USA) and the proportion of CD4+and CD8+ T cells that secreted IFN-γ and TNF-α
were determined.
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Protection experiments

Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was
approved for work with select agents. Female BALB/c mice of 4-6 weeks of age (Harlan
Laboratories, USA) were used for the studies. Mice were housed in individually ventilated
cages with high-efficiency particulate arresting-filtered air. Feed and water were provided
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled
humidity (55%) and room temperature (22oC). After 1 week of acclimatization, mice were
administered with vaccine or control formulation.

Analysis of protective efficacy of the different prime-boost immunization regimens
Groups of 5 mice were vaccinated by oral inoculation of 1×1011 CFU-equiv. of gammairradiated RB51 and/or gamma-irradiated B. neotomae in a prime-boost immunization
regimen; immunizations were performed (as as per Immunization of mice section:
comparison of different prime-boost immunization strategies). A group (n=5) of mice
inoculated with saline alone served as control. Two weeks p.i, each mouse was challenged
by i.p. inoculation with 1×104 CFU of B. abortus 2308. Two weeks post challenge, the
mice were euthanized and the number of bacterial CFUs in their spleens, lungs and livers
were enumerated as previously described [17,18]. Briefly, two weeks post challenge, the
mice were euthanized and their spleens, lungs and livers were collected aseptically. Organs
were suspended in 1 ml of sterile PBS and were separately homogenized using tissue
grinders. Ten-fold serial dilutions of the tissue homogenates were prepared in saline, and
50 µl of each dilution was plated on TSA. After 3-5 days of incubation at 37 °C, the
Brucella CFUs were counted and the bacterial burden per organ was calculated.

Analysis of the protective efficacy of different vaccine doses of B. neotomae
Groups of 10 mice were vaccinated by three oral inoculations on days 0, 3 and 10 with
either 1×109 CFU-equiv. or 1×1010 CFU-equiv. or 1×1011 CFU-equiv. of gamma-irradiated
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B. neotomae (as per Immunization of mice section: comparison of different vaccine doses
of the B. neotomae vaccine). A group (n=10) of mice inoculated with saline alone served
as control. Two weeks p.i. (2 weeks after the inoculation of the last booster dose), five mice
from each group were challenged by i.p. inoculation with 5×104 CFU of B. abortus 2308,
and the remaining five mice were challenged by i.n. inoculation with 4×106 CFU of B.
abortus 2308. Two weeks post challenge, the mice were euthanized and the bacterial
burden per organ was calculated.

Statistical analyses

Absorbance values of ELISA and flow cytometry data were analyzed for differences
among different vaccinated groups by performing analysis of variance with post hoc Tukey
for pair-wise comparison using SPSS version 21.0 (SPSS Inc., an IBM company, USA).
Following bacterial challenge experiments, student t-test modified for unequal variances
between groups was carried out to compare the log transformed CFU values in organs
obtained from each vaccinated group of mice with the respective saline group. P values of
<0.05 were considered significant.

Ethics statement

The protocols of the mice experiments conducted in this study were approved by the
Institutional Animal Care and Use Committees at Purdue University (Approval #
1112000488) and Virginia Tech (Approval # CVM-10-048). The animal studies were
carried out in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from
the retro-orbital plexus from mice under anesthesia. A commercially available rodent
anesthesia machine that uses oxygen and an isoflurane precision-vaporizer for supplying
regulated concentration of anesthetic mixture (Vetamac, Inc., Rossville, Indiana) was used
for anesthetizing mice. To reduce pain following the bleeding, a drop of proparacaine
hydrochloride ophthalmic solution (Bausch & Lomb, Tampa, Florida) was placed on the
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eye. Mice infected with virulent Brucella abortus do not develop any clinical disease or
show signs of suffering for the duration of the experiments conducted in this study.
Therefore, no humane endpoints were utilized for the mice in this study.

Results

Persistence of gamma-irradiated B. neotomae in mice spleens and mesenteric lymph nodes
following oral immunization

The translocation of orally administered gamma-irradiated B. neotomae from gut lumen to
mesenteric lymph node (MLN) and spleen was determined by extracting DNA from tissues
and performing a quantitative real-time PCR specific to Brucella. Following oral
inoculation of 1011 CFU-equivalent of gamma-irradiated B. neotomae, the bacterial DNA
could be detected in mesenteric lymph nodes and in spleens by day 1 and persisted there
for at least three days (Fig. 6.1).

Induction of antigen-specific antibody immune responses following oral prime-boost
immunization with gamma-irradiated B. neotomae and/or gamma-irradiated B. abortus
RB51

Levels of antibodies specific to B. neotomae-smooth LPS and RB51 total antigens in serum
samples collected at 1 and 2 weeks p.i. (1 and 2 weeks after the inoculation of the last
booster dose, respectively) were determined by indirect ELISA. Immunization of mice
with IRBn, IRBn/RB51 and IRRB51/Bn resulted in the induction of significantly higher
levels of serum IgG and IgM antibodies specific to LPS when compared with the saline
inoculated mice and the group of mice vaccinated with IRRB51 (Fig. 6.2A). However,
there was no significant differences among the three vaccination groups (Fig. 6.2A).
Significantly higher levels of LPS-specific IgG2a, IgG2b and IgG3 were present in the
serum samples of mice immunized with IRBn and IRBn/RB51 at 1 week and 2 week p.i.
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(Fig. 6.2A). Also, mice vaccinated with IRBn and IRBn/RB51 had higher levels of LPSspecific IgG1 antibodies at 2 weeks p.i.; however, only mice vaccinated with IRBn had
significantly increased levels of serum IgG1 antibodies specific to LPS at 1 week p.i. (Fig.
6.2A). In contrast, vaccination of mice with IRRB51/Bn did not lead to the induction of
significant levels of LPS-specific IgG1 antibodies (Fig. 6.2A). Furthermore, significantly
higher levels of LPS-specific IgG2a, IgG2b and IgG3 antibodies were detected in the serum
of mice vaccinated with IRRB51/Bn only at 2-weeks p.i. (Fig. 6.2A).
Oral immunization of mice with IRBn, IRRB51/Bn and IRBn/RB51 led to the induction
of significantly higher levels of LPS-specific IgG antibodies in the intestinal secretions
when compared with the saline inoculated control and the IRRB51 vaccinated group (Fig.
6.3A). Only vaccination of mice with IRBn resulted in the induction of significantly
increased levels of LPS-specific IgM and IgA antibodies in the intestinal secretions when
compared to the other vaccinated groups (Fig. 6.3A).
All four vaccinated groups of mice had significantly higher levels of IgG serum antibodies
specific to RB51 total antigens (Fig. 6.2B), as well as significantly higher levels of RB51specific IgG, IgM and IgA antibodies in the intestinal secretions (Fig. 6.3B) than the saline
inoculated control mice. There was no difference in the levels of RB51-specific antibodies
among the different groups (Fig. 6.2B and 6.3B).

Induction of antigen-specific cell-mediated immune responses following oral prime-boost
immunization with gamma-irradiated B. neotomae and/or gamma-irradiated B. abortus
RB51

Significantly higher proportions of antigen-specific IFN-γ-and TNF-α-secreting CD4+ and
CD8+ T cells were detected in all vaccinated groups when compared to the respective
unstimulated controls and the saline inoculated control group (Fig. 6.4A and B).
Stimulation of the splenocytes with irradiated RB51 resulted in the induction of
significantly increased proportions of RB51-specific CD4+ T cells secreting IFN-γ and
TNF-α in mice immunized with IRRB51 than the other vaccinated groups (Fig. 6.4A and
B). There was no significant difference in the proportion of IFN-γ and TNF-α secreting
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CD8+ T cells specific to RB51 and those that were specific to B. neotomae among the
different vaccinated groups (Fig. 6.4A and B).

Protective efficacy against intra-peritoneal challenge with virulent B. abortus 2308
following oral prime-boost immunization with gamma-irradiated B. neotomae and/or
gamma-irradiated B. abortus RB51

Immunization with IRBn and IRBn/RB51 resulted in a significant reduction in the number
of bacterial CFUs of the virulent Brucella in the spleen after i.p. challenge with virulent B.
abortus 2308 (Table. 6.2). In contrast, the bacterial burden in the spleen of mice immunized
with IRRB51 was not significantly different from that of the saline inoculated control group
(Table. 6.2). All three vaccinations resulted in reduced bacterial load of virulent strain in
livers (Table. 6.2). The bacterial loads in lungs of the vaccinated mice were not statistically
different from that of the saline group (Table. 6.2).

Induction of antigen-specific antibody immune responses following oral homologous
prime-boost immunization with different vaccine doses of gamma-irradiated B. neotomae

We examined the effect of different doses of gamma-irradiated B. neotomae vaccine on
induction of specific immune responses and protection against parenteral and mucosal
challenge with virulent B. abortus. Three different doses, 1×109 CFU-equiv. or 1×1010
CFU-equiv. or 1×1011 CFU-equiv. of gamma-irradiated B. neotomae were tested in a
prime-boost immunization strategy, consisting of a priming dose and two booster doses.
Significantly increased levels of LPS-specific IgG antibodies at 1 and 2 weeks p.i. and
LPS-specific IgM antibodies at 1 week p.i. were detected in the serum of the three
vaccinated groups when compared to the saline inoculated control group (Fig. 6.5). In
addition, mice vaccinated with the 1011 CFU-equiv. dose developed significantly increased
levels of LPS-specific IgG antibodies in the serum at 1 week p.i. when compared to the
other vaccinated mice (Fig. 6.5).
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Significantly higher levels of LPS-specific IgG and IgM antibodies in the intestinal
secretions were present in all vaccinated mice (Fig. 6.6). Mice vaccinated with the 1011
CFU-equiv. dose contained the highest levels of IgG, IgM and IgA antibodies (Fig. 6.6).

Induction of antigen-specific CMI following oral homologous prime-boost immunization
with different vaccine doses of gamma-irradiated B. neotomae

Upon in vitro stimulation of splenocytes with irradiated B. neotomae and irradiated RB51,
significantly higher proportions of IFN-γ secreting CD4+ and CD8+ T cells were detected
in all vaccinated groups (Fig. 6.7A). Stimulation of splenocytes with irradiated RB51
resulted in induction of significantly increased proportions of CD4+ and CD8+ T cells
secreting IFN-γ in mice immunized with the 1011 CFU equiv. dose than the other groups
(Fig. 6.7A). Significantly increased proportion of TNF-α secreting CD4+ and CD8+ T cells
were detected upon stimulation of splenocytes of vaccinated mice with specific antigens
(Fig. 6.7B).

Protective efficacy against intra-peritoneal and intra-nasal challenge with virulent B.
abortus 2308 following oral homologous prime-boost immunization with different vaccine
doses of gamma-irradiated B. neotomae

Upon i.p. challenge with B. abortus 2308, significantly reduced bacterial loads were
detected in spleens and livers of all vaccinated mice (Table. 6.3); mice immunized with the
1011 CFU-equiv. dose showed the highest resistance with an average of 2.61 log and 2.49
log reduction in spleens and livers, respectively. Although the lung bacterial burden in all
vaccinated groups was lower than that of the saline inoculated control group, the difference
was not statistically significant (Table. 6.3); again, mice immunized with the 1011 CFUequiv. dose showed the highest resistance in lungs with a 1.47 log difference in bacterial
load compared to those of the saline control group.
Following intranasal challenge with B. abortus 2308, the bacterial CFUs in lungs and
spleens of mice immunized with the 1011 CFU-equiv. dose were significantly lower than
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those of mice inoculated with saline (Table. 6.4). Reduced bacterial burden was also
detected in the livers of mice immunized with the 1011 CFU-equiv. dose, though the
reduction was not statistically significant from the saline group (Table. 6.4).

Discussion

Vaccination by oral route is a desirable method to induce acquired immunity against
infectious diseases in humans as well as animals. In most human brucellosis cases, the
infection is acquired through mucosal routes. However, human brucellosis is a systemic
disease, where the bacteria penetrate the epithelial barrier, spread to mononuclear
phagocytic system, and affect different organ systems [19]. Therefore, an effective oral
brucellosis vaccine must induce systemic immunity. Several research groups previously
used live attenuated Brucella strains as oral vaccines [18,20,21]. The inherent safety risks
associated with bacterial replication may preclude the use of attenuated Brucella strains as
live vaccines for human brucellosis. Our previous research demonstrated that gammairradiated B. abortus strain RB51 and B. neotomae cannot replicate, but can induce
protective antibody and CMI responses when used as vaccines to immunize mice by
intraperitoneal route [11,12]. In this study, we asked if these vaccines can be administered
by oral route to immunize mice against a challenge infection with virulent B. abortus. Our
empirical selection to give multiple doses of the vaccine was driven by the currently
recommended oral vaccination regimen for Salmonella typhi, the only oral bacterial
vaccine in human use at present, which consists of 4 doses at 1-day intervals [22]. We first
examined the effect of prime-boost strategy on induction of immune responses and
protection. Contrary to our initial hypothesis, priming with B. neotomae and boosting with
B. abortus RB51, or vice versa, did not significantly change the type of antibody and CMI
responses. The only notable difference was that the mice primed with B. abortus RB51 and
boosted with B. neotomae did not develop significant levels of IgG1 antibodies specific to
smooth LPS even at 2 weeks p.i. (Fig. 6.2A). It is interesting that priming with B. neotomae
and boosting with B. abortus RB51 did not dampen the overall antibody response to smooth
LPS (Fig. 6.2A). In fact, mice subjected to this vaccination regimen had significantly
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higher levels of smooth LPS-specific IgG2a and IgG2b antibodies at 1 week p.i., but the
difference disappeared by 2 weeks p.i. (Fig. 6.2A). Majority of the surface proteins of
Brucella spp. are highly conserved [23]. Therefore, it is not surprising that all tested
vaccination regimens induced similar levels of RB51-specific antibodies in serum and
intestinal secretions (Fig. 6.2B and 6.3B).
Our detection of smooth LPS- and RB51-specific antibodies in the intestinal secretions of
the vaccinated mice is suggestive of induction of a mucosal immune response. However,
the role of mucosal immunity in protection against brucellosis remains to be determined.
A recent study demonstrated that mice orally vaccinated with live attenuated strains B.
abortus RB51 or B. melitensis ∆znuA developed both systemic and mucosal Th1 as well
as Th17 responses, but the Th17 responses played a role only in the B. abortus RB51induced protection [21]. The important role of Th1 responses in protection against
brucellosis is well-documented in the literature [4]. All the vaccines tested in our study
induced antigen-specific CD4+ and CD8+ T cells that secrete IFN-γ or TNF-α in spleens,
suggesting the generation of a systemic Th1 response.
In mouse brucellosis models, reduced bacterial load in spleens, livers or both, of the
vaccinated mice compared to those of the unvaccinated animals is the generally used
criterion for determining the vaccine-induced protective responses [24-26]. Based on this
standard, only mice vaccinated with B. neotomae and IRBn/RB51, but not RB51,
developed significant protection against intraperitoneal challenge with B. abortus 2308
(Table 6.2). This was corroborated by the reduced bacterial burden in lungs also, though
the reduction was not significantly different from the unvaccinated mice. This observation
suggests that oral vaccines that elicit antibodies to smooth LPS are effective in affording
protection in mouse brucellosis models. Since the protection induced by the IRBn/RB51
vaccination regimen was not different from that of the IRBn vaccine, we then examined
the effect of reduced dose of B. neotomae vaccine on induction of protection. All tested
vaccine doses induced significant protection against the intraperitoneal challenge.
However, only the highest dose provided significant protection against the intranasal
challenge. Why the lower doses of vaccine could not provide protection against the
intranasal challenge could not be answered based on our immune response analyses. There
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was a trend of reduced serum and mucosal antibody levels to smooth LPS with reduced
vaccine dose, which could have contributed to this difference. A thorough analysis of T
cell responses in lungs following immunization and challenge may reveal important
differences between the different vaccination doses. Additionally, determining the effect
of different vaccine doses on the persistence of the vaccine bacteria in lymphoid organs
may also yield information relevant to understanding the magnitude of immune responses
induced at different mucosal sites. Our preliminary study indicates that following oral
inoculation of mice with 1011 CFU-equivalent of gamma-irradiated B. neotomae, the
bacterial DNA could be detected in mesenteric lymph nodes and in spleens by day 1 and
persisted there for at least three days (Fig. 6.1).
In conclusion, these studies demonstrate the feasibility of using gamma-irradiated B.
neotomae as oral vaccine to induce protection against both parenteral and mucosal
challenge with virulent Brucella spp. This type of vaccine is a safer alternative to live
vaccines for human brucellosis. Future studies should focus on formulating the vaccine to
bypass the acidic conditions of human stomach, assessing the shelf-life of the vaccines and
determining the duration of the vaccine-induced protective response.
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Table 6.1. Immunization schedule.
Vaccine group designation

11

11

Prime (1×10 CFU)

Boost (1×10 CFU)

Day 0

Day 3, 7 and 10

IRRB51

Irradiated RB51

Irradiated RB51

IRBn

Irradiated B. neotomae

Irradiated B. neotomae

IRRB51/Bn

Irradiated RB51

Irradiated B. neotomae

IRBn/RB51

Irradiated B. neotomae

Irradiated RB51
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Table 6.2. Protection against intra-peritoneal challenge with virulent B. abortus 2308
following oral prime-boost immunization of mice with gamma-irradiated B. neotomae
and/or gamma-irradiated B. abortus RB51.

a

Vaccine

Bacterial

load

in Units of

(gamma-irradiated)

log10CFU (mean ± SD)

protection

Log10 CFU in

None (saline)

4.66 ± 0.77

-

spleen

RB51

4.03 ± 0.93**

0.63

B. neotomae

2.55 ± 0.21*

2.11

B. neotomae/RB51

2.97 ± 0.22*

1.69

Log10 CFU in

None (saline)

3.61 ± 0.11

-

liver

RB51

2.82 ± 0.32*

0.79

B. neotomae

2.53 ± 0.21*

1.08

B. neotomae/RB51

2.62 ± 0.25*

0.99

Log10 CFU in

None (saline)

2.59 ± 1.18

-

lung

RB51

2.71 ± 0.53

-

B. neotomae

1.85 ± 0.46**

0.74

B. neotomae/RB51

1.70 ± 0.28**

0.89

a

Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated

group from the mean log10 CFU of the corresponding saline control group.
* Significantly different from the corresponding saline group (P < 0.05).
** Not significantly different from the corresponding saline group (P > 0.05).
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Table 6.3. Protection against intra-peritoneal challenge with virulent B. abortus 2308
following oral homologous prime-boost immunization of mice with multiple vaccine doses
of gamma-irradiated B. neotomae.
Vaccine

Bacterial

(gamma-irradiated)

log10CFU (mean ± SD)

protection

Log10 CFU in

None (saline)

6.53 ± 0.03

-

spleen

B. neotomae 10

9

5.27 ± 0.53*

1.26

10

5.18 ± 0.50*

1.35

3.92 ± 1.29*

2.61

4.48 ± 0.19

-

9

3.47 ± 0.27*

1.01

10

3.69 ± 0.61*

0.79

1.99 ± 1.64*

2.49

3.61 ± 0.88

-

9

3.47 ± 0.32**

0.14

10

3.16 ± 0.28**

0.45

2.14 ± 1.15**

1.47

B. neotomae 10
B. neotomae10

11

Log10 CFU in

None (saline)

liver

B. neotomae 10
B. neotomae 10
B. neotomae10

11

Log10 CFU in

None (saline)

lung

B. neotomae 10
B. neotomae 10
B. neotomae10

a

11

load

in Units of
a

Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated

group from the mean log10 CFU of the corresponding saline control group.
* Significantly different from the corresponding saline group (P < 0.05).
** Not significantly different from the corresponding saline group (P > 0.05).
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Table 6.4. Protection against intra-nasal challenge with virulent B. abortus 2308 following
oral homologous prime-boost immunization of mice with multiple vaccine doses of
gamma-irradiated B. neotomae.
Vaccine

Bacterial

(gamma-irradiated)

log10CFU (mean ± SD)

protection

Log10 CFU in

None (saline)

5.10 ± 0.61

-

spleen

B. neotomae 10

9

5.23 ± 0.74

-

10

5.34 ± 0.39

-

3.89 ± 0.31*

1.21

3.33 ± 0.65

-

9

3.36 ± 0.48

-

10

3.25 ± 0.63**

0.08

2.12 ± 1.12**

1.21

5.30 ± 0.12

-

9

5.40 ± 0.21

-

10

4.67 ± 0.94**

0.63

4.08 ± 0.91*

1.22

B. neotomae 10
B. neotomae10

11

Log10 CFU in

None (saline)

liver

B. neotomae 10
B. neotomae 10
B. neotomae10

11

Log10 CFU in

None (saline)

lung

B. neotomae 10
B. neotomae 10
B. neotomae10

a

11

load

in Units of
a

Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated

group from the mean log10 CFU of the corresponding saline control group.
* Significantly different from the corresponding saline group (P < 0.05).
** Not significantly different from the corresponding saline group (P > 0.05).
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Figure 6.1. Persistence of gamma-irradiated B. neotomae in mouse spleens and mesenteric
lymph nodes as detected by real-time quantitative PCR. A group of 8 female BALB/c mice
were orally administered with 1×1011 CFU-equivalent of gamma-irradiated B. neotomae.
On days 1 and 3 post-vaccination, 4 mice from the group were euthanized and their spleens
and mesenteric lymph nodes were collected aseptically. The organs were homogenized in
PBS and DNA from the homogenates were extracted using a commercial kit (DNeasy
Blood and Tissue Kit, Qiagen Inc.). Quantification of B. neotomae DNA in the samples
was accomplished using real-time PCR as described in Methods and materials.
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Figure 6.2. ELISA detection of (A) B. neotomae-specific antibodies, and (B) RB51-specific
IgG antibody in serum of mice vaccinated with gamma-irradiated prime-boost regimens.
Mice were vaccinated with gamma-irradiated RB51, B. neotomae, RB51/B. neotomae and
B. neotomae/RB51, or inoculated with saline. Serum samples were collected at 1 and 2
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weeks after the last booster vaccination, were diluted 1 in 200 and assayed for the presence
of (A) LPS-specific IgG, IgM, IgG1, IgG3, IgG2a and IgG2b and (B) RB51-specific
antibodies. Results are shown as mean ± standard deviation (n = 4) of absorbance at 450 nm
of the color developed. *Significantly different from the corresponding saline group at
week 1 (P < 0.05). **Significantly different from the corresponding saline group at week
2 (P < 0.05). ff Significantly different from the corresponding vaccination groups at week
1 (P < 0.05). OD, optical density.
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Figure 6.3. ELISA detection of IgG, IgM, IgA antibodies specific to (A) B. neotomae LPS,
and (B) RB51 total antigens in the intestinal secretions of mice vaccinated with gammairradiated prime-boost regimens. Mice were vaccinated with gamma-irradiated RB51, B.
neotomae, RB51/B. neotomae and B. neotomae/RB51, or inoculated with saline. Intestinal
secretions were collected at 2 weeks after the last booster vaccination, were diluted 1 in 10
and assayed for the presence of (A) LPS-specific and (B) RB51-specific antibodies. Results
are shown as mean ± standard deviation (n = 4) of absorbance at 450 nm of the color
developed. *Significantly different from the corresponding saline group (P < 0.05).

ff

Significantly different from the corresponding vaccination groups (P < 0.05). OD, optical
density.
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Figure 6.4. Flow cytometric analysis showing the percentage of (A) interferon-γ secreting,
and (B) tumor necrosis factor-α secreting CD4+ and CD8+ T cells in the spleens of BALB/c
mice immunized with gamma-irradiated prime-boost regimens. Mice were vaccinated
with RB51, B. neotomae, RB51/B. neotomae and B. neotomae/RB51, or inoculated with
saline. Splenocytes from the vaccinated mice were stimulated with media (unstimulated),
gamma-irradiated B. neotomae and gamma-irradiated RB51 and the percentage of IFN-γ
secreting and TNF-α secreting CD4+ and CD8+ T cells were analyzed by flow-cytometry.
*Significantly different from the corresponding unstimulated control (P < 0.05).

ff

Significantly different from the corresponding vaccination groups with irradiated RB51
stimulation (P < 0.05).
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Figure 6.5. ELISA detection of IgG and IgM antibodies specific to B. neotomae LPS in
serum of mice vaccinated with different doses of gamma-irradiated B. neotomae. Mice
were vaccinated with 109 CFU-equivalent or 1010 CFU-equivalent or 1011 CFU-equivalent
of gamma-irradiated B. neotomae, or inoculated with saline.Serum samples were collected
at 1 and 2 weeks after the last booster vaccination, were diluted 1 in 200 and assayed for
the presence of LPS-specific antibodies. Results are shown as mean ± standard deviation
(n = 4) of absorbance at 450 nm of the color developed. *Significantly different from the
corresponding saline group at week 1 (P < 0.05). **Significantly different from the
corresponding saline group at week 2 (P < 0.05).

ff

Significantly different from the

corresponding vaccination groups at week 1 (P < 0.05). OD, optical density.
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Figure 6.6. ELISA detection of IgG, IgM and IgA antibodies specific to B. neotomae LPS
in the intestinal secretions of mice vaccinated with different doses of gamma-irradiated B.
neotomae. Mice were vaccinated with 109 CFU-equivalent or 1010 CFU-equivalent or 1011
CFU-equivalent of gamma-irradiated B. neotomae, or inoculated with saline. Intestinal
secretions were collected at 2 weeks after the last booster vaccination, were diluted 1 in 10
and assayed for the presence of LPS-specific antibodies. Results are shown as
mean ± standard deviation (n = 4) of absorbance at 450 nm of the color developed.
*Significantly different from the corresponding saline group (P < 0.05).

ff

Significantly

different from the corresponding vaccination groups (P < 0.05). OD, optical density.
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Figure 6.7. Flow cytometric analysis showing the percentage of (A) interferon-γ secreting,
and (B) tumor necrosis factor-α secreting CD4+ and CD8+ T cells in the spleens of BALB/c
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mice immunized with different doses of gamma-irradiated B. neotomae. Mice were
immunized with 109 CFU-equivalent or 1010 CFU-equivalent or 1011 CFU-equivalent of
gamma-irradiated B. neotomae, or inoculated with saline. Splenocytes from the vaccinated
mice were stimulated with media (unstimulated), gamma-irradiated B. neotomae and
gamma-irradiated RB51 and the percentage of IFN-γ secreting and TNF-α secreting CD4+
and CD8+ T cells were analyzed by flow-cytometry. (C) Representative figure of the flow
cytometric analysis. *Significantly different from the corresponding unstimulated control
within a vaccination group (P < 0.05). aa Significantly different from the corresponding
vaccination groups with irradiated B. neotomae stimulation (P < 0.05).

ff

Significantly

different from the corresponding vaccination groups with irradiated RB51 stimulation
(P < 0.05).
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CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS

Research conducted in this dissertation was aimed at developing improved vaccines for
brucellosis using B. abortus RB51 and B. neotomae. Th1 type of cell-mediated immunity
is crucial for vaccine-induced protection against brucellosis. In addition, antibodies to the
O-polysaccharide (O-PS) of the lipopolysaccharide (LPS) play a protective role against
infections with B. abortus, B. melitensis and B. suis. B. abortus RB51, an attenuated rough
strain, is used as a live vaccine in the control of bovine brucellosis. Animals do not produce
antibodies to the O-PS in response to the RB51 vaccination. We asked if engineering RB51
to synthesize O-PS and smooth LPS would enhance its vaccine efficacy. In this regard, we
first tested whether overexpression of two glycosyltransferases WbkA and WbkE, which
are essential for O-PS synthesis in Brucella, in RB51 results in O-PS synthesis and confers
it a smooth phenotype. Quite unexpectedly, we found that overexpression of wbkA in RB51
leads to an extreme clumpy phenotype and synthesis of an exopolysaccharide (EPS). Our
study, for the first time, demonstrates the novel role of wkbA in EPS synthesis. This finding
extends the growing evidence for the genetic competence of Brucella to synthetize EPS.
Lectin binding studies demonstrated that the exopolysaccharide contains mannose,
galactose, N-acetylglucosamine and N-acetylgalactosamine. The EPS production resulted
in enhanced adherence of the bacteria to polystyrene matrices. However, EPS did not
change the attenuation characteristic of strain RB51WbkA. Also, our results indicate that
EPS has minimal, if any, role in modulating immune responses in mice; the RB51WbkA
vaccine induced a similar level of protective response against virulent B. abortus challenge
as strain RB51. Future studies should focus on the translational implication of this finding;
studies to determine how EPS affects bacterial fitness under different environmental
conditions would help delineate the precise role of EPS during Brucella infection.
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Purification and structural characterization of the EPS would also aid in the understanding
of its possible function during infection. Lastly, as wbkA gene is a target of quorum sensing
(QS)-regulators, it would be interesting to investigate the role of QS-regulators in altering
the expression of wbkA under specific conditions and the effect on EPS synthesis. From
practical point of view, it would be interesting to examine if EPS production has any benefit
to RB51 vaccine manufacturing, such as increased stability during lyophilization or
increased shelf-life of the vaccine.
The second objective was to determine whether increasing the amount of bactoprenol
primed molecules in strain RB51WboA would increase the expression of O-PS and restore
the smooth phenotype. Gene wbkF encodes undecaprenyl-glycosyltransferase enzyme that
catalyzes the transfer of an acetyl-aminosugar to undecaprenylphosphate leading to the
priming of this carrier for O-PS polymerization. Interestingly, B. ovis contains a nonfunctional wbkF while B. canis carries a deletion in the region encompassing wbkF and
wbkD. In our study (Chapter 5), we overexpressed the wbkF gene in strain RB51WboA to
generate strain RB51WboAKF. Our study indicates that strain RB51WboAKF produces
smooth LPS but does not exhibit smooth colony phenotype or increased virulence.
Immunization with strain RB51WboAKF induces enhanced antigen-specific antibody as
well as cell-mediated responses, primarily of Th1 type, in mice. Also, strain
RB51WboAKF confers a superior level of protection against virulent B. abortus 2308 and
B. melitensis 16M than strain RB51 and RB51WboA in mice. These results are extremely
promising and suggest that strain RB51WboAKF could be a more efficacious vaccine than
its parent strain in natural hosts. Future studies should focus on determining the vaccine
efficacy of RB51WboAKF in cattle and small ruminants against infections with virulent
Brucella spp. An important consideration is that safety concerns may preclude the use of
antibiotic resistant plasmids in vaccines. Alternate strategies to ensure plasmid
maintenance need to be exploited for increasing the safety profile of the vaccine. One way
to engineer an antibiotic resistance-marker free system is to construct an auxotrophic
bacterial strain by mutating an essential gene. The growth of this strain will be restored by
complementation or introduction of a plasmid carrying the deleted gene. Another important
consideration that can affect the widespread use of this strain is the induction of anti-O-PS
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antibodies. Most of the serodiagnostic assays for brucellosis are based on the detection of
anti-O-PS antibodies. To prevent confounding serology, we will need alternate methods
for differentiation of vaccinated animals from animals infected with wild-type Brucella
spp. Previously, efforts have been directed towards modifying the O-PS of Brucella to
express a distinct immunogenic epitope that does not react with the antibodies from
naturally infected animals. Also, recent unpublished data proposes that O-PS of Brucella
is capped by a M-specific tetrasaccharide sequence. Therefore, it is feasible to designing
appropriate assays that utilize specific oligosaccharide antigens for the detection of
antibodies in animals infected with wild-type Brucella. Our present study also suggests
that, in addition to wboA gene, mutations affecting expression of several other genes
involved in the synthesis of O-PS and smooth LPS contribute to rough phenotype of strain
RB51. Identification of the other contributing mutations in RB51 will help to fully reveal
the biosynthetic pathway of Brucella smooth LPS and its regulation in response to different
microenvironments.
Human brucellosis is a major public health concern in several developing countries.
Emergence of new foci of zoonotic Brucella spp. around the world has significantly
changed the epidemiology of human brucellosis. There is a need to develop a safe and
effective vaccine for use in humans. The third objective of the current study was to test the
ability of orally inoculated gamma-irradiated B. neotomae and B. abortus RB51 in a primeboost immunization approach to induce antigen-specific humoral and cell mediated
immunity and protection against challenge with virulent B. abortus 2308. Our results
indicated that heterologous prime-boost vaccination with B. abortus RB51 and B.
neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the
production of serum and mucosal antibodies specific to the smooth LPS. Also, all oral
vaccination regimens induced antigen-specific CD4+ and CD8+ T cells capable of secreting
IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae
showed the highest level of resistance against virulent B. abortus 2308 colonization in
spleen and liver. The next set of experiments with different doses of B. neotomae showed
that all tested doses of 109, 1010 and 1011 CFU-equivalent conferred significant protection
against the intra-peritoneal challenge. However, the highest tested dose of 1011 CFU-
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equivalent of B. neotomae was required for affording protection against intranasal
challenge as shown by the reduced bacterial colonization in spleens and lungs. Future
studies should focus on a comprehensive analysis of T cell responses in lungs following
immunization and challenge to reveal any important differences between the different
booster-dose combinations. Additionally, determining the persistence of gamma-irradiated
bacteria in lymphoid organs will be important to enhance our understanding of the
magnitude of immunity induced at different mucosal sites following vaccination with
different doses. An equally important future direction would be to study the effect of the
number of boosters of the highest tested dose on the protective efficacy against mucosal
and systemic challenge. Also, efforts should be focused on the formulation of vaccine to
overcome the physiological barriers at mucosal routes including the acidic conditions of
human stomach, and determination of the shelf-life of the gamma-irradiated vaccine and
the duration of the vaccine-induced immune response.
Taken together, our studies discovered the novel role of wbkA in EPS synthesis in Brucella.
Also, the recombinant strain RB51WboAKF is more effective than its parent strain in
inducing protection in mice. The last part of the present research demonstrates the
feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to
induce protection against respiratory and systemic infections with virulent Brucella.
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